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The immune system
For humans to protect themselves against harmful pathogens it is crucial that the immune 
system can discriminate between self and non-self antigens. The fi rst line of defence against 
foreign pathogens is the eff ective and rapid, but non-specifi c innate immune system that 
consist of the physiological epithelial barrier, plasma proteins such as those of the complement 
system, phagocytic cells like macrophages, mast cells, neutrophils, and natural killer cells that 
destroy cells expressing non-self patterns, and dendritic cells. These dendritic cells can also 
act as a bridge with the adaptive immune system.
This adaptive immune system is diverse and specifi c as it consists of the humoral immune 
response consisting of antibodies produced by B cells, and the cellular immune response that 
is mainly driven by T cells. Both these responses are only induced when specifi c antigens are 
recognised by the somatically rearranged receptors expressed on B and/or T cells. Once B or 
T cells have encountered an antigen for the fi rst time, the primary response, a proportion of 
the naïve cells will diff erentiate into long-lived memory cells, which can induce a more rapid 
and eff ective response upon re-exposure to the same antigen, the secondary response.
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Polymorphic
Oligomorphic
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Figure 1: HLA class I and HLA class II molecules. HLA-A, HLA-B and HLA-C molecules have a highly 
polymorphic alpha chain in complex with a monomorphic β2-microglobulin. HLA-DR molecule has a highly 
polymorphic beta chain and an oligomorphic alpha chain. HLA-DQ and HLA-DP molecules consist of 
polymorphic alpha and beta chain.
HLA system
One of the key players of the human immune system are the human leukocyte antigens (HLA) 
of which there are two classes. HLA class I consist of the classical HLA-A, -B and -C antigens 
of which the genes encode for a polymorphic α-chain which forms a molecular complex with 
the monomorphic β2-microglobulin (Figure 1).1,2 In contrast, the HLA class II HLA-DR, -DQ and 
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-DP genes code for two chains (Figure 1), the α- and β chains. Both chains are polymorphic 
for HLA-DQ and -DP whereas for HLA-DR only the β-chain is polymorphic and the α-chain 
oligomorphic. There are four HLA-DRB genes, namely HLA-DRB1, -DRB3, -DRB4, and -DRB5.3-5 
An individual inherits one HLA haplotype from the mother and one from the father and can 
thus express up to fourteen different HLA molecules.
HLA class I molecules are expressed on all nucleated cells and platelets, and their function 
is to present peptides derived from proteins inside the cell to cytotoxic T cells (CD8+). In case 
these are non-self peptides (for example viral origin) this subsequently results in killing of the 
target cell. In contrast, HLA class II molecules are mainly expressed on antigen presenting cells, 
such as dendritic cells, monocytes, macrophages and B cells, and on activated endothelial 
cells. These HLA class II antigens present peptides derived from proteins outside the cell to 
helper T cells (CD4+), which can activate macrophages, cytotoxic T cells, or B cells to secrete 
antibodies.6 As different HLA antigens can present different peptides there are a wide variety 
of HLA alleles across individuals. This high polymorphism of HLA ensures that there is always 
an individual that can present a peptide of a particular pathogen, which protects the human 
population from new or mutated pathogens. So far 18.742 HLA class I and 7.060 HLA class II 
alleles have been identified, but this number is still growing mainly due to more sophisticated 
typing methods.7
Alloimmune response in transplantation
While the high diversity of HLA allele is beneficial for immunological defence against 
pathogens, it is unfavourable for (solid organ) transplantation. Already in 1960’s it was 
observed that HLA matching is pivotal in kidney transplantation, as it was associated with 
a better allograft survival.8 Donor HLA molecules of the graft can be recognised as foreign 
by the recipient’s immune system, and the higher the number of HLA mismatches the 
higher the chance that this occurs. Early after transplantation recipient T cells can recognise 
intact HLA molecules expressed on antigen presenting cells of the donor, which can lead to 
cytotoxic T cell response. This phenomenon is known as direct allorecognition.9,10 In addition, 
indirect allorecognition can occur when foreign HLA molecules of the donor are taken up 
and processed by recipient antigen presenting cells and subsequently presented as peptide 
in the context of self HLA to helper T cells.10,11 Lastly, there is evidence that intact allogeneic 
HLA molecules can be expressed on recipient antigen presenting cells, known as semi-direct 
allorecognition.10 While direct allorecognition is often associated with early graft rejection 
and indirect allorecognition with chronic rejection, the different pathways can interact 
and therefore can cause both acute and chronic rejection. Due to the crucial role of T cell 
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alloimmunity in graft rejection, the vast majority of current immunosuppressive treatment 
is aiming at suppression of T cell activation.12
During more recent years it became apparent that also the humoral alloimmune response, 
induced upon transplantation, plays an important role. The B cell receptor (BCR) on 
alloreactive recipient B cells recognise the donor HLA molecule as foreign (Figure 2) and 
produce HLA-specifi c antibodies. For a full-blown antibody response, B cells need to switch 
from IgM towards IgG antibody production which can be accomplished by the interaction 
with T helper cells that recognise T cell epitopes, derived from the donor HLA, presented by 
recipient’s HLA class II molecules on the B cells (Figure 2).13,14
T cell
donor 
cell
B cell
Plasma
cell
T cell ac�va�on leads 
to cytokine prodcu�on
Pep�de of foreign HLA presented 
by HLA class II molecules 
to CD4+ T cells
Differen�a�on to plasma cells
that produce isotype-switched 
an�bodies
B cell receptor recognise an 
epitope on foreing HLA molecule
Figure 2: HLA-specifi c antibodies are produced after B cell receptor recognise donor HLA molecule 
as foreign. B cell receptor on alloreactive B cells recognise foreign epitope on donor HLA molecule. As 
a result, donor HLA molecule is internalised and degraded into peptides of which one is presented by 
recipient HLA class II molecules to CD4+ helper T cells. Subsequently, the helper T cell is activated and 
start producing cytokines and other immunoregulatory molecules that lead isotype-switched antibody 
production by plasma cells.
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Indeed, recipients that receive an HLA mismatched graft can form de novo donor-specific 
antibodies (DSA) which are associated with inferior graft survival.15-18 In addition, the 
presence of these DSA reduces the chance of repeat transplantation,19 as these antigens are 
defined as unacceptable. This is done to reduce the risk of hyperacute rejection that may 
occur when antibodies already present before transplantation are able to react with donor 
HLA on a graft.20,21 For that reason a serological or virtual crossmatch is performed prior to 
transplantation in order to exclude transplantation of a graft towards which the potential 
recipient has DSA. This matter is further complicated since DSA are not only specific for the 
mismatched HLA, the immuniser, but can also cross-react with other HLA antigens, due to 
the sharing of determinants or antibody epitopes between different HLA antigens.22-24 These 
detrimental HLA antibodies are not only found after transplantation but can also be formed 
after pregnancy,25 or blood transfusion.26,27
Outline of thesis
Despite the improved surgical techniques and more potent immunosuppression HLA matching 
on the antigen level is still beneficial for kidney transplantation.28,29 However, due to the high 
polymorphism of HLA and scarcity of organs the chance of finding a fully HLA matched donor 
is slim. The development of high resolution HLA typing, luminex single antigen bead assay 
and HLA crystal structures has resulted in increased knowledge about HLA molecules. It has 
become clear that each HLA molecule consists of a unique set of polymorphic amino acid 
configurations, often referred to as epitopes, but an individual epitope can be shared by 
multiple HLA molecules.30 As a result, the number of epitope mismatches for one HLA antigen 
mismatch depends on both the HLA phenotype of the recipient and the donor HLA mismatch 
(Figure 3). Recent studies suggest that epitope matching might be the basis of novel allocation 
strategies to prevent de novo DSA formation after transplantation.31-34
While the B cell epitope or structural epitope is the complete surface area of antigen 
that interacts with antibody, a small configuration of amino acids, the functional epitope, 
determines the specificity of antibody response via its interaction with complementarity-
determining region 3 of the heavy chain (CDR-H3).35-37 To prevent de novo DSA formation, it 
is pivotal to define the immunogenic polymorphic amino acids that can trigger an antibody 
response. Defining to which polymorphic amino acid configurations an antibody can actual 
bind to will contribute in defining acceptable and unacceptable HLA antigens for immunised 
recipients.
Cynthia_Binnenwerk_V3.indd   13 9-8-2020   14:52:44
14
Recipient HLA
HLA Donor A
2 epitope mismatches
HLA Donor B
1 epitope mismatch
HLA Donor C
3 epitope mismatch
Figure 3: The number of epitope mismatches depends on epitope repertoire of recipient’s HLA.
From all three potential donors, donor B is the best option as it only has 1 epitope mismatch compared 
to recipient, while donor A has 2 epitope mismatches and donor C has 3 epitope mismatches and therefore 
are more likely to be immunogenic.
Various approaches have been introduced over the years to predict the immunogenicity 
of HLA molecules and subsequently the chance of developing de novo DSA. In Chapter 2
and Chapter 3, we reviewed the strategies of these approaches to defi ne immunogenicity, 
which all have been shown to associate with de novo DSA formation on the population level. 
In addition, the diff erences between immunogenicity and antigenicity is described, which is 
crucial for defi ning the clinical relevant epitopes (Chapter 2). We also highlight the diff erential 
immunogenicity of individual epitopes and that therefore novel matching strategies should 
not only be based on numbers (Chapter 3).
Eplets are one of these approaches and are theoretically defi ned confi gurations of surface 
exposed polymorphic amino acids within 3 to 3.5 Å radius. Eplet mismatches between 
donor and recipient have been associated with dnDSA formation,32-34,38-41 transplant 
glomerulopathy,42 and antibody-mediated rejection.43-45 However, not every eplet mismatch 
will induce an antibody response, and the theoretically defi ned eplets require experimental 
verifi cation to establish whether an antibody can actual bind to these residues. Human mAbs46
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and absorption and elution studies47,48 have shown to be useful for antibody-verification, 
but those of HLA class II are limited due to lack of HLA class II mAbs.49,50 Therefore our aim 
was to develop recombinant human HLA class II mAbs to facilitate the definition of actual 
antibody epitopes. In Chapter 4, we used established human B‐cell heterohybridomas to 
verify a method to generate recombinant human HLA mAbs of all four IgG subclasses. Next 
in Chapter 5, we used this method to generate recombinant human HLA-DR-specific mAbs 
from low frequency HLA-DR specific memory B cells that were isolated from peripheral blood 
of pregnancy immunised individuals using HLA-DR tetramers. Reactivity analysis of these 
generated HLA-DR mAbs was performed to define uniquely shared amino acid or amino acid 
configurations on the reactive HLA alleles, and those were mapped to the pre-defined eplets.
Another way to define the relevant epitopes is by identifying the immunogenic polymorphic 
amino acid to define relevant amino acid configurations. In Chapter 6, we describe the 
development of the software program HLA-EMMA to compare the amino acid sequence of 
the mismatched donor HLA allele with the amino acids sequences of the recipient of the same 
locus. HLA-EMMA provides not only the number of solvent accessible amino acid mismatches, 
but also the type and position of the mismatched amino acids. As de novo DSA directed 
against HLA class II are the most prominent after transplantation, we aimed to define the 
most immunogenic HLA class II amino acids. For this, we performed a pilot study of non-
immunised male renal transplant recipients with at least one HLA class II antigen mismatch, 
who lost their graft due to immunological failure (Chapter 7). With HLA-EMMA the solvent 
accessible amino acid mismatches were determined and these mismatches were associated 
with de novo DSA formation.
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ABSTRACT
Transplantation of an human leukocyte antigen (HLA) mismatched graft can lead to the 
development of donor-specific antibodies (DSA), which can result in antibody mediated 
rejection and graft loss as well as complicate repeat transplantation. These DSA are induced 
by foreign epitopes present on the mismatched HLA antigens of the donor. However, not 
all epitopes appear to be equally effective in their ability to induce DSA. Understanding 
the characteristics of HLA epitopes is crucial for optimal epitope matching in clinical 
transplantation. In this review, the latest insights on HLA epitopes are described with a special 
focus on the definition of immunogenicity and antigenicity of HLA epitopes. Furthermore, the 
use of this knowledge to prevent HLA antibody formation and to select the optimal donor for 
sensitized transplant candidates will be discussed.
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INTRODUCTION
Human leukocyte antigen (HLA) matching in renal transplantation is an important factor 
influencing long-term graft survival.1,2 The chance of finding an unrelated fully matched kidney 
donor is slim due to the high level of polymorphism of HLA antigens.3 So far, matching in renal 
transplantation has mainly been done for HLA-A, -B, and -DR antigens and even then, most 
recipients receive a graft mismatched for at least one or more HLA antigens. Recipients of 
a mismatched graft have an increased chance to develop donor-specific antibodies (DSA), 
which are associated with poor allograft survival.4-6 Furthermore, the development of DSA 
complicates repeat transplantation, a problem that is most obvious for highly sensitised 
patients, who generally experience long waiting times.
Immunisation by a single HLA antigen mismatch can result in antibodies directed against 
numerous other HLA antigens, which is called cross-reactivity.7-9 It has previously been shown 
that this cross-reactivity is caused by sharing of determinants to which an antibody can bind, 
called epitopes, by various HLA antigens.9-11 In the early 1990’s, HLA antigens that shared an 
epitope were assigned to cross-reactive antigen groups (CREG)12,13 and matching based on 
these CREGs appeared to be associated with a better graft survival.14 The antibody-reactivity 
patterns observed in sensitised patients also indicated that a relatively small number of 
epitopes are involved in antibody induction and that the emerging antibodies are directed 
against common epitopes.15,16
Identifying antibody -or B cell- epitopes on HLA antigens and understanding their 
immunogenicity and antigenicity will be imperative for the development of novel matching 
strategies that aim at reduced antibody induction after transplantation, as well as 
identification of acceptable mismatches for highly sensitized patients. The application of 
high resolution molecular HLA typing has resulted in an increased knowledge of the amino 
acid sequences of HLA alleles, enabling the identification of polymorphic positions, as well as 
a better understanding of the quaternary structure of the HLA by modelling of the crystalline 
HLA molecule structures.17-20 These tools have become very useful for defining polymorphic 
areas harbouring theoretical antibody epitopes. In addition, highly sensitive single antigen 
bead (SAB) based HLA antibody identification assays have been introduced, providing 
antibody-reactivity patterns with extensive specificity patterns on the allele level.21 The 
latter is of great importance to determine the actual epitopes recognised by HLA antibodies. 
In this review, we will discuss the latest insights into antibody epitopes and the difference 
between immunogenicity and antigenicity. A proper definition of the immunogenic HLA 
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epitopes and understanding the interaction between HLA antigen and antibody is crucial for 
the improvement of matching strategies in clinical transplantation.
Box 1. Various definitions of epitopes
Eplet/functional epitope: polymorphic amino acid configuration that triggers an antibody response 
(defined by R. Duquesnoy)
Immunogenic epitope: polymorphism that triggers an antibody response
Structural epitope: all polymorphisms that are covered by an antibody footprint
STRATEGIES TO DEFINE HLA EPITOPES
Theoretical epitopes
Epitopes are defined as parts of an HLA molecule that are recognised by the immune system as 
foreign, which implies the involvement of amino acids (or amino acid sequences) not present 
on self-HLA antigens (Box 1). In case of antibody epitopes, the polymorphic amino acids must 
be at sites that are accessible by an antibody molecule. Antibodies recognise conformational 
epitopes, which can be both linear strands of amino acids (linear epitope), or amino acids 
in close proximity in the three-dimensional structure of a molecule (discontinuous epitope). 
In a pioneering attempt to define antibody epitopes on HLA molecules, Duquesnoy et al. 
used linear amino acid sequences of serologically defined HLA antigens together with known 
molecular three-dimensional structures to determine polymorphic amino acids at antibody 
accessible positions for each HLA class I locus.22 These residues were proposed as being the 
critical components of an immunogenic linear epitope and resulted in the identification of 
linear sequences of maximal three polymorphic amino acids at the molecular surface that 
were referred to as triplets.22,23
As mentioned above, antibodies can also recognise epitopes formed by polymorphic amino 
acids from different parts of the molecule that come into close proximity due to the folding of 
the protein. Indeed, analyses of the available quaternary HLA molecule structures with Cn3D 
software (https://www.ncbi.nlm.nih.gov/Structure/CN3D/cn3d.shtml)19 clearly show that the 
triplet concept does not fully cover all theoretical epitopes, as discontinuous polymorphic 
amino acids form patches, with a radius of approximately 3 angstrom (Å), on or near the 
molecular surface. Consequently, a cluster of polymorphic amino acids, either linear or 
discontinuous, within a 3-3.5 Å radius of an antibody-accessible sequence position was 
defined as being capable of inducing an antibody response and was named an eplet.24,25 So 
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far, many theoretical HLA class I and HLA class II eplets have been defined using this method 
and are listed in the HLA epitope registry (http://epregistry.ufpi.br/terms/index).26,27
It has become clear that each HLA allele consists of a unique combination of epitopes, but 
that the three classical HLA class I loci share certain epitopes. In addition, the location of 
the polymorphic amino acids of the three classical HLA class I loci turned out to be similar. 
Consequently, for epitope analysis, HLA class I alleles should not only be compared with 
alleles from the same locus, called intralocus, but also interlocus by which the alleles are 
additionally compared with the alleles of the other HLA class I loci. This principle has been 
applied for almost every HLA class I epitope study. In contrast, the epitopes of HLA class II loci 
are analysed intralocus due to the fact that HLA-DR has a highly polymorphic beta chain and 
an oligomorphic alpha chain, while HLA-DQ and HLA-DP molecules have two polymorphic 
chains. Therefore, the defined clusters of antibody accessible polymorphic amino acids are 
different between the three loci and thus HLA class II epitope should be analysed separately 
per locus. Regardless, further studies are necessary to prove that the use of interlocus 
comparison of HLA class I and intralocus comparison of HLA class II is the optimal way to 
define the number of eplet/epitope mismatches.
A computer algorithm named HLAMatchmaker was developed by Rene Duquesnoy, originally 
based on triplets, and later modified for eplets as the critical component of immunogenic 
epitopes that can elicit an antibody response (http://www.epitopes.net/). An important 
component of the algorithm is that antibodies cannot be induced against eplets present on 
a self-HLA antigen.22,23,25,28 This algorithm can be used to determine for each mismatched 
donor HLA antigen which eplet is non-self, compared to the repertoire of self-eplets on the 
HLA antigens of the recipient, resulting in a quantification of eplet mismatches. Additionally, 
the algorithm can identify eplets involved in antibody-reactivity patterns detected in patient’s 
serum.
Antibody-verified epitopes
Eplets have been defined based on sequence comparisons and available quaternary three-
dimensional structures of HLA molecules. However, this does not mean that every eplet 
defined is indeed able to induce antibodies. These potential antibody-inducing patches 
need verification by laboratory tests showing antibody binding to these structures. Studies 
by various groups using monoclonal antibodies (mAbs) directed at defined HLA molecules 
showed that these reagents are very useful to identify shared antibody eplets between HLA 
antigens.29,30 Especially human mAbs have been used in SAB assays to successfully verify 
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an extensive number of eplets.31,32 Despite this, many eplets should for the moment be 
considered as theoretical eplets until it is proven that they are indeed being recognised by 
alloantibodies.
El-Awar et al. used an alternative approach to define antibody-verified epitopes.33 
Alloantibodies and mAbs were absorbed and eluted from recombinant single HLA antigen 
expressing cell lines and HLA antibody specificity was determined with SAB assays. The amino 
acid sequences of the reactive HLA alleles were compared and the exposed polymorphic 
amino acids within an antibody-binding region of approximately 700-900 Å, that were 
exclusively shared between the reactive HLA alleles, were considered to define the antibody 
epitope. The number of unique amino acids of these epitopes is between one and four, located 
in discontinuous positions. The epitopes defined by this method have been named Terasaki 
epitopes (TerEp).34-38 As the TerEps are defined by one or a combination of amino acids it can 
occur that a residue at a specific position of an epitope on the immunising allele is also present 
on an allele of the recipient, yet this is not defined as a self-epitope as the combination of 
amino acids of the epitope is different.39
Similar to the mAb-verified eplets, for TerEps it has formally been proven that these are targets 
for antibodies. Likewise, for this method the limited number of mAbs and allosera studied so 
far makes it likely that the current list of TerEps is not complete. Comparative studies observed 
a huge overlap between eplets and TerEps, with only a small number of TerEps lacking a 
corresponding eplet.40,41 Another limitation of the use of mAbs for the verification of antibody-
verified epitopes is the restriction to common HLA alleles. As a consequence, the epitopes 
that are currently verified are mainly present on common HLA alleles, whereas epitopes on 
rare HLA alleles remain unverified. This poses a disadvantage for ethnic minorities as it will 
be more difficult to identify antibody-verified epitopes for these populations.
Other means of verifying epitopes on HLA antigens have been described, but one should 
be cautious to draw any definitive conclusions from these approaches. In a recent study, 
postpartum sera of women were used to screen for novel antibody-verified eplets.42-44 Sera 
from women after one or two pregnancies were screened with SAB assays and the antibody-
reactivity pattern was analysed for new antibody-verified epitopes. In contrast to the TerEp 
studies, no absorption and elution assays were performed. On basis of this type of reagents 
it is impossible to rule out that the antibodies are produced by more than one B cell clone, 
leaving the possibility that multiple epitopes are involved in the final antibody reactivity. 
Furthermore, analysis of sera obtained after a second pregnancy may be complicated by the 
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interference of antibodies induced after the first pregnancy by a different haplotype. This 
emphasises the importance of strict guidelines for verifying epitopes based on antibody-
reactivity pattern observed in sera. In our opinion, the only way to formally verify an antibody 
epitope is by (human) mAbs and/or absorption-elution studies.
IMMUNOGENICITY OF AN ANTIBODY EPITOPE
For a proper use of epitope matching in clinical transplantation, the immunogenicity and 
antigenicity of epitopes should be defined first. Although these are different characteristics of 
an epitope, these terms are used often interchangeably, which is not correct. Immunogenicity 
is the ability to induce an antibody response while antigenicity is based on the actual 
interaction between an antibody and an antigen, which involves both the polymorphic 
amino acids comprising the immunogenic epitope and other crucial polymorphic amino acid 
configurations that act as contact sites.
Induction of antibodies
In theory, any amino acid on a particular position of a donor HLA molecule that is not present 
on the recipient’s HLA molecules has the ability to trigger an antibody response. However, 
whether an epitope truly induces an antibody response is dependent on the total make up 
of HLA molecules of the recipient. Dankers et al. showed that HLA-A28 positive women who 
delivered an HLA-A2 positive child more often form antibodies against HLA-A2, while women 
who have HLA-A2 themselves and delivered an HLA-A28 child did not develop antibodies 
against this HLA antigen. These observations could be explained by an immunogenic epitope 
that is unique for HLA-A2. Thus, when HLA-A2 is a self-antigen, the unique immunogenic 
epitope is self and will not trigger an antibody, while in case of an HLA-A2 mismatch the 
epitope is more likely to trigger an antibody response.45
In population studies, various groups have shown (a) correlation between the number of 
epitope mismatches between donor and recipient, and DSA development, thus demonstrating 
a quantitative effect of mismatches on the immunogenicity of an HLA molecule. However, 
one or a few epitope mismatches can be sufficient to induce an antibody response.46-48 This 
indicates that immunogenicity is not merely a quantitative issue. The characteristics of the 
amino acid substitution, in relation to the patient’s own HLA molecules, are important for the 
induction of an antibody. A high number of epitope mismatches can be an indicator for the risk 
of forming an antibody because the chance is higher that one of these mismatched epitopes 
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is immunogenic. However, for an individual patient the nature of the epitope mismatch 
determines if an antibody response is actually triggered.
A prerequisite for an epitope to be immunogenic is that the induced DSA reacts with that 
particular epitope. Upon transplantation, patients receive maintenance immunosuppression, 
which may interfere with DSA formation.49,50 It is conceivable that not every epitope mismatch 
results in an antibody response due to the immunosuppressive medication. DSA detected 
in transplant recipient might be restricted to highly immunogenic epitope mismatches that 
escape the suppressive properties of the medication.48
As discussed above, both eplets and TerEps are polymorphic amino acid configurations on 
donor HLA alleles that are non-self. However, while amino acids on a specific position can 
be shared between donor and recipient, the combination of amino acids in a configuration 
can be mismatched. The question is whether such configurations are indeed necessary 
for antibody induction or if a single amino acid difference between recipient and donor on 
an antibody accessible position can already determine its immunogenicity. Possibly both 
scenarios are valid, since some of the eplets and TerEps consist of only a single non-self amino 
acid.26,27,37 Recently, Kosmoliaptsis and colleagues compared the number of eplet mismatches 
and the number of HLA class I and II amino acid mismatches after intralocus and interlocus 
comparison between donor and recipient alleles as predictive parameters for DSA induction. 
This population study showed that both the number of eplet mismatches and the number 
of polymorphic amino acid mismatches are predictors of DSA formation. In this study, no 
advantage of the eplet approach over the number of amino acid mismatches was observed.51-53
Furthermore, the same group demonstrated that physiochemical properties of the amino acid 
substitution can predict immunogenicity. Each amino acid has unique characteristics, which 
are determined by the hydrophobicity and electrostatic charge of the side chains. In addition 
to the number and position of individual mismatched amino acids, the hydrophobicity and 
electrostatic charge can be determined for each mismatched amino acid, resulting in a 
hydrophobicity mismatch score (HMS) and electrostatic mismatch score (EMS). Both HMS 
and EMS appeared to be strong predictors of HLA class I and II de novo DSA formation after 
kidney transplantation.51,53 The HMS and EMS had superior predictive value for DSA formation 
compared to eplet mismatches and amino acid mismatches, which warrants further studies.52
Nonself-self paradigm
The above-mentioned strategies define immunogenic epitopes as mismatched or foreign 
epitopes, which are absent on the HLA alleles of the recipient and trigger an antibody 
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response. Although HLAMatchmaker is also based on this principle, Duquesnoy more recently 
proposed a nonself-self paradigm to explain some antibody reactivity that otherwise remains 
unexplained. According to this paradigm, some antibody responses towards foreign HLA 
cannot solely be induced by an immunogenic eplet mismatch, but require a self-amino 
acid configuration to be present on the mismatched allele.54,55 This theory is based on the 
assumption that B cells with low-affinity immunoglobulin receptors for self-HLA epitopes 
are present but their affinity for mere self-epitopes is too low to trigger B-cell activation 
and antibody production. These B cells do become activated when confronted with the 
combination of a few amino acids which are non-self, and a self-amino acid configuration. The 
hypothesis implies that the presence of a self-eplet is required to induce an antibody response 
for a certain group of epitopes. However, not every eplet present in the epitope registry meet 
the non-self-self criterion and many non-self-eplets are antibody verified.26,27 While the non-
self-self paradigm is interesting, it is difficult to conceive why HLA antibodies would have 
self-reactive properties. Unlike T cell receptors, B cell receptors are not selected on basis of 
a low affinity for self HLA antigens. So far, laboratory data confirming the presence of low 
affinity self-HLA reactive immunoglobulin receptors are lacking. An alternative explanation 
for the involvement of a self-amino acid configuration on the mismatched donor allele is 
that HLA molecules share many amino acids. If an amino acid or eplet induces an antibody 
response, a number of these adjacent nonpolymorphic amino acids will be shared with the 
patient’s own HLA molecules.
T cell epitope
The immunogenicity of antibody epitopes becomes even more complex when considering 
the requirement for CD4+ T cell help for a full-blown B cell response resulting in class-
switched antibodies. Helper T cells play an essential role in the differentiation of B cells into 
IgG producing plasma cells.56 After recognition by the B-cell receptor, the target antigen can 
be internalised and degraded into peptides, finally resulting in peptides being presented 
in context of self HLA class II on the B cell. The presence of peptides that can be presented 
by the particular self-HLA class II molecules determines whether B cell clones receive T cell 
help. Upon cognate interaction between B and T cell, enhanced CD40 ligand expression and 
cytokine production by the T cell results in B cell differentiation into plasma cells. Indeed, it has 
been shown that the HLA class II phenotype of the recipient determines the immunogenicity 
of HLA class I antigens of the donor.57 For instance, the production of HLA-Bw4 antibodies 
preferentially occurred in HLA-DRB1*01 and HLA-DRB1*03 positive patients.58
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Following this work, Spierings and colleagues investigated the role of donor HLA-derived 
T-helper epitopes in formation of de novo DSA in silico. To predict T-helper epitopes, an 
algorithm was developed to determine the number of HLA class II-restricted predicted 
recognizable HLA epitopes (PIRCHE-II) for each HLA class I antigen mismatch. PIRCHE-II are 
theoretical epitopes consisting of nine amino acids present on the mismatched HLA class I 
antigen and absent on all HLA class I antigens of the recipient, which are able to be presented 
in peptide binding groove of the HLA class II molecules of the recipient.
In a cohort study of non-immunised renal transplant patients, a correlation was observed 
between a low number PIRCHE-II, and the lack of de novo antibody responses against specific 
HLA class I mismatches.59 The role of PIRCHE-II in antibody formation was subsequently 
confirmed in a pregnancy cohort.60 Noteworthy, these studies indicate a predictive value 
of PIRCHE-II on the population level, but it does not show any clinical relevance for the 
individual patient. Furthermore, the PIRCHE-II algorithm likely overestimates the number 
over PIRCHE-II as it is unlikely that the proteasome indeed processes all these theoretical 
peptides. Additionally, the functional role of these T-helper epitopes with respect to the 
activation of CD4+ T cells remains to be proven.
Interestingly, in both transplantation and pregnancy cohorts no correlation between the 
number of PIRCHE-II and eplet mismatches was found. This might be explained by the fact 
that the eplet model is restricted to polymorphisms at antibody accessible sites. Furthermore, 
this model does not take into account the restriction of presentation capacity by HLA antigen 
towards helper T cells. An alternative, yet not exclusive explanation could be the involvement 
of noncognate T-helper responses to multiple HLA disparities, in which B cells and T-helpers 
cell do not necessarily have to recognise the same antigen. The group of Pettigrew showed 
in murine models of transplantation that B cells specific for an alloantigen can receive help 
from T-helper cells with another allospecificity. Long-lasting humoral alloimmune responses 
can be explained by this mechanism as memory T-helper cells recognising one alloantigen can 
give CD4-independent help to B cells that are specific for another alloantigen.61 To optimally 
predict the immunogenicity of an HLA mismatch for an individual patient, both antibody 
epitopes and T cell epitopes should be considered.
Immunogenicity of epitopes in clinical renal transplantation
The immunogenicity of epitopes in clinical renal transplantation has been extensively 
studied.22,46-48,51-53 In these studies, the HLAMatchmaker computer algorithm was used to 
determine the epitope load of certain HLA mismatches in order to correlate these with 
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the development of de novo DSA. A significant correlation between the number of epitope 
mismatches between recipient and donor and the chance to develop de novo DSA was 
observed.
Wiebe et al. used HLAMatchmaker in a population study and observed no DSA production in 
recipients with 10 or less HLA-DR eplet mismatches and 17 or less HLA-DQ eplet mismatches.48 
In addition, recipients who were nonadherent to their immunosuppressive medication and 
received a transplant with an HLA class II eplet load above these thresholds were more likely 
to develop DSA, acute rejection and graft failure compared to adherent recipients with an 
epitope load beneath the thresholds, indicating a synergistic effect of nonadherence and HLA 
class II eplet load.62 It is important to note that in this study the HLA class II eplet threshold was 
based on all potential eplets, rather than antibody-verified eplets. Using the same threshold 
another group found that paediatric recipients of a graft with a DQ eplet load below the 
threshold were at a low risk to develop both DR and DQ specific de novo DSA.63
As a possible consequence of the association between the number of HLA class I and II 
epitope mismatches and development of de novo DSA, the number of epitope mismatches 
appeared to be a predictive parameter for the outcome of graft survival and long-term 
outcome of renal transplant recipients.62,64-67 Sapir-Pichhadze et al. even described an 
association between the number of HLA-DR and -DQ eplet mismatches and development 
of transplant glomerulopathy.68 The sum of HLA-DR and -DQ eplet mismatches was found 
to be an independent risk for antibody mediated rejection and transplant glomerulopathy. 
Besides renal transplants, epitope matching appears also to be beneficial for other types of 
solid organ transplants. In both lung transplant recipients and heart transplant recipients the 
number of HLA eplet mismatches correlated with the development of DSA and consequently 
the outcome of the transplantation.69,70
Altogether, these studies indicate the higher the number of HLA class I and II epitope 
mismatches the higher the risk of developing de novo DSA, without yet considering the 
differential immunogenicity of the individual epitopes.
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ANTIGENICITY OF AN ANTIBODY EPITOPE
Reactivity of existing antibodies
So far, we have discussed that the trigger for antibody production by a B cell is the presence 
of a foreign immunogenic epitope on a mismatched donor HLA molecule. Subsequently, the 
reactivity pattern of the induced antibody determines the antigenicity of an epitope. Not only 
the immunogenic epitope, but also other amino acids in its proximity are involved in the actual 
reactivity of the antibody and formation of the antigen-antibody complex.
Antigen-antibody complexes are formed by three complementary determining regions (CDR) 
on the variable heavy chain (VH) and three CDRs on the variable light chain (VL)71 that bind to 
six contact sites on the immunising HLA molecule, forming an antibody ‘footprint’ of 700-900 
Å on the molecular surface of an HLA molecule. The VH3 binds to the immunogenic epitope 
and is responsible for the strength and specificity of the antibody reactivity. The remaining 
CDRs are important for stability and affinity of the antibody binding and will bind to amino 
acids within the antibody footprint.
As mentioned, HLA molecules can share amino acid configurations and thus also the contacts 
sites involved in antigen-antibody complexes. This may explain the broad reactivity of 
antibodies observed in SAB assays when screening sera which not only contain DSA but 
also non-donor specific antibodies (NDSA).72,73 All the reactive HLA molecules contain the 
immunogenic epitope of the mismatched HLA molecule that triggered the antibody response 
and often one or more critical amino acid configurations important for antibody binding 
(Figure 1). This immunogenic epitope and/or critical amino acid configurations are absent on 
the non-reactive HLA molecules. So, the actual reactivity of antibodies depends on both the 
immunogenic epitope and the other crucial amino acid configurations of the epitope that act 
as contact sites necessary to form a stable antigen – antibody complex.
Duquesnoy defines the antibody footprint as a structural epitope consisting of 15-22 amino 
acids. In the centre 2-5 amino acid residues reside of which at least one is non-self, also known 
as the eplet, or functional epitope, to which the VH3 of antibodies bind, similar to what we 
described above.24,25,74
Based on this antibody footprint, Duquesnoy analysed the broad reactivity observed in 
SAB assay of various mAbs with the HLAMatchmaker algorithm and proposed different 
reactivity patterns.31,32,55 In one reactivity pattern, all the reactive HLA molecules contain 
the immunogenic eplet that induced the antibody response, which implies that the VH3 site 
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of antibody can bind to this eplet, while the non-reactive HLA molecules do not have this 
immunogenic eplet and as a result the VH3 has no binding site on these molecules.26 In some 
cases, it appeared that the non-reactive HLA molecules do have the immunogenic eplet to 
which the VH3 can bind to, but lack additional crucial amino acid confi gurations within the 
antibody footprint that are present on the reactive HLA molecules (Figure 1). The need for two 
confi gurations to establish an antigen – antibody complex is designated as eplet pairs.31,32,55
An�body footprint 
on HLA molecule
VH3
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VH1
VL3
VL2
VL1
VH3
VH2
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Figure 1. Crucial amino acid confi gurations determine the reactivity of an HLA antibody. Schematic 
representation of an antibody footprint present on an HLA molecule. The VH3 of the antibody binds to 
the immunogenic epitope (blue), while binding of other contact sites of the antibody to crucial amino acid 
confi gurations (red) is essential for reactivity. The remaining amino acid confi gurations within the antibody 
footprint are indiff erent to the reactivity.
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Additionally, Duquesnoy et al. showed different reactivity patterns detected when screening 
human HLA-specific mAbs with IgG SAB assays, C1q SAB assays, and complement-dependent 
cytotoxicity (CDC) assays.75 Based on these data, they proposed that certain specific 
polymorphic amino acid configurations of structural epitopes are not only crucial for antibody 
binding, but also affect the release of free energy, which determines whether complement 
can be activated.
Complexity of HLA class II reactive antibodies
Defining epitopes of the HLA class II reactive antibodies is in its infancy, as mainly HLA class 
I-specific human mAbs are currently available. Moreover, epitopes on HLA-DQ and-DP are 
more complex due to the fact that both α and β chains are polymorphic. Tambur et al. have 
touched on this complexity and the importance of understanding the reactivity of HLA-DQ 
antibodies.76,77 Upon analysis of HLA-DQ antibodies, immunogenic eplets are present on 
either the mismatched DQα or DQβ chain. The antibody footprint can cover an additional 
crucial polymorphic amino acid configuration on HLA molecule, as indicated in Figure 1, and 
depending on the location of immunogenic eplet these crucial configurations are located on 
either one or both DQ chains. As a consequence, it appears that antibodies can react with 
a self DQβ chain and a non-self DQα chain or vice versa in SAB assays, which complicates 
the analysis of the reactive antibodies. Tambur emphasises that for assigning the epitope 
specificity of HLA-DQ antibodies both the DQα and DQβ chains should be considered.78,79
Analysis of HLA-DQ antibodies becomes even more complicated when considering the two 
possible forms of the HLA-DQ antigens, which can be expressed on the cell surface. The first 
one is the cis-heterodimer, in which the β-chain and α-chain are derived from genes on the 
same chromosome, the second one is the trans-heterodimer, where the chains are derived 
from genes on two different chromosomes. Thus, HLA-DQ DSA can theoretically be formed 
against a DQβ-chain, DQα-chain, or both in either cis- or trans-heterodimer.80 Extensive 
analysis of HLA-DP antibodies reactivity is lacking, but the structure of DPβ chain seems less 
complicated than that of HLA-DQ.
To simplify analysis of HLA class II antibody reactivity the previously mentioned computer 
model based on physiochemical properties of amino acids can be used.51,53 With this computer 
model, high-resolution three-dimensional structural models of HLA class I alleles have 
been developed to understand the binding of antibodies to an epitope. These models can 
contribute to the prediction of HLA antigenicity by providing more insight in the antigen-
antibody interaction.81-83 This tool together with the antibody-reactivity patterns, especially 
Cynthia_Binnenwerk_V3.indd   34 9-8-2020   14:52:47
35
Towards HLA epitope matching in clinical transplantation
2
those of mAbs observed in SAB assays, will contribute to a better understanding of the role of 
both the immunogenic epitope and additional crucial polymorphic amino acid configurations 
in the antigen-antibody interaction.
USING EPITOPE KNOWLEDGE IN THE CLINIC
Epitope matching
Preventing DSA formation is pivotal in clinical transplantation and therefore it is important 
to avoid the antibody trigger, which can be any immunogenic epitope. This is especially 
important for paediatric patients who most likely need more than one transplant in their 
lifetime. Recently, Kausman et al. applied HLA eplet loads for the selection of donors in 
paediatric kidney transplantation.84 This group used HLA class I <10 eplets and HLA class II 
<30 eplets as the threshold for each antigen. In the first year post-transplantation, an excellent 
early graft function and a low de novo DSA incidence was observed. This study indicates that 
paediatric patients benefit from epitope matching.
Implementation of an epitope matching algorithm for donor selection in renal transplantation 
may prevent the allocation of kidneys with highly immunogenic epitopes and prevent the 
induction of DSA. To achieve optimal epitope matching, a proper definition of the actual 
epitopes and their immunogenicity is of great importance.
Virtual crossmatching
As mentioned, the presence of DSA complicates repeat transplantation, especially for highly 
sensitised patients as the antibodies will cause a positive crossmatch with the majority of 
donors. The identification of acceptable and unacceptable HLA antigens on basis of extensive 
antibody screening85,86 is currently used to predict beforehand which donor HLA antigens will 
result in a negative or positive crossmatch87: the so called virtual crossmatch.
However, this review shows that epitopes determine antibody reactivity. Therefore, future 
virtual crossmatching should be based on epitopes (Figure 2). Epitopes present on the 
non-reactive HLA molecules are instrumental for the definition of acceptable epitopes 
whereas unacceptable epitopes can be defined on basis of antibody reactivity. For virtual 
crossmatching, the combination of self-epitopes, acceptable epitopes, and unacceptable 
epitopes will determine the selection of a suitable donor. Suitable donors will have HLA 
molecules that consist only of self-epitopes and acceptable epitopes, as these will predict 
a negative crossmatch. The advantage of the use of acceptable and unacceptable epitopes 
compared to current strategies of virtual crossmatching, which are based on HLA antigens, 
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is the fact that one can even predict the antibody reactivity with HLA alleles, that are absent 
in antibody detection assays such as SAB assay, and thus have never been tested before.
1 2 3 4
Self epitope
Acceptable epitope
Unacceptable epitope
Predic�ve crossmatch: +-- +
HLA:
Figure 2. The use of epitope knowledge for virtual crossmatching. Each HLA molecule consists of a set 
of epitopes. HLA molecules with self-epitopes (blue triangles) and/or acceptable epitopes (green stars) 
will predict a negative crossmatch, while HLA molecules with unacceptable epitopes (red hexagons) will 
predict a positive crossmatch.
Highly sensitised patients
As indicated earlier, acceptable epitopes defined by the absence of antibody reactivity can 
be used to identify donors with acceptable HLA antigen mismatches for highly sensitised 
patients. The chance of finding a donor with HLA antigens towards which highly sensitized 
patients have no detectable circulating antibodies is very small. In order to increase this 
chance, Eurotransplant runs the Acceptable Mismatch (AM) program, in which the sera of 
highly sensitized patients are screened to determine the acceptable HLA mismatches to 
which the patient did not form any antibodies.85,86 This knowledge is used for the selection 
of compatible donors. A donor kidney with an HLA type consisting of the combination of the 
patient’s own HLA antigens and acceptable HLA mismatches will be mandatorily shipped to 
that specific highly sensitized patient. Nowadays, the AM program uses HLAMatchmaker to 
identify additional HLA class I antigens which are likely to be acceptable mismatches due to lack 
of antibody epitopes. This led to an increased number of HLA class I acceptable mismatches, 
and subsequently increases the chance of finding a suitable donor.88-90 Altogether, defining 
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epitopes absent in antibody-reactivity patterns of sensitized patients will be beneficial for 
the selection of a donor with HLA molecules consisting of acceptable epitopes.
TOWARDS EPITOPE MATCHING
HLA epitope matching will be beneficial for preventing sensitization, selection of donors for 
highly sensitised patients, and improvement of transplant outcomes.
To identify the clinically relevant epitopes, cohort studies on antibody induction are extremely 
useful. However, many studies suffer from limitations, such as restricted numbers of patients 
included in the analysis. Additionally, the (partial) lack of second field HLA typing (current 
allocation is often based on intermediate typing of HLA-A, -B, and -DRB1) is an inhibitory 
factor. To circumvent this problem, HLAMatchmaker contains an algorithm that assigns most 
likely high-resolution typing based on race of the recipient and/or donor (http://www.epitopes.
net/). When second field typing is available for HLA-A, -B, and –DR, the high-resolution typing 
of the other loci are assigned based on common associations of B-C, and DR-DQ antigens in 
the given population. While this approach is useful, to move the field forward, high resolution 
typing is pivotal.91 While the antibody specificities from SAB assays are on the second-field 
level, it can appear that an allele-specific antibody is directed against a self-antigen, in case 
the HLA typing of the patient is only performed at first field level. This is due to differences 
in polymorphic amino acids that exist between alleles of the same serological antigen. 
Thus, for understanding the epitope that induced antibodies to a certain HLA mismatch and 
determining the relevance of these antibodies in transplantation, second field typing of the 
donor is an absolute requirement.
Most epitope studies used SAB assays for the identification of DSA in sera of recipients. 
However, analysis of multispecific sera is challenging, especially when more than one 
immunising event has occurred. In addition, when defining acceptable and unacceptable 
epitopes based on antibody reactivity observed in SAB analysis, it is essential that the data 
are interpreted with caution, and that a possible prozone effect is excluded.92-97
Several approaches are used to determine the immunogenicity of epitopes, but a systematic 
study on a large population of patients has not been performed. Large cohort studies 
combining the different approaches described in this review are essential to discriminate 
the immunogenic and non-immunogenic epitopes. For the patients carrying rare HLA alleles, 
it will be difficult to determine immunogenic epitopes, so for the time being these patients 
will have to take advantage of matching strategies based on theoretical epitopes.
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Definition of antibody epitopes is one of the main subjects of the 17th International HLA and 
Immunogenetics Workshop (IHIWS) that will be held in Palo Alto, CA in September 2017. For 
this collaborative effort, (high resolution) HLA typing of recipient and donor, screening data 
from sera of recipient with various SAB assays, and graft outcome data from transplant 
centres all over the world are collected for various projects, including definition of the 
immunogenicity of individual epitopes (http://ihiws.org/).
Conclusion
The broad antibody reactivity observed in recipients after transplantation of an HLA antigen 
mismatched graft can be explained by the presence of mismatched epitopes on the HLA of 
the donor, which are shared with other HLA alleles. Identification of the immunogenicity of 
the individual epitopes and avoiding transplantation in the presence of highly immunogenic 
epitope mismatches will prevent DSA formation. In addition, understanding the complex 
interaction between the induced antibody and the reactive HLA molecules will contribute 
to the identification of acceptable mismatches and virtual crossmatching even for highly 
sensitised patients. It is to be expected that future HLA matching strategies will change from 
antigen or allele matching towards HLA epitope matching.
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ABSTRACT
Recent data suggest that HLA epitope matching is beneficial for the prevention of de novo 
donor specific antibody (DSA) formation after transplantation. In this review, different 
approaches to predict the immunogenicity of an HLA mismatch will be discussed. The 
parameters used in these models are often called epitopes but the actual antibody epitope 
is far more complex. Exact knowledge of the antibody epitope is crucial if epitope matching 
is also used as a tool to select compatible donors for (highly) sensitized patients. Evidence is 
provided that it is not always possible to give an exact definition of an antibody epitope. We 
conclude that HLA “epitope” matching is superior over HLA antigen matching with respect 
to the prevention of de novo DSA formation and will enhance the prediction of acceptable 
HLA mismatches for sensitized patients. However, epitope matching at our current level of 
knowledge will not solve all histocompatibility problems as unexpected antibody reactivity 
still may occur.
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INTRODUCTION
After the discovery that blood transfusion and pregnancy can lead to the induction of 
leucocyte-reactive antibodies,1-3 it soon became clear that the antigens recognised by 
these antibodies played a pivotal role in the immune response leading to graft rejection 
after kidney transplantation. When donors and recipients had the same HLA type, graft and 
patient survival was significantly better than in case of HLA mismatched transplants.4 These 
first results were obtained with transplants using living related donors, often siblings of 
the patient, which made the chance of transplanting an HLA identical graft relatively high. 
Selection of an HLA identical unrelated donor is far more difficult, due to the enormous 
polymorphism of the HLA system. Only in case a large pool of unrelated donors is available, 
full HLA matching on the serological level might become feasible. In order to reach this goal, 
the international organ exchange organization “Eurotransplant” was founded in 1967 by Jon 
van Rood.5 By creating a common waiting list and a common donor pool of several countries 
in Europe, HLA matching became a realistic option, at least for a subpopulation of patients. It 
appeared that this initiative was successful, as about 20% of the patients within Eurotransplant 
were transplanted with an HLA-A, -B, -DR identical donor, which was associated with superior 
graft survival compared to HLA mismatched transplants.6 Unfortunately, still the majority of 
patients were transplanted with a (partially) HLA mismatched graft. Nonetheless, it appeared 
that decreasing the number of HLA mismatches was already a tool to minimise sensitization 
and prevent early graft loss. During the years following, more efficient immunosuppression 
became available leading to prolonged graft survival, also in HLA mismatched transplants. 
Nevertheless, sensitization towards HLA still occurs, and those patients are at risk for early 
graft loss.7 Moreover, once sensitized the chance of finding a suitable donor organ for a patient 
becomes far more difficult. Recently, several approaches of alternative HLA matching have 
been described to prevent the induction of DSA in order to improve graft survival. Knowledge 
of the exact amino acid sequence of the different HLA antigens appears to be crucial for 
the selection of an optimally HLA mismatched donor.8 In this review, we will focus on the 
differential immunogenicity of epitopes, the requirement for T cell help and the difficulties 
in determining the exact binding determinants of HLA antibodies.
From HLA antigens towards HLA epitopes
Soon after the serological identification of HLA antigens it became clear that HLA molecules 
belonged to a highly polymorphic system. While the introduction of molecular typing was 
crucial for a more accurate definition of HLA antigens, it also resulted in an enormous increase 
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of the number of HLA alleles reported. At the moment, more than 15 000 alleles are known 
and it is to be expected that this number will increase far more by broader application of next 
generation sequencing as a tool for HLA typing. At fi rst glance, these developments make the 
selection of an HLA mismatched donor organ that will not induce DSA a mission impossible.
Fortunately, knowledge on the exact amino acid sequence of the diff erent HLA alleles has 
given more insight in the crucial positions on the HLA molecules for the induction and 
reactivity of allo-antibodies. Already in the early days of HLA, when the HLA antigens were 
still serologically characterised with allo-anti-sera, it became clear that the diff erent HLA 
molecules share antigenic determinants that we now call epitopes9. Several CREGs (Cross 
REactive Groups) could be identifi ed based on their shared reactivity with the same allo-
antibodies.10 However, for an optimal characterization of the epitopes expressed by the 
diff erent HLA antigens, molecularly HLA typing at the allele level is crucial.8 Nowadays it is 
clear that every HLA antigen consists of a unique set of antibody epitopes, while the individual 
epitopes can be shared by multiple HLA antigens.11 The consequence is that the number of 
foreign antibody epitopes varies within the same level of HLA antigen mismatches (Figure 1). 
Some HLA mismatches have many epitopes not shared by the HLA antigens of the patient. 
These mismatches are likely to be more immunogenic compared to an HLA mismatch which 
shares most epitopes with the patient. Several tools have been developed to determine the 
relative immunogenicity of an HLA mismatch on basis of this principle.
Patient HLA
Donor A: 4 epitope mismatches
Donor B: 3 epitope mismatches
Donor C: 1 epitope mismatch
Figure 1: HLA alleles can be considered as a string of potential antibody epitopes. A specifi c HLA 
allele consists of a unique set of epitopes while the individual epitopes can be shared with other alleles. 
The consequence is that the number of foreign epitopes on an individual HLA mismatch can diff er and 
depends on the HLA type of the potential antibody producer.
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Tools to define the immunogenicity of an HLA mismatch
The first individual who realised that the patchwork character of HLA molecules with respect 
to antibody epitopes could provide a basis to determine the immunogenicity of foreign 
HLA molecules, was Rene Duquesnoy in Pittsburgh. He defined HLA molecules as strings 
of crucial amino acid polymorphisms, which potentially can trigger an antibody response.12 
Originally these polymorphisms were defined as consisting of three amino acids, adjacent 
to each other on antibody accessible sites of the molecule, called triplets. Later, Duquesnoy 
redefined the crucial polymorphism as amino acids within 3 Ångstrom radius, structurally 
near to each other on the tertiary conformation of the HLA molecule, called eplets.13 The 
computer algorithm HLAMatchmaker made it possible to compare the triplets or eplets on 
a foreign HLA molecule with those present on the patient’s own HLA molecules.14 During the 
past years, several studies demonstrated clear associations between the number of triplets or 
eplets on a mismatched HLA antigen and the chance that a patient develops de novo DSA.15-18 
Both in case of mismatched HLA class I and HLA class II antigens, the incidence of antibody 
formation increases with the number of foreign triplets or eplets. Some studies even suggest 
that it is possible to define a threshold of a certain number of eplets, which predicts whether 
antibody production will occur.19 However, even a very low number of mismatched eplets 
can already give rise to DSA formation as was already shown by the studies of Dankers et al., 
which demonstrated a clear association between the number of mismatched triplets and 
the chance that a patient will develop de novo DSA.16 In case of 12 or more triplet mismatches 
100% of the patients, who rejected their graft, had developed DSA but also in case of one or 
two triplet mismatches respectively 10% and 22% of the patients produced DSA. Furthermore, 
it remains to be established whether the definition of the number of foreign eplets is the 
optimal way to predict the immunogenicity of an HLA antigen. A similar predictive value has 
been demonstrated if one considers the total number of antibody-accessible amino acid 
substitutions of the mismatched HLA antigen in comparison with the own HLA antigens of 
the patient.20
A completely different approach has been developed by the Cambridge group. Their studies 
show a clear role of the physiochemical properties of mismatched amino acids. If the 
physiochemical properties of mismatched amino acids are very different from those of the 
own HLA antigens of the patients, induction of donor specific antibodies is far more likely 
than in case of similar properties.20-22 They have validated a score system (EMS-2D), which 
determines the degree of foreignness of the physiochemical characteristics, both for the 
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induction of DSA after renal transplantation and after blood transfusion. The higher the score, 
the more likely it is that a patient will make antibodies.
The different approaches, which consider polymorphisms on antibody accessible sites of 
the donor HLA molecule, all suggest that quantitative aspects i.e. the number of foreign 
triplets, eplets, amino acids play a crucial role but do not consider a potential difference in 
the immunogenic properties of the individual polymorphisms.23
Differential immunogenicity of individual “epitopes”
Although the relationship between the number of triplet/eplet mismatches and the chance to 
develop DSA is well established, the immunogenicity of the individual triplets/eplets may vary. 
Not every polymorphic site has the same immunogenic potential and one could hypothesise 
that a higher number of triplet/eplet mismatches makes it likely that one of these is particularly 
immunogenic. This is also suggested by a study on the development of DSA associated with 
graft loss in a cohort of 1311 previously nonimmunized males, who returned on the waiting 
list of Eurotransplant after failure of their first transplant. This study, which focused on the 
development of antibodies against HLA-A and -B showed that some mismatched triplets led 
to antibody formation in about 50% of the cases whereas others led to a lower incidence of 
DSA or hardly induced any antibodies (Table 1). Similarly to the frequencies of HLA alleles, 
which differ amongst populations, the frequency of potential antibody epitopes will also 
be different between populations in the world (www.allelefrequencie s.net). The chance 
that a particular HLA allele mismatch will induce antibodies depends amongst others on 
the frequency of its most immunogenic epitope in the population. If this frequency is high, 
it is more likely that donor and recipient share this epitope, resulting in a low number of 
patients with that antibody specificity. If the frequency of the immunogenic epitope is low 
in a population, the incidence of antibody formation against that HLA allele in case that it is 
mismatched will be high. A preliminary study comparing the incidence of antibody formation 
in transplant recipients in Israel versus Eurotransplant confirms this hypothesis (Israeli et al. 
manuscript in preparation). These data suggest that future matching strategies should not 
only focus on the number of mismatched eplets, triplets or amino acids but, especially, on 
prevention of mismatches for highly immunogenic polymorphisms. In order to be able to 
reach this goal, it is crucial to identify the immunogenicity of the different polymorphisms with 
respect to the induction of allo-antibodies. This is one of the aims of the 18th International 
Histocompatibility workshop, which will take place in Amsterdam in 2021. By collecting 
information on the incidence of de novo DSA in a large group of high resolution typed donor 
recipient combinations from different populations, it should be feasible to identify the most 
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immunogenic antibody epitopes. In future allocation, these should be avoided as a mismatch 
in order to prevent the induction of DSA. The other side of the coin is the identification of 
polymorphisms, who do not lead to allo-antibodies in an individual patient and are likely to 
serve as acceptable mismatches.
Table 1. The immunogenicity of individual epitopes differs as demonstrated by analysing the epitope 
specificity of donor specific antibody (DSA) developed in previously nonsensitized males, who returned 
on the waiting list after failure of their first kidney transplant
Positions + amino acids Yes DSA No DSA % DSA Donor mismatches
79G 80T 81L 30 23 56.6 A23 A24 A25 A32
11A 12M 13S 55 49 52.9 B7 B18 B27 B37 B38 B39 B46 B48 B61
150A 151H 152V 104 95 52.3 A1 A3 A11 A23 A25 A26 A29 A30 A31 A32 A33
126L 127K 128E 102 94 52 A1 A3 A11 A25 A26 A29 A30 A31 A32 A33
130L 131S 132S 30 30 50 B7 B8
73I 74D 75R 14 47 23 A31 A33
73R 76E 77D 20 69 22.5 B27 B37 B47
185P 186R 187T 1 15 6.3 A33
Very immunogenic epitopes are associated with specific antibodies in more than 50% of the cases at risk 
whereas other epitopes are less immunogenic.
An additional role for T cell epitopes
The majority of the donor specific antibodies that develop after transplantation belong to 
the IgG class. Production of IgG antibodies is only feasible if CD4+ T cells provide help to the 
B cells, as without such an interaction activation of B cells will only lead to IgM antibodies. 
T cell help is based on the recognition of peptides derived from allogeneic HLA molecules 
presented by the HLA class II molecules on the B cell (Figure 2). Whereas B cell epitopes 
solely reside on antibody accessible locations, polymorphisms throughout the HLA molecule 
can theoretically give rise to T cell epitopes. Indeed, studies on the location of B cell and T 
cell epitopes showed overlapping regions, as one would expect, but also the presence of T 
cell epitopes in areas where no B cell epitopes were present.24 Identification of the actual 
peptides, which function as targets for this so called indirect allorecognition by CD4+ T cells, 
has shown to be very difficult due to the low frequency of indirectly recognizing T cells.25 
Nonetheless, a computer algorithm has been developed, which calculates the number of 
potential allogeneic peptides derived from the mismatched HLA molecule that are able to 
bind to the HLA-DR molecules present on the B cells of the recipient.26 This PIRCHE approach 
(Predictable Indirectly ReCognizable HLA Epitopes) has shown to be of additional value for 
the prediction of the chance that donor specific antibodies will be produced.26-28 An increased 
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number of theoretical T cell epitopes is associated with a higher chance that a patient will 
start to make antibodies to a mismatched HLA antigen. A recent publication showed that the 
number of PIRCHE mismatches and the number of eplet mismatches were independent risk 
factors for both the development of DSA after transplantation, and graft outcome.18 Similar 
to B cell epitopes, the challenge is to discriminate the actual immunogenic PIRCHEs from 
the non-immunogenic theoretical ones. It is to be expected that a combinatorial approach, 
focussing on the identification of both B cell and T cell epitopes, will be the optimal basis of 
future matching strategies.
1
2
3
T cell
B cell
5
4
CD40L
ICOS
Cytokines
Figure 2: The production of IgG antibodies depends on a specific interaction between CD4+T cells 
and B cells. 1: The B cell receptor recognises an epitope on a foreign HLA molecule. 2: This leads to inter-
nalization of the target antigen, which is then degraded into peptides. 3: Some of these peptides bind to 
the HLA class II molecules on the B cell and the foreign (non-self) peptides are recognised by CD4+ T cells. 
4: This leads to activation of the T cells associated with the production of immunoregulatory molecules. 
5: These molecules trigger a class switch of the antibodies produced.
Immunogenic determinants versus actual antibody epitopes
So far, the immunogenicity of an HLA mismatch for the humoral immune response has 
been discussed with a special emphasis on the predictive value of polymorphic structures 
which serve as a trigger for, or are associated with, the induction of an antibody response. 
As discussed above, these structures are rather simple and consist of one or a few amino 
acids. However, the actual antibody epitope, which consists of the crucial contact sites on 
the HLA molecule necessary for the interaction with antibody molecule is far more complex. 
In principle, an antibody molecule has a paratope, consisting of six so called complementary 
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determining regions (CDRs), three on the heavy chain and three on the light chain, which 
interact with the HLA antigen recognised. The interaction of the epitope with these CDRs 
leads to a kind of footprint on the HLA molecule (Figure 3). The specificity of the antibody is 
determined by the amino acids on the HLA molecule, which interact with the CDR3 on the 
heavy chain of the immunoglobulin molecule. These amino acids include the triplets/eplets, 
which were responsible for the induction of the antibody response. The other contact sites 
contribute to the stability and avidity of the interaction between antibody and antigen. In 
order to be able to predict the HLA antigen reactivity pattern of an antibody, it is essential 
to determine which of these interactions are crucial for proper binding of the antibody. In 
some cases, antigens only sharing the polymorphism interacting with the CDR3 with the 
immunizing antigen, are already targets for an alloantibody. In other cases an additional 
requirement is that one or more other CDRs bind exactly the same amino acids as present 
on the immunizing antigen. The use of human HLA-specific monoclonal antibodies (mAbs) 
has been instrumental for the definition of actual antibody epitopes, while also absorption 
elution experiments are suitable to define the crucial polymorphisms defining an antibody 
epitope. A dedicated website has been developed to register the actual antibody epitopes 
on the different HLA antigens.29,30 It is clear that some of the epitopes can be easily defined, 
while others are more complex, as shown below.
Definition of the actual HLA antibody epitope can be difficult, even with 
monoclonal antibodies
Both human mAbs and absorption/elution studies with alloantisera have been very 
instrumental for the definition of the actual antibody epitopes on the HLA molecules.31-33 
These verified epitopes are registered at the epitope registry (http://www.epregistry.com.br). 
As mentioned above, antigen-antibody interaction involves six CDRs of which the CDR3 binds 
to the immunogenic epitope and determines the specificity of the antibody. In most cases, 
the presence of this immunogenic epitope, alone or in combination with one or two other 
polymorphic sites, can explain the antibody reactivity pattern with the different HLA alleles 
(Table 2, Figure 3A, B, monoclonal antibodies MUS4H4 and VTM9A10). However, sometimes 
very complicated reaction patterns are observed, which make it virtually impossible to define 
an epitope that explains all antibody reactivities.
Here we describe an example of an HLA-A*11:01 induced mAb, WIM8E5, derived from a 
woman who became sensitised during pregnancy by paternal antigens. The trigger of the 
antibody response can be any foreign amino acid on the mismatched HLA, dependent on 
the phenotype of the mother. In this case, comparison of all the HLA class I molecules of 
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the mother with the immunising HLA-A*11:01, reveals that there are only two amino acid 
differences, which may have triggered the antibody response. However, if we compare only 
the HLA-A molecules of the mother with HLA-A*11:01, there are six amino acid differences.
When WIM8E5 was screened with single antigen bead (SAB) assays of two independent 
vendors, a broad HLA antigen reactivity was observed, including specificities of all three 
classical HLA class I loci. In contrast to other mAbs, the reactivity of WIM8E5 cannot be 
explained by the fact that the reactive alleles share the immunogenic epitope and some other 
crucial amino acid configurations, which are absent on the non-reactive antigens. Almost 
all HLA-A antigens are reactive, except for three, including the self-antigens. In addition, 
some HLA-B and HLA-C antigens were reactive. Extensive comparisons of the amino acid 
composition of the different reactive HLA antigens did not lead to a clear definition of an 
antibody epitope (Figure 3C).
Others have shown that dilution of serum samples can clarify the patterns observed in SAB 
assays.34 Dilution of WIM8E5 led to a decrease in the breadth of reactive HLA antigens. One 
group of HLA-A antigens, including the immunising HLA-A*11:01, remained highly reactive 
in SAB assays upon dilution. The reactivity of the other HLA-A antigens was less consistent 
and decreased with each dilution step, while the reactivity of the HLA-B and HLA-C antigens 
decreased rapidly upon dilution.
Most of the HLA class I epitopes have been defined on the basis of interlocus comparisons 
of amino-acid sequences. However, for WIM8E5 the reactive HLA-C antigens do not have any 
amino acid configuration in common with the reactive HLA-A antigens. However, they do share 
a unique amino acid that is absent on the non-reactive HLA-C antigens. These data suggest 
that the induction of the WIM8E5 antibody was induced by an epitope mismatch specific for 
HLA-A and that the crossreactivity with HLA-B and HLA-C is not based on reactivity of the 
antibody with the same, HLA-A specific epitope.
This example shows that verification of HLA epitopes using mAbs involves more than 
screening the mAb with SAB assay, and just identifying the shared amino acid configurations 
of the reactive antigens. The different reactivity patterns upon dilution of WIM8E5 do support 
the conclusion that different epitopes are involved and that the affinity of the antibody 
for the different target antigens is different. An alternative explanation for the observed 
crossreactivity might be that the reactive antigens have similar physiochemical properties, 
despite amino acid variation within the critical contact site.
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79R 82L
83R
A B
C
173K
MUS4H4 footprint VTM9A10 footprint
WIM8E5 footprint
on HLA-A
WIM8E5 footprint
on HLA-C
Immunogenic Epitope
Crucial amino acid configura�on
Alterna�ve reac�vity
69A
71A
65Q
66I
161E
109F
WIM8E5 footprint
on HLA-B
?
Indifferent
Figure 3: Footprints of human monoclonal antibodies on their target antigens. A) The reactivity of 
monoclonal MUS4H4 depends only on sharing of the immunogenic epitope with the HLA molecule, which 
has triggered the production of this antibody. B) For the reactivity of monoclonal antibody VTM9A10 
sharing of both the immunogenic epitope and an additional contact site with the immunizing antigen is 
crucial. C) The reactivity of monoclonal antibody WIM8E5 is very complex. It appears that the reactivity 
with HLA-A antigens depends on sharing of the immunogenic epitope and an additional contact site. The 
observed cross reactivity with HLA-B and -C antigens has completely diff erent requirements. The reactive 
HLA-C alleles have one particular polymorphic position in common (in green) whereas the basis of the 
reactivity with HLA-B targets remains unclear. Note: more details on the immunizing eff ect leading to the 
production of these antibodies is given in Table 2.
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Table 2. HLA types of the antibody producer and immuniser and epitope specificity of the three monoclonal 
antibodies depicted in Fig. 3
Human mAb HLA antibody 
producer
HLA 
immuniser
Epitopes on reactive HLA class I alleles
HLA-A HLA-B HLA-C
MUS4H4 (IgG)
A*02:01, A*26:01, 
B*39:01, B*41:01, 
C*12:03, C*17:01
A*24:02 79R82L83R 79R82L83R -
VTM9A10 (IgG)
A*25:01, A*29:02, 
B*44:03, B*15:01, 
C*05:01, C*16:01
B*07:02 -
69A71A
(65Q61I)
-
WIM8E5 (IgG)
A*03:01, A*03:02, 
B*47:01, B*51:01, 
C*06:02, C*15:02
A*11:01 161E(109F) ? 173K
? indicates the epitope recognised on HLA-B is unclear.
Concluding remarks
For many years, HLA matching strategies have focused on the selection of donors with a 
minimal number of HLA antigen mismatches. However, it is clear that the immunogenicity 
of mismatched HLA antigens can differ. If one would like to prevent the induction of de novo 
DSA, which is known to be associated with a poor outcome, then limiting the number of HLA 
antigen mismatches is not the optimal strategy. Our view on HLA antigens as possible targets 
for antibodies has been changed considerably over time. Antibodies are not specific for an HLA 
antigen but for an epitope present on the HLA molecule. Every HLA antigen can be considered 
as a string of antibody epitopes. A particular HLA antigen consists of a unique combination 
of epitopes while the individual epitopes can also be expressed on other HLA antigens. This 
is the reason why the number of foreign epitopes present on a mismatched HLA antigen will 
differ and depends on the HLA type of the recipient. Some HLA mismatches express many 
epitopes whereas others have only a few or even no foreign epitope. As a consequence, the 
presence of two HLA antigen mismatches on a donor organ may, for some recipients, be 
associated with fewer epitope mismatches than the presence of a single antigen mismatch. 
Therefore, novel matching strategies aim at the limitation of the number of foreign epitopes 
rather than the number of HLA antigen mismatches. 
Current activities in the field of epitope matching can be divided in two categories. The 
first one is aiming at the prevention of de novo DSA formation by limiting the number of 
potentially antibody inducing polymorphisms on the mismatched HLA molecules. Indeed, 
several tools have been described, which can successfully predict the chance that DSA will 
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be induced.23 These include the number of foreign eplets/triplet, amino-acids or PIRCHE’s, 
and the physicochemical properties of the mismatched HLA molecule. Such parameters are 
already excellent predictors of the immunogenicity of an HLA mismatch and as soon as we are 
able to distinguish the very immunogenic polymorphisms from the non-immunogenic ones, 
their prediction will be even better. However, none of these parameters can be considered as 
the actual antibody epitope. Exact knowledge of the antibody epitope is crucial if one would 
like to introduce epitope matching as a tool for virtual crossmatching of (highly) sensitized 
patients. Human monoclonal antibodies and absorption/elution studies have been very 
helpful for the definition of several antibody epitopes, which are described in the HLA epitope 
registry. At the moment, this collection is far from complete and the example described in 
this review suggests that it will not always be feasible to explain the possible reactivity of an 
HLA antibody based on the knowledge of the amino acid sequence of the immunizing antigen. 
In conclusion, “epitope” matching is superior over antigen matching with respect to the 
prevention of de novo DSA formation and will enhance the prediction of acceptable HLA 
mismatches for sensitized patients. However, one should realise that epitope matching at our 
current level of understanding will not solve all histocompatibility problems, as unexpected 
antibody reactivity still may occur. 
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ABSTRACT
In the field of transplantation, the humoral immune response against mismatched HLA 
antigens of the donor is associated with inferior graft survival, but not in every patient. Donor-
specific HLA antibodies (DSA) of different IgG subclasses may have differential effects on the 
transplanted organ. Recombinant technology allows for the generation of IgG subclasses of 
a human monoclonal antibody (mAb), while retaining its epitope specificity. 
In order to enable studies on the biological function of IgG subclass HLA antibodies, we 
used recombinant technology to generate recombinant human HLA mAbs from established 
heterohybridomas. We generated all four IgG subclasses of a human HLA class I and a class 
II mAb and showed that the different subclasses had a comparable affinity, normal human Fc 
glycosylation, and retained HLA epitope specificity. For both mAbs, the IgG1 and IgG3 isotypes 
were capable of binding C3d and efficient in complement-dependent cell lysis against their 
specific targets, while the IgG2 and IgG4 subclasses were not able to induce cytotoxicity. 
Considering the fact that the antibody-binding site and properties remained unaffected, these 
IgG subclass HLA mAbs are excellent tools to study the function of individual IgG subclass 
HLA class I and class II-specific antibodies in a controlled fashion.
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INTRODUCTION
In the field of transplantation, the induction of a humoral immune response to mismatched 
HLA antigens on the donor kidney is associated with graft rejection and inferior graft survival, 
but only in a subpopulation of patients.1-3 The various clinical effects may be caused by the 
(mixture of) IgG subclass of produced donor-specific antibodies (DSA).4-7 Indeed, various 
patterns of IgG subclasses have been observed in sera of transplanted patients that developed 
de novo DSA. However, their relative contribution to graft damage remains elusive, due to 
conflicting results on their clinical significance.7,8
The pathogenicity of an HLA antibody is determined by both the affinity for the HLA epitope 
recognised by the Fab part and the effector function of the antibody, defined by the Fc part. 
Indeed, the degree of complement activation and the binding capacity to Fc gamma receptors 
(FcγR) differs per IgG subclass.9-11 In renal transplantation, DSA capable of complement 
activation, e.g. IgG1 and IgG3, are associated with allograft loss.7,12-14 However, other studies 
have implied that the presence of IgG2 and IgG4 can act either synergistically or inhibitory 
on complement activation, depending on the epitopes recognised.15,16 Additionally, HLA 
IgG antibodies have been associated with graft damage independent of the complement 
cascade.17-19 Binding of DSA to endothelial cells can lead to infiltration of macrophages causing 
antibody-mediated rejection, of which the severity is increased in case of IgG1 and IgG3 
antibodies, due to their capacity to bind FcγR.19 Furthermore, binding and crosslinking of HLA 
targets on endothelial cells can result in intracellular signalling, resulting in cell proliferation 
and initiation of coagulation.18,20,21
Thus, understanding the underlying mechanisms of IgG HLA antibody-mediated graft 
damage can contribute to the establishment of risk factors associated with antibody-
mediated rejection. Several methodological studies on the effect of HLA antibodies in renal 
transplantation have been performed using human HLA monoclonal antibodies (mAbs).16,19,22-25 
However, these studies are restricted to the available human HLA mAbs, which are mainly of 
the IgG1 subclass. Therefore, we adapted a method to recombinantly generate and produce 
human mAbs of all four IgG subclasses, with the aim to generate HLA class I and class II-
specific mAbs of all IgG subclasses recognising the same HLA epitope with the same affinity.
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MATERIALS AND METHODS
B cell heterohybridomas
Human B cell heterohybridomas WIM8E5 (IgG1, κ) and RTLK1E2 (IgG1, κ), that had been 
established from two women who had been immunised during pregnancy by mismatched 
HLA-A*11:01 and HLA-DRB1*03:01 respectively, were used to generate recombinant human 
HLA class I and class II-specific mAbs.25 Heterohybridoma cells were cultured in Iscove’s 
modified Dulbecco’s medium supplemented with 100 U/ml penicillin, 100 μg/ml streptomycin, 
10% fetal bovine serum, 200 mM L-glutamine (all Gibco, Invitrogen, Paisley, UK), 50 μM 2 
mercapto-ethanol (Sigma-Aldrich, Zwijndrecht, the Netherlands).
Generation of human recombinant IgG1 HLA mAbs
RNA was isolated from heterohybridoma cells using RNeasy mini kit (Qiagen, Hilden, Germany). 
Next, SMART cDNA synthesis was performed using PrimeScript Reverse Transcriptase (Takara, 
Saint-Germain-en-Laye, France), and variable heavy chain (VH) IgG1, and variable light chain 
(VL) kappa (k) or lambda (l) gene products were amplified by 5’-RACE PCR. The VH and VL 
PCR products were purified with QIAquick gel extraction kit (Qiagen) and treated with T4 
DNA polymerase (Bioké, Leiden, the Netherlands). Subsequently, the VH and VL products 
were ligation-independently cloned into pcDNA3.3 expression vectors26 with the constant 
domains of the human IgG1 (IGHG1*03), k (IGKC), or l (IGLC2*01). The vectors were used 
for transformation of One Shot MAX Efficiency DH5α-T1R competent cells (ThermoFisher 
Scientific, Waltham, MA, USA) by heat shock. The transformed cells were cultured on LB-agar 
plates supplemented with 50 μg/ml ampicillin (Sigma-Aldrich) and after overnight incubation 
at 37°C, multiple single colonies were picked and grown overnight in LB medium containing 
ampicillin. From the cultures, plasmids were isolated using either QIAprep Spin Miniprep 
kit (Qiagen) or NucleoBond Xtra Midi EF (Bioké). The plasmids were sequenced by Sanger 
sequencing (Macrogen, Amsterdam, the Netherlands) to verify the hybridisation of VH and 
VL products with the expression vector. All kits were used according to manufacturer’s 
instructions.
Generation of human recombinant IgG subclass HLA mAbs
To generate recombinant IgG subclass HLA mAbs, the IgG1 plasmid was double digested with 
the appropriate restriction enzymes (Bioké). Simultaneously, pMK vectors containing IgG2 
(IGHG2*02), IgG3 (IGHG3*01), or IgG4 (IGHG4*01) constant domains (ThermoFisher Scientific) 
were double digested the same way to obtain the constant domains. Next, the IgG subclass 
constant domain was ligated with the digested vector by T4 DNA ligase (Bioké). Subsequently, 
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plasmids were generated as described above. Plasmids were sequenced to verify ligation of 
constant domain with the vector and to check if any mutations had occurred. No adaptation 
was made to the light chain.
Production of human recombinant IgG HLA mAbs
For recombinant mAb production, heavy and light chain containing vectors were used for 
transient co-transfection of Expi293F cells with ExpiFectamine, Opti-MEM, and Expi293 
expression medium (ThermoFisher Scientific) according to the instructions provided by the 
manufacturer. After five days of culture, supernatants containing the recombinant mAbs were 
harvested and filtered. The presence of IgG was determined by total IgG ELISA, as previously 
described.27 IgG specificity of the different subclasses was confirmed by a human IgG subclass 
ELISA kit (ThermoFisher Scientific).
Purification of recombinant IgG HLA mAbs
The recombinant mAbs were purified using Amicon ProAffinity Concentration Kit Protein G 
(Merck Millipore, Burlington MA, USA). A maximum of 1000 μg mAb was loaded onto 200 μl 
Protein G resin and incubated for 60 min at room temperature on a roller bench. After wash 
steps, mAb was eluted and neutralised. Next, the buffer was exchanged with phosphate 
buffered saline (PBS, B Braun, Melsungen, Germany) using a Slide-a-lyzer 0.5-3 ml dialysis 
cassette (ThermoFisher Scientific) by incubating the cassette in beaker with PBS for 21 h at 4°C, 
PBS was refreshed a couple of times during incubation. The concentrations of purified mAbs 
were measured using the protein A280 protocol of NanoDrop2000 (ThermoFisher Scientific), 
and molar concentration were calculated for each mAb.
HLA antibody detection
For verification of the IgG subclasses, the supernatants were screened with Lifecodes 
Lifescreen Deluxe screening kit (Immucor Transplant Diagnostics, Stamford, CT, USA) modified 
by using anti-IgG1 (10 μg/ml; HP6001), anti-IgG2 (2.5 μg/ml; HP6002), anti-IgG3 (10 μg/ml; 
HP6050), and anti-IgG4 (2.5 μg/ml; HP6025) PE-conjugated detection antibodies (Southern 
Biotech, Birmingham, AL, USA). 
The HLA specificities of the recombinant mAbs were determined by screening the recombinant 
mAbs with Lifecodes HLA class I or II single antigen beads (SAB) using goat anti-human Pan-
IgG PE-conjugated on a luminex platform (Immucor). The ability of recombinant mAbs to 
bind C3d was tested with Lifedcodes C3d detection (Immucor). Both Lifecodes kits were used 
according to manufacturer’s instructions. The data was analysed with Match It! Antibody 
software version 1.3.0 (Immucor).
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Bio-layer interferometry 
Affinity of antibody to antigen was determined via bio-layer interferometry (BLI) using the 
Octet RED96 system (FortéBio, Fremont, CA, USA). HLA IgG subclasses from WIM8E5 were 
immobilised to anti-human IgG Fc kinetic biosensors with a response threshold of 0.6 nm. To 
determine the association phase, parallel sensors were dipped into wells containing soluble, 
recombinant HLA-A*11:01 in a two-fold titration from 200 nM to 6.25 nM for 300 seconds 
so an equilibrium could be reached. Next, sensors were placed into buffer alone-containing 
wells for a further 1000 seconds to determine the dissociation phase. Affinity values (KD) 
were calculated via steady state analysis, where the response equilibrium (Req) was plotted 
against the HLA analyte concentration for each sensor and KD values were measured as the 
HLA concentration of 50% of the overall calculated maximum response (Rmax). All experiments 
were carried out using standard kinetic buffer (1x PBS, 0.1% bovine serum albumin, 0.02% 
Tween-20), at a temperature of 30°C and a constant plate shake speed of 1000 rpm. 
Fc domain glycosylation profiling
Of WIM8E5 and RTLK1E2 IgG subclasses, 2 µg sample was added to a final volume of 20 µl 
PBS and affinity captured with ProtG beads. After desalting, the mAbs were eluted with 100 
µl 100 mM formic acid and subsequently vacuum dried at 60°C. The dried samples were 
resuspended in 40 µl digestion solution consisting of 25 mM ammonium bicarbonate and 
5 ng/µl sequencing grade trypsin and followed by overnight digestion at 37°C to obtain 
tryptic glycopeptides. Fc glycosylation was measured by nano liquid chromatography mass 
spectrometry of glycopeptides followed by data processing using LaCyTools as previously 
described.28 From the relative abundances of the glycopeptides the levels hybrid-type, high-
mannose, and complex-type Fc N-glycans as well as the level of galactosylation, fucosylation, 
bisection, and sialylation were calculated.
Cells
HLA-typed peripheral blood mononuclear cells (PBMCs) were isolated from buffy coats 
obtained from healthy donors after informed consent (Sanquin Blood Supply, Amsterdam, 
the Netherlands). PBMCs were isolated by Ficoll-Hypaque density gradient centrifugation and 
cryopreserved until further use. For the cytotoxicity experiment with RTLK1E2 mAbs, B cells 
were magnetically isolated from PBMCs using EasySep direct HLA cross-match B cell isolation 
kit (Stemcell Technologies, Köln, Germany) with a purity of >90%.
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Complement-dependent cytotoxicity assay
Terasaki plates (Greiner) were oiled and filled with 1 μl of supernatant containing the mAb 
of interest in triplicate. Then, 3000 HLA typed PBMCs or B cells were added to each well and 
incubated for 60 min at 20°C. Next, 5 μl rabbit complement (Inno-train, Kronberg, Germany) 
was added and incubated for 60 min at 20°C. To visualise cytotoxicity, 5 μl propidium iodide 
ink was added to each well, and after 15 min incubation in the dark the plates were analysed 
with Patimed (Leica Microsystems, Amsterdam, the Netherlands).
Statistical analysis
The Kruskal-Wallis test was used for unpaired analysis and the Friedman test was used for 
paired analysis. Statistical level of significance was defined as p<0.05, and analyses were 
performed with GraphPad Prism, version 7.02 (GraphPad Software, La Jolla, CA, USA).
RESULTS
Recombinant human IgG subclass HLA mAbs
Genes encoding the variable heavy chain and light chain domains were cloned into expression 
vectors, after which recombinant antibodies can be expressed by transient co-transfection 
of both vectors.29-31 Here, we generated recombinant human HLA class I and class II mAbs, 
WIM8E5 and RTLK1E2 respectively, of all four IgG subclasses. To verify IgG subclass, the 
supernatant of all four IgG subclass mAbs were screened with IgG subclass ELISA and a 
modified luminex screening assay using detection antibodies specific for each IgG subclass. As 
shown in Figure 1, the specific IgG constant domains were recognised by the correct detection 
antibody, indicating that mAbs of all four IgG subclasses were produced.
To corroborate that HLA specificities remained unaffected by the recombinant technology, 
original hybridoma-generated mAbs and recombinant human IgG subclass mAbs were 
screened with HLA class I or II SAB luminex assay. Upon comparison of the background 
corrected mean fluorescence intensity (BCM) values of both WIM8E5 (Figure 2A) and RTLK1E2 
(Figure 2B) mAbs, no difference in HLA specificities was observed with the original hybridoma-
generated mAb for both recombinant IgG subclass HLA mAbs.
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Figure 1: Recombinant IgG subclass HLA mAbs could be detected by the corresponding IgG-specific 
detection antibody. IgG subclass could be detected with IgG subclass ELISA kit for both WIM8E5rec-IgG 
mAbs (A) and RLTK1E2rec-IgG mAbs (B). Positive control is a human serum. (C) Similar findings were ob-
served when screening recombinant WIM8E5 IgG subclass mAbs with Lifecodes Lifescreen Deluxe kit. 
The kit contains seven groups of HLA class I beads and each data point represents a single bead group. 
Kruskal-Wallis test was used to compare median of all four detection antibodies per IgG subclass mAb. 
Error bars represent median ± interquartile range. MFI is mean fluorescence intensity. OD is optical den-
sity. ***P<0.001, ****P<0.0001
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Figure 2: The same HLA epitope is recognised by the recombinant IgG subclass HLA mAbs. HLA 
specificities of recombinant IgG1, IgG2, IgG3, and IgG4 of WIM8E5 mAb (A) and RTLK1E2 mAb (B, only DRB 
beads shown as all other loci were negative) as detected by luminex SAB assay. Purified recombinant mAb 
concentration tested was 62.5nM. BCM is background corrected mean fluorescence intensity.
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Affinity and Fc domain glycosylation is similar between IgG subclasses
As the recombinant IgG subclass HLA mAbs have the same HLA specificity, we next questioned 
whether these mAbs have the same affinity for the immunizing HLA allele. Therefore, the 
recombinant IgG subclass WIM8E5 mAbs were tested with bio-layer interferometry (BLI). The 
affinity values (KD) observed for the target HLA-A*11:01 were in the range of 25-32 nM for all 
four IgG subclass WIM8E5 mAbs (Figure 3).
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Figure 3: Recombinant IgG subclass HLA mAbs have similar affinity. The affinity (A) and dissociation 
rates (B) of recombinant IgG subclass WIM8E5 mAbs were determined via bio-layer interferometry. Calcu-
lated values are consistently similar across all IgG subclasses against the target HLA-A*11:01. The dotted 
lines represent the affinity (A) and dissociation constant (B) average across all four IgG subclasses. Error 
bars represent the mean ± standard deviation of 3 experiments.
For mAb production Expi293F cells are used, so we wanted to determine if the correct 
human glycosylation was present on the Fc part of the generated mAbs. The glycosylation 
characterisation of the generated recombinant IgG subclass HLA class I and class II mAbs 
showed that the IgG subclasses have a similar profile (Figure 4). In addition, the observed 
glycosylation traits of the mAbs are in accordance with those found on IgG in human serum 
using the same method.32 However, the relative levels of bisection (the presence of a bisecting 
N-acetylglucosamine) and sialylation are lower on the mAbs, as compared to what is generally 
found on IgG in human serum, while the abundance of high mannose-type species is higher.32 
For IgG3, we detected partial occupancy of the O-glycosylation sites in the hinge region (data 
not shown), which is in line with the hinge region O-glycosylation of IgG3 from the human 
circulation.33
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Figure 4: The glycosylation profile of recombinant IgG subclass HLA mAbs is similar. Relative intensity 
values of derived traits for the recombinant IgG1, IgG2, IgG3, and IgG4 of WIM8E5 mAb (A) and RLTK1E2 
mAbs (B) are shown.
Cytotoxicity of recombinant human IgG subclass HLA mAbs
To determine whether the recombinantly generated IgG subclass HLA-specific mAbs showed 
the anticipated cytotoxicity patterns, we performed complement-dependent cytotoxicity 
(CDC) assays. Incubation of WIM8E5 recombinant IgG subclass mAbs with PBMCs expressing 
HLA antigens recognised by WIM8E5 (HLA-A11, -A1) showed that WIM8E5rec-IgG1 and -IgG3 
mAbs were highly cytotoxic in a dose-dependent manner (Figure 5A). Both IgG2 and IgG4 
subclasses did not show cytotoxicity. For the HLA class II mAb RTLK1E2 a CDC using purified B 
cells (HLA-DR17, -DR13) was performed. Both RTLK1E2rec-IgG1 and -IgG3 were highly cytotoxic 
(Figure 5B). While CDC with rabbit complement is standard practice in transplantation, it 
does not show if mAbs can also activate human complement. Testing the recombinant IgG 
subclass HLA mAbs with C3d SAB assay showed that only IgG1 and IgG3 mAbs are capable 
of binding human C3d (Supplementary Figure 1), suggesting that these mAbs can activate 
human complement.
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Figure 5: Recombinant IgG1 and IgG3 HLA mAbs are cytotoxic. (A) Recombinant IgG subclass WIM8E5 
mAbs were incubated with PBMC expressing HLA-A1, -A11, -B8, -B55, -Cw3, and -Cw7. WIM8E5rec-IgG1 
and -IgG3 induced cell lysis (>60%), while IgG2 and IgG4 were unable to induce complement cytotoxicity. 
(B) Recombinant IgG subclass RTLK1E2 mAbs were incubated with B cells expressing HLA-DR17, -DR13 
and -DR52. RTLK1E2rec-IgG1 (>80%) and -IgG3 (>60%) induced cell lysis, while no cell lysis was observed 
for RLTK1E2rec-IgG2 and RTKL1E2rec-IgG4. mAbs were added in various concentrations (1000, 500, 250, 
125, 62.5, 31.25, and 15.62nM). Error bars represent the mean ± standard deviation of triplicate wells. The 
Kruskal-Wallis test was used per dilution to compare the IgG subclass HLA mAbs. Dotted line indicates 
background. ****P<0.0001 ***P<0.001, **P<0.01, *P<0.05
DISCUSSION
In this study, we show the generation and production of recombinant human HLA class I and 
class II-specific mAbs of all four IgG subclasses from established B cell heterohybridomas. 
The generated recombinant HLA mAbs of all four IgG subclasses recognise the same HLA 
epitope with the same binding affinity. Currently, we were only able to determine the affinity 
for the HLA class I mAbs, due to lack of recombinant HLA class II. Furthermore, we show 
that all recombinant IgG subclass HLA mAbs have human-type Fc glycosylation and the 
glycosylation profiles were similar between the mAbs. The conserved N-glycans located at 
asparagine 297 of the Fc part play a role in the function of an antibody and the different levels 
of specific glycosylation traits could have pronounced effects on complement activation and 
FcγR binding.34,35 Both IgG1 and IgG3 HLA class I and class II mAbs are capable of complement 
activation, while a weak or no cytotoxicity was observed for the IgG2 and IgG4 mAbs. 
Preliminary data suggest that IgG1 and IgG3 can induce antibody-dependent cell-mediated 
cytotoxicity (ADCC), but only a low percentage of cell lysis was observed (Supplementary 
Figure 2). This can be explained by the high levels of fucosylation (>96%) on the recombinant 
IgG subclass HLA mAbs, as it has been shown that high levels of fucosylation on IgG negatively 
influences ADCC activity.36 Glyco-engineering of our recombinant IgG subclass HLA mAbs may 
further allow altering their functional properties.37
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Currently available human HLA mAbs are mainly derived from multiparous women by Epstein-
Barr virus transformation and electrofusion using mouse myeloma cell line, are primarily 
directed against HLA class I, and are restricted to an IgM or IgG1 isotype.25,38,39 These human 
HLA mAbs have been widely used in various applications, such as flow cytometry assays,40-42 
B-cell ELISPOT assays,43-45 blocking assays,46 assays to determine HLA expression levels,47-49 
or functional assays of HLA antibodies.16,19,22-24 Commercial chimeric IgG subclass HLA mAbs 
are available, but those have a mouse variable part, while W6/32 and F3.3 recognise all HLA 
class I molecules and majority of HLA class II molecules respectively.50 
Recently, Gu et al.51 elegantly characterised an HLA class I mAb generated by a germline 
phage display from a non-sensitised individual, resulting in an antibody that likely can be 
generated during an alloimmune response. In contrast we have produced human recombinant 
HLA mAbs generated from heterohybridomas that were derived from B cells of immunised 
individuals. Therefore, the mAbs we produced are truly representative of HLA antibodies 
produced through alloimmunisation. In addition, we generated both human HLA class I and 
class II mAbs of all four IgG subclasses. Especially the latter is unique, as there are only a 
limited number of HLA class II mAbs available and those are mainly IgG1.
Antibody effector function is determined by its isotype. As mentioned, complement binding 
HLA DSA is associated with graft loss, but in sera of renal transplant patients both complement 
binding, IgG1 and IgG3, as well as non-complement binding, IgG2 and IgG4 HLA antibodies 
are observed.8,12-14 Previous studies have showed by mixing IgG subclass mAbs that IgG2 
and/or IgG4 can inhibit complement activation of IgG1 and/or IgG3 when recognising the 
same epitope.15,51 Others performed mixing experiments with human HLA mAbs directed 
against different epitopes of same HLA antigens and showed that combining these HLA mAbs 
promote complement activation, while individually the mAbs had no effect.16 Additional 
mixture studies with human mAbs directed to HLA class I and class II molecules of different 
IgG subclasses, comparing different specificities and avidities, should be performed as this 
will allow greater understanding of the interaction of antibodies of different IgG subclasses 
recognising different epitopes on the same HLA molecules.
In addition, HLA mAbs have been used for functional assays to study HLA-antibody-induced 
graft damage independent of the complement cascade. HLA class I antibodies can cause 
crosslinking on endothelial and smooth muscle cells inducing intracellular signalling, resulting 
in inflammatory activation, and leukocyte recruitment such as P-selectin-induced monocyte 
adhesion.17-19,52-54 Although crosslinking is irrespective of the IgG subclass, the level of P-selectin 
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on endothelial cells and the monocyte recruitment via FcγR mechanism are increased with 
IgG1 and IgG3 antibodies. The levels of P-selectin and FcγR-dependent monocyte recruitment 
have been well studied with human IgG1 HLA mAb,19 but due to lack of IgG3, IgG2, and IgG4 
HLA mAbs, the exact influence of antibodies with these isotypes, especially the latter two, 
is not fully clear.
Human HLA mAb do not represent the polyclonal response observed in sera. However, due to 
the mixture of antibody specificities, concentrations and isotypes of HLA antibodies present 
in sera it is difficult to study the role and function of HLA antibodies. By using human HLA 
mAbs, mixture experiments can be performed in a controlled manner, even with normal 
human serum as matrix. For future studies it is essential to extend the specificities of the 
available mAbs, since especially mAbs for HLA class II are currently lacking.
In conclusion, we show here that recombinant human HLA class I and class II mAbs of all 
four IgG subclasses recognising the same HLA epitope can be generated from established 
B cell heterohybridomas. This method enables us to generate more IgG subclass HLA mAbs 
recognising different epitopes on the same HLA antigen, which can be used in mixing 
experiments to study the role and function of HLA DSA of different IgG subclasses in a 
controlled fashion. These IgG subclass HLA class I and class II mAbs can provide mechanistic 
insights into the role of DSA in renal transplantation and in other clinical settings.
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Supplementary Figure 1: Human recombinant IgG1 and IgG3 HLA mAbs can bind to human C3d. 
Recombinant IgG subclass WIM8E5 mAbs (A) and RTLK1E2 mAbs (B, only DRB beads shown as all other loci 
were negative) were screened with Lifecodes C3d detection assay according to manufacturer’s instruc-
tions. Purified recombinant mAb was tested with concentration 62.5nM. BCM is background corrected 
mean fluorescence intensity
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Supplementary Figure 2: Human recombinant IgG1 and IgG3 HLA mAbs can induce antibody-depen-
dent cell lysis. HLA-typed phytohemagglutinin (PHA) blast cells expressing HLA-A11, -A24, -B35, -B40, 
-Cw10, and -Cw4 were generated by culturing PBMCs for 7 days in RPMI 1640 medium (Gibco) containing 
10% human serum S357, 200 mM L-glutamine, 10 CU/ml IL-2 (Proleukin Novartis, Arnhem, the Netherlands), 
and 4 µg/ml PHA (ThermoFisher Scientific). These PHA blasts were labelled with chromium-51 (51Cr), and 
incubated with different concentrations non-purified WIM8E5rec-IgG1, -IgG2, -IgG3, and -IgG4 for 30 min 
at 37°C. Next, the effector cells, the HLA-typed PBMCs, were added and after 4 hours of incubation at 37°C, 
51Cr release was measured with γ-counter (PerkinElmer, Waltham, MA, USA). The percentage of cell lysis 
was calculated by the following formula: (experimental 51Cr release – spontaneous 51Cr release) / (maximum 
51Cr release – spontaneous 51Cr release) x 100. 51Cr-labeled PHA blasts incubated with medium alone gave 
spontaneous 51Cr release and maximum 51Cr release was determined by adding TritonX100. Experiment 
was performed at different effector:target (E:T) ratios. Cell lysis was only observed with WIM8E5rec-IgG1 
and -IgG3 induced cell lysis. Per mAb concentration the Friedman test paired for E:T ratio was performed 
to indicate difference between the four IgG subclass mAbs. Error bars represent the mean ± standard 
deviation of triplicate wells. ND is not determined. ***P<0.001, **P<0.01, *P<0.05 
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ABBREVIATIONS
ADCC: Antibody-dependent cell-mediated cytotoxicity
BCM: Background corrected mean fluorescence intensity
CDC: Complement-dependent cytotoxicity
C1q: Complement component 1q
C3d: Complement component 3d
DNA: Deoxyribonucleic acid
DSA: Donor-specific antibodies
ELISA: Enzyme-linked immunosorbent assay
FcγR: Fc gamma receptors
HLA: Human leukocyte antigen
IgG: Immunoglobulin G
IgM: Immunoglobulin M
IL: Interleukin
LB: Lunia-Bertani
mAbs: Monoclonal antibodies
MFI: Mean fluorescence intensity
PBMCs: Peripheral blood mononuclear cells
PBS: phosphate buffered saline
PCR: Polymerase chain reaction
PHA: Phytohemagglutinin
RACE: Rapid amplification cDNA ends
RNA: Ribonucleic acid
SAB: Single antigen beads 
VH: Heavy chain variable domain
VL: Light chain variable domain
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ABSTRACT
In kidney transplantation, eplet mismatches between donor and recipient have been 
associated with de novo donor-specific antibody development. Eplets are theoretically 
defined configurations of polymorphic amino acids and require experimental verification 
to establish whether they can be bound by allo-antibodies. Human HLA-specific monoclonal 
antibodies (mAbs) have been instrumental for this purpose but are largely lacking for HLA 
class II. In this study, we isolated single HLA-DR specific memory B cells from peripheral 
blood of immunized individuals (n=3) using HLA class II tetramers to generate recombinant 
human HLA-DR antigen-reactive mAbs (n=5). Comparison of the amino acid composition of 
the reactive HLA alleles in relation to the antibody reactivity patterns, led to identification 
of three configurations i.e. 70Q 73A, 31F 32Y 37Y, and 14K 25Q recognised respectively by 
HLA-DRB1*01:01, HLA-DRB1*04:01 and HLA-DRB1*07:01 antigen-reactive mAbs. The former 
two correspond to eplets 70QA and 31FYY and can now be considered antibody-verified. The 
latter indicates that eplet 25Q needs to be redefined before being considered as antibody-
verified. Generation and reactivity analysis of human HLA-DR mAbs allowed for identification 
of amino acid configurations corresponding to known eplets, while the other patterns may 
be used to redefine eplets with similar, but not identical predicted amino acid composition.
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INTRODUCTION
In kidney transplantation, mismatched donor human leucocyte antigens (HLA) can lead to 
formation of de novo donor-specific antibodies (dnDSA), which are associated with inferior 
graft survival.1 These dnDSA are induced by polymorphic amino acid (AA) configurations on 
mismatched HLA molecules that have been theoretically defined as eplets,2,3 which are listed 
in an online registry.4,5 Eplets are defined as configurations of surface exposed polymorphic 
AA within 3-3.5 Å radius.2,3 Various studies have shown an association between the number 
of eplet mismatches and dnDSA formation,6-8 especially for HLA-DR and HLA-DQ.9,10
Eplets resemble functional epitopes but they are not necessarily identical. A functional 
epitope determines the specificity of an antibody through interaction, in most cases, with 
the complementarity-determining region 3 of the heavy chain (CDR-H3) of the antibody.11-13 
The complete surface area of an antigen that interacts with the paratope of an antibody is 
referred to as the structural epitope, which consists of additional AA configurations within 
15 Å radius that are essential for binding and affinity.14-16
Since not every individual eplet is necessarily immunogenic due to the nature of the AA 
substitution, due to physiochemical properties, as well as the absence or presence of an 
accompanying T helper cell epitope, verification of the actual interaction of eplets with human 
antibodies is required to determine their clinical relevance.
For antibody-verification of eplets human HLA-specific mAbs17-19 have been instrumental 
alongside HLA antibodies purified by absorption and elution from sera of alloimmunized 
individuals.20-22 Several eplets have been listed as being verified based on mouse mAbs and/
or polyclonal sera,4,5,23-26 which, in our opinion, is not sufficient to determine whether a single 
human antibody can interact with an eplet. The limited array of available HLA class II-specific 
mAbs, hampers verification of many HLA class II eplets. Indeed, Sapir-Pichhadze et al. recently 
observed a strong effect of HLA class I antibody-verified eplet mismatches on graft survival, 
with no residual effect of HLA class I non-verified eplets. For HLA class II, a similar effect was 
shown, albeit with a residual effect of HLA class II non-verified eplets.27 These data indicate 
that for HLA class II verification of additional eplets will allow for better risk stratification for 
individual patients.
Human mAbs can be generated from isolated antigen-specific B cells using recombinant 
technology.28-30 Low frequency HLA-specific memory B cells in peripheral blood can be 
detected using flow cytometry and HLA-tetramers.31-37 Here, we isolated HLA-DR specific 
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memory B cells from peripheral blood using HLA-DR tetramers for the subsequent generation 
of recombinant human HLA-DR mAbs. Subsequently, uniquely shared AA within 3-3.5 Å radius 
were deducted from SAB reactivity patterns and referred to as functional epitopes. These 
were also mapped to eplets, from which the reactive AAs are theoretically pre-defined. 
Overall, we present five recombinant human HLA-DR mAbs and antibody-verification of three 
functional epitopes/eplets.
MATERIALS AND METHODS
Cells
Peripheral blood and serum samples were collected from healthy women (n=3) who had 
developed HLA class II antibodies due to pregnancy, as detected with luminex single antigen 
bead (SAB) assays. All samples were collected with informed consent under guidelines issued 
by the medical ethics committee of Leiden University Medical Centre (Leiden, the Netherlands). 
Peripheral blood mononuclear cells (PBMC) were isolated by Ficoll-Paque (LUMC Pharmacy, 
Leiden, the Netherlands) density gradient centrifugation and kept frozen in liquid nitrogen 
until further use. HLA typed Epstein-Barr virus-transformed lymphoblastoid cell lines (EBV-
LCLs) were cultured in Iscove’s modified Dulbecco’s medium (IMDM) (Gibco Invitrogen, Paisley, 
UK) containing 10% fetal bovine serum (FBS) (Sigma-Aldrich, Zwijndrecht, the Netherlands), 
50 µM 2-mercaptoethanol (Sigma-Aldrich), 2mM L-glutamine (Gibco Invitrogen), and 100 U/ml 
penicillin with 100 µg/ml streptomycin (Gibco Invitrogen) in T75 flasks (Greiner, Frickenhausen, 
Germany).
HLA typing
All subjects were HLA typed for HLA-A, -B, -C, -DRB1, -DRB3/4/5, -DQB1, -DQA1, -DPB1, 
and -DPA1 loci by next-generation sequencing (NGS). Genomic DNA was automated bead-
based isolated from PBMC (Chemagen, Perking Elmer, Baesweiler, Germany). NGSgo-AmpX 
kit (GenDx, Utrecht, the Netherlands) was used for the amplification of HLA genes. Next, 
library and sequence preparation were performed with NGSgo-LibrX/IndX kit (GenDX) and 
subsequent sequencing was carried on an Illumina MiniSeq (Illumina, San Diego, CA, USA). 
NGS data were analysed with NGSengine software version 2.11.0 (GenDx).
HLA-DR specific memory B cell isolation and expansion
After thawing, B cells were enriched from 40-60x10^6 PBMC by negative selection using 
EasySep Human B cell enrichment kits (Stem Cell Technologies, Grenoble, France), according 
to the manufacturer’s instructions (purity >95%). Enriched B cells were incubated for 45 min 
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at 4°C with phycoerythrin (PE) and allophycocyanin (APC)-labelled HLA-DR tetramers (Table 1, 
ProImmune, Oxford, UK) and the following mouse anti-human antibodies: CD3 (pacific blue, 
SP34-2), IgD (PE-Cy7, IA6-2) (both from BD Biosciences, Breda, the Netherlands), and CD27 
(fluorescein isothiocyanate, FITC, CLB-CD27/1, 9F4) (Sanquin, Amsterdam, the Netherlands). 
A FACSAria III sorter (BD Biosciences) was used to sort CD3-CD27+IgD- tetramer-APC+ and 
tetramer-PE+ cells at one cell per well in 96-well flat-bottom plates (Costar, Corning, NY, USA), 
containing 100,000 irradiated (50Gy) CD40L-expressing EL4-B5 cells.38 B cells were expanded 
for thirteen days in IMDM containing 10% FBS, supplemented with 50 µM 2-mercaptoethanol, 
2mM L-glutamine, 100 U/ml penicillin with 100 µg/ml streptomycin, 20 µg/ml insulin-
transferrin-sodium selenite (Sigma-Aldrich), 50 ng/ml IL-21 (Gibco), 1 ng/ml IL-1β (Miltenyi, 
Leiden, the Netherlands), 0.3 ng/ml TNFα (Miltenyi), 0.5 µg/ml R848 (Toll-like receptor 7/8 
agonist, resiquimod) (Sigma-Aldrich).39
Table 1: HLA-DR tetramers used for cell sorting
HLA Allele Peptide Peptide Sequence Fluorochrome
DRB1*07:01 / DRA1*01:01 CMV PDDYSNTHSTRYVTV PE & APC
DRB1*01:01 / DRA1*01:01 Negative control / CLIP PVSKMRMATPLLMQA PE & APC
DRB1*04:01 / DRA1*01:01* Negative control / CLIP PVSKMRMATPLLMQA PE & APC
DRB1*04:05 / DRA1*01:01* Negative control / CLIP PVSKMRMATPLLMQA PE & APC
*DRB1*04:01 and DRB1*04:05 were used together in one sort
HLA-specific antibody detection
After expansion, supernatants were tested for the presence of IgG by ELISA, as previously 
described,40 after which IgG positive supernatants were screened for the presence of HLA 
antibodies with Lifecodes Lifescreen Deluxe screening kit (LMX, Immucor Transplant Diagnostics, 
Stamford, CT, USA). The specificity of the HLA antibodies in positive supernatants was 
determined by Lifecodes HLA class II SAB assays (Immucor). Serum samples were treated with 
ethylenediaminetetraacetic acid (6% EDTA) prior to testing. Data were analysed with Match It! 
Antibody software version 1.3.0 (Immucor). The screening data were analysed using raw mean 
fluorescence intensity (MFI), while for the SAB data background corrected MFI (BCM) was used.
Production of recombinant human monoclonal antibodies
RNA was isolated from HLA-antibody positive B cell clones using TRIzol (ThermoFisher Scientific, 
Waltham, MA, USA). Next, the genes encoding the variable heavy chain (VH) and variable light 
chain (VL) were obtained and recombinant monoclonal antibodies (mAbs) were generated 
and purified as previously described.41 Briefly, SMART cDNA synthesis and 5’-RACE PCR were 
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performed to obtain the PCR products of VH and VL, which were cloned into pcDNA3.3 expression 
vectors containing the constant domains of human IgG1 (IGHG1*03), and kappa (κ) (IGKC) or 
lambda (λ) (IGLC2*01). Recombinant mAbs were expressed by transient co-transfection of 
heavy and light chain vectors of Expi293F cells with SV40-LT plasmid,42 ExpiFectamine, Opti-
Mem, and Expi293 expression medium (ThermoFisher Scientific). Further purification was 
done using Amicon ProAffinity Concentration Kit Protein G (Merck Millipore, Burlington, MA, 
USA). Concentrations of the purified mAbs were determined using the protein A280 protocol 
of Nanodrop2000 (ThermoFisher Scientific), yielding the molecular concentration of each mAb 
based on AA sequence.
Sequence analysis
Plasmids were sequenced by Sanger sequencing (Macrogen, Amsterdam, the Netherlands) to 
obtain nucleotide sequence data of VH and VL. The sequence data were analysed with IgBLAST43 
to define the V(D)J genes of the VH and VL domains and clonality of B cell clones.
Flow cytometric crossmatch assays
EBV-LCLs, 0.5x106, were incubated with 25 µl mAb or PBS for 30 min at room temperature (RT). 
Cells were washed thrice with phosphate-buffered saline (PBS) supplemented with 0.1% bovine 
serum albumin (BSA, Sigma). Next, cells were stained with mouse anti-human CD3 (PE, SK7), CD19 
(APC, HIB19, both from BD Biosciences), and rabbit anti-human IgG F(ab’)2 (FITC, Dako, Leiden, the 
Netherlands) for 30 min at 4°C in the dark. After washing with 0.1%BSA/PBS, cells were fixed with 
1% paraformaldehyde. Data were acquired using an Accuri C6 flow cytometer (BD Biosciences) 
and analysed using FlowJo V10 software (Ashland, OR, USA).
Complement-dependent cytotoxicity (CDC) assay
Terasaki plates (Greiner) were oiled and filled with 1 μl of supernatant containing the mAb of 
interest in triplicate. Then, 3000 EBV-LCLs were added to each well and incubated for 60 min at 
RT. Next, 5 μl rabbit complement (Inno-train, Kronberg, Germany) was added and incubated for 
60 min at RT. To visualise cytotoxicity, 5 μl propidium iodide ink was added to each well, and after 
15 min incubation in the dark at RT the plates were analysed using a Patimed (Leica Microsystems, 
Amsterdam, the Netherlands).
Antibody reactivity pattern analyses of mAbs
AA sequences of HLA alleles present in the Immucor SAB assay were obtained from IPD-IMGT/HLA 
(https://www.ebi.ac.uk/ipd/imgt/hla/ accessed on January, 2019), in order to define shared AA of 
the reactive HLA alleles. To determine the eplets present on the reactive HLA alleles, reactivity 
patterns were analysed with HLAMatchmaker (HLA DRDQDP Matching, version v2.0 and v3.0; 
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http://www.epitopes.net/). Eplet antibody-verification status was extracted from http://www.
EpRegistry.com.br (accessed on July 15, 2019 and February 12, 2020).
The positions of uniquely reactive AA were visualised with Swissviewer44 using the following 
HLA-DR crystal structures: PDB 3PDO and 4MD4 (downloaded from https://www.rcsb.org/ on 
February 4, 2019). Swissviewer allows for the distance between two atoms to be estimated as 
well as for the display of atoms that are at a certain distance from a specific atom. These options 
were used to determine whether AAs were within 3-3.5 Å or 15 Å radius of each other.
RESULTS
HLA-DR specific memory B cell clones isolated from peripheral blood
Flow cytometric cell sorting of HLA-specific memory B cells using HLA-DR specific tetramers 
(Figure 1A) yielded an average of 44 (range 9-88) single memory B cells. After B cell expansion, 
IgG could be detected in 50.7% (range 40.9%-66.7%) of sorted wells with a wide concentration 
range (Figure 1B). HLA class II antibodies were present in 36.8% (range 8.3%-68.8%) of the IgG 
positive B cell clones with a wide MFI range (MFI 811-18168) (Figure 1C). Subsequent SAB assays 
confirmed that the HLA-specific B cell clones produced antibodies with the same specificity as 
the tetramers used for cell sorting (Figure 1D). Eventually, from the total pool of memory B cells 
an average of 0.008% (range 0.002%-0.014%) HLA-specific B cells were acquired (Figure 1E) and 
18.7% (range 3.4%-30.6%) of the sorted cells produced HLA antibodies after expansion (Figure 1F). 
Overall, an average of 5 (range 2-11) HLA antibody producing B cell clones were obtained, which 
is an average of 0.001% of memory B cells and 0.0002% of total B cells.
Recombinant human HLA-DR antigen-reactive mAbs generated from HLA posi-
tive B cell clones
From several HLA-specific B cell clones HLA-DR antigen-reactive mAbs were generated, and in 
this proof of principle study we describe one DR1 mAb (LB_DR1_B), one DR4 mAb (LB_DR4_A) and 
three DR7 mAbs (LB_DR7_A, B and D). The specificity of these mAbs was confirmed by SAB analysis 
(Figure 2). As expected, the HLA-DR antigen-reactive mAbs showed almost identical reactivity 
to the supernatants of the B cell clones they were derived from. Flow cytometric crossmatches 
and CDC assays with EBV-LCL lines expressing HLA alleles corresponding to the tetramers used 
for B cell isolation confirmed binding of the mAbs to their physiologically expressed HLA target 
(Supplementary Figure 1A-C), as well as their cytotoxicity capacity (Supplementary Figure 2A-C). 
Additionally, the mAbs also bound to other natively expressed HLA alleles that were reactive in 
SAB assays, while no binding was observed for non-reactive HLA alleles (Supplementary Figure 1).
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Figure 1: HLA-DR specific memory B cell clones isolated from peripheral blood. A) Representative 
example of three independent experiments depicting the flow cytometry gating strategy to live single 
cell sort CD3-CD27+IgD-HLA-DR tetramer double positive B cells from PBMC. B) IgG antibody production 
by the clones was determined by ELISA. C) IgG positive clones were screened with HLA class II Lifecodes 
Lifescreen Deluxe kit to detect HLA antibody. The kit contains five groups of HLA class II beads and each 
data point represents a single bead group. D) HLA-specific B cell clones were tested with SAB assays to 
confirm tetramer specificity used for cell sorting. Each dot presents one clone and only MFI of bead with 
tetramer specificity is depicted. E) Percentage of sorted HLA-specific B cells from total memory B cells. F) 
Percentage of HLA antibody producing B cell clones from sorted B cells. On the x-axis are the specificity 
of the tetramers used depicted. OD: optical density MFI: mean fluorescence intensity.
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Figure 2: Recombinant human HLA-DR monoclonal antibodies have the same reactivity as the B cell 
clones. HLA-DR specificities in serum, supernatants of B cell clones (italic) and generated IgG1 mAbs. A) 
Serum of individual used for HLA-DRB1*01:01 sort and the generated LB_DR1_B mAb and with its respec-
tive B cell clone. B) Serum of individual used for HLA-DRB1*04:01/04:05 sort and the generated LB_DR4_A 
mAb and its respective B cell clone. C) Serum of individual used for HLA-DRB1*07:01 sort and the generated 
LB_DR7 mAbs with their respective B cell clones. Only DRB1/3/4/5 beads are shown as all other loci were 
negative for the B cell clones and mAbs. Purified recombinant monoclonal antibody concentration tested 
was 62.5nM. BCM: background corrected mean fluorescence intensity.
Reactivity analysis of LB_DR1_B mAb
Next, we analysed the mAb reactivity patterns to determine if the reactive HLA alleles in SAB 
assays uniquely share AA within a 3-3.5 Å radius acting as the functional epitope, determining 
the antibody specificity.11-13 Furthermore, we analysed whether additional AA configurations 
within 15 Å radius of the functional epitope were an absolute requirement for the interaction 
between antibody and HLA alleles.45 
The HLA type of the immuniser of LB_DR1_B was unknown (Table 2). This mAb has a broad 
reactivity pattern including DRB1*01:01 and DRB1*01:02, but not DRB1*01:03 (Figure 2A). 
Interestingly, no individual AA at a specific position was uniquely shared between reactive HLA 
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alleles and absent on non-reactive HLA alleles, but the combination of 70 glutamine (Q), and 
73 alanine (A) was only present on the reactive alleles (Figure 3A). Indeed, HLAMatchmaker 
v3.0 also showed that the reactive alleles share eplet 70QA (70Q 73A). These AAs are located 
on top of the HLA molecule (Figure 3B) and within 3 Å radius of each other, suggesting that 
70Q and 73A are comprising the functional epitope (Figure 3C). This is in accordance with 
cellular assays, as LB_DR1_B binds only to cells expressing HLA alleles containing 70Q and 
73A (Supplementary Figure 1).
Some of the reactive alleles showed a lower MFI in SAB analysis, suggesting that additional 
AAs are involved in binding and affinity. Indeed, the alleles showing the highest MFI values 
share arginine (R) on position 71 and 74A, which are located near positions 70 and 73, within 
the area of the functional epitope. DRB1*04:03 also harbours a 71R but lacks 74A, which might 
explain the lower MFI values against this allele.
Together, these data suggest that all four AAs are involved in binding of LB_DR1_B to HLA 
alleles with high MFI (Figure 3D). As the identified functional epitope corresponds to eplet 
70QA, the latter can be considered as antibody-verified by LB_DR1_B.
Reactivity analysis of LB_DR4_A mAb
LB_DR4_A mAb showed a broad reactivity pattern in SAB assays with high reactivity observed 
for all included DR4 alleles, whereas eleven other alleles were reactive with low MFI values 
(Figure 2B and 4A). From the AA mismatches of the immunizing DRB1*04:04 with the HLA-DR 
constitution of antibody-producer (DRB1*03:01 DRB1*13:01 DRB3*01:01 DRB3*02:02), only 
tyrosine (Y) on position 32 was shared by all reactive HLA alleles. However, 32Y is also present 
on non-reactive HLA alleles, suggesting that other AAs are involved in interaction with this 
mAb (Figure 4A). HLAMatchmaker v3.0 identified eplet 37YV (37Y 38V), which was present 
on eleven out of sixteen reactive alleles. The other identified eplets were 96Y (96Y) present 
on all tested DR4 alleles, and 142M (142M) shared by five reactive HLA alleles with lowest MFI 
values in the positive range. These eplets are likely not involved in binding of this mAb since 
they are shared by a limited number of reactive alleles.
To identify the AA configuration involved, we analysed the DRB1*04:01 crystal structure and 
observed that 37Y is located within 4 Å radius of 32Y, while 38 valine (V) is 6 Å away from 32Y, 
and not surface exposed (Figure 4B). In addition, 31 phenylalanine (F) is located within 3.5 Å 
radius of 32Y, and also 37Y is located within 3.5 Å radius of 31F. 
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BCM Antigen 70 71 73 74
19292 DRB1*01:01 Q R A A
19091 DRB1*01:02 Q R A A
16810 DRB1*04:04 Q R A A
15554 DRB1*04:05 Q R A A
12255 DRB1*04:01 Q K A A
10191 DRB5*02:02 Q A A A
10011 DRB1*15:03 Q A A A
7071 DRB1*04:03 Q R A E
7011 DRB1*15:01 Q A A A
5227 DRB1*15:02 Q A A A
0 DRB1*01:03 D E A A
0 DRB1*04:02 D E A A
0 DRB5*01:01 D R A A
0 DRB1*03:01 Q K G R
0 DRB1*07:01 D R G Q
0 DRB1*08:01 D R A L
0 DRB1*09:01 R R A E
0 DRB1*10:01 R R A A
0 DRB1*11:01 D R A A
0 DRB1*13:01 D E A A
0 DRB1*14:01 R R A E
0 DRB1*16:01 D R A A
0 DRB3*02:02 Q K G Q
0 DRB3*03:01 Q K G Q
0 DRB4*01:01 R R A E
0 rest
A
s
s
s
B
71
70 73
74
C
70Q 
73A
D
70Q 
73A
71R
74A
Figure 3: Reactivity analysis of LB_DR1_B monoclonal antibody. A) Comparison of the amino acid 
positions of interests of the reactive HLA-DR alleles of LB_DR1_B mAb and a selection of the non-reactive 
HLA-DR alleles. B) Locations of amino acid 70Q (yellow), 71R (magenta), 73A (green) and 74A (orange) are 
indicated on crystal structure of DRB1*01:01 (PDB: 3PDO). C) LB_DR1_B mAb interacts with HLA-DR alleles 
containing the functional epitope 70Q 73A. D) Schematic representation of the footprint of LB_DR1_B 
mAb that is highly reactive for HLA-DR alleles containing the functional epitope 70Q 73A (cyan) and 
additional amino acids 71R and 74A. In crystal structures the β chain is coloured dark blue, α chain light 
blue and peptide is grey. Purifi ed recombinant monoclonal antibody concentration tested was 62.5nM. 
BCM: background corrected mean fl uorescence intensity, negative values are presented as zero. s: self 
HLA alleles of antibody-producer.
Interestingly, the previous version of HLAMatchmaker (v2.0) identifi ed eplet 31FYY (31F 32Y 
37Y) present on the same eleven reactive alleles as defi ned for eplet 37YV. Therefore, we 
deduced that positions 31F, 32Y, and 37Y together form the functional epitope, and indeed this 
confi guration is unique for the reactive HLA alleles, but only for the highly reactive HLA alleles. 
Five of the lower reactive HLA alleles have a serine (S) instead of 37Y, and the combination of 
31F, 32Y, and 37S is absent on the non-reactive HLA alleles. CDC assays showed that LB_DR4_A 
mAb can lyse cells expressing HLA alleles carrying 31F 32Y 37Y (Supplementary Figure 2C-D), 
whereas no specifi c lysis was observed for cells expressing HLA alleles with 31F 32Y 37S 
(Supplementary Figure 2F-H).
Since 32Y was the AA shared by all reactive HLA alleles, and mismatched with the antibody-
producer, we deduce that the functional epitope of LB_DR4_A consists of 31F 32Y 37Y (Figure 
4D) with the mAb weakly binding to HLA alleles containing 37S instead of 37Y (Figure 4E). 
Cynthia_Binnenwerk_V3.indd   91 9-8-2020   14:52:52
92
Ta
b
le
 2
: I
n
fo
rm
at
io
n 
of
 t
h
e 
fi
ve
 h
u
m
an
 H
LA
-D
R 
m
o
n
o
cl
o
n
al
 a
n
ti
b
o
d
ie
s 
an
d 
d
es
cr
ip
ti
o
n 
of
 t
h
e 
re
ac
ti
ve
 H
LA
-D
R 
al
le
le
s
O
n 
re
ac
ti
ve
 H
LA
 D
RB
1/
3/
4/
5 
al
le
le
s
H
um
an
 m
A
b
H
LA
-D
R 
an
tib
od
y 
pr
od
uc
er
H
LA
 im
m
un
is
er
H
LA
 te
tr
am
er
Re
ac
ti
ve
 H
LA
 D
RB
1/
3/
4/
5 
al
le
le
s
A
m
in
o 
ac
id
s*
Ep
le
t
Te
rE
p
LB
_D
R1
_B
D
RB
1*
13
:0
1 
D
RB
1*
13
:0
2 
D
RB
3*
02
:0
2 
D
RB
3*
03
:0
1
D
RB
1*
01
:0
1
D
RB
1*
01
:0
1 
D
RB
1*
01
:0
2 
D
RB
1*
04
:0
1 
D
RB
1*
04
:0
3 
D
RB
1*
04
:0
4 
D
RB
1*
04
:0
5 
D
RB
1*
15
:0
1 
D
RB
1*
15
:0
2 
D
RB
1*
15
:0
3 
D
RB
5*
02
:0
2
70
Q
 7
3A
(7
1R
 7
4A
)
70
Q
A
LB
_D
R4
_A
D
RB
1*
03
:0
1 
D
RB
1*
13
:0
1 
D
RB
3*
01
:0
1 
D
RB
3*
02
:0
2
D
RB
1*
04
:0
4
D
RB
1*
04
:0
1/
04
:0
5
D
RB
1*
04
:0
1 
D
RB
1*
04
:0
2 
D
RB
1*
04
:0
3 
D
RB
1*
04
:0
4 
D
RB
1*
04
:0
5 
D
RB
1*
13
:0
3 
D
RB
1*
08
:0
1 
D
RB
1*
08
:0
2 
D
RB
1*
11
:0
3 
D
RB
1*
11
:0
4 
D
RB
1*
11
:0
1 
D
RB
1*
16
:0
1 
D
RB
1*
16
:0
2 
D
RB
1*
15
:0
1 
D
RB
1*
15
:0
2 
D
RB
1*
15
:0
3
31
F 
32
Y 
37
Y/
S
(1
3H
 3
3H
)
37
YV
LB
_D
R7
_A
D
RB
1*
11
:0
1 
D
RB
1*
15
:0
1 
D
RB
3*
02
:0
2 
D
RB
5*
01
:0
1
D
RB
1*
07
:0
1
D
RB
1*
07
:0
1
14
K 
25
Q
 1
1G
 3
0L
25
Q
#1
00
8,
 #
14
05
, #
16
02
LB
_D
R7
_B
 &
 
LB
_D
R7
_D
D
RB
1*
11
:0
1 
D
RB
1*
15
:0
1 
D
RB
3*
02
:0
2 
D
RB
5*
01
:0
1
D
RB
1*
07
:0
1
D
RB
1*
07
:0
1 
D
RB
1*
09
:0
1
78
V
96
H
 9
8E
 1
20
S
77
TV
 9
8E
S
#1
02
9
* A
m
in
o 
ac
id
s 
in
 p
ar
en
th
es
es
 a
re
 p
re
se
nt
 o
n 
th
e 
hi
gh
ly
 re
ac
tiv
e 
H
LA
 a
lle
le
s,
 a
m
in
o 
ac
id
s 
in
 it
al
ic
 a
re
 n
ot
-e
xp
os
ed
 o
n 
po
si
tio
n 
71
 a
nd
 7
4A
, w
hi
ch
 a
re
 lo
ca
te
d 
ne
ar
 p
os
iti
on
s 
70
 a
nd
 7
3,
 w
it
hi
n 
th
e 
ar
ea
 o
f t
he
 fu
nc
tio
na
l e
pi
to
pe
. D
RB
1*
04
:0
3 
al
so
 h
ar
bo
ur
s 
a 
71
R 
bu
t l
ac
ks
 7
4A
, w
hi
ch
 m
ig
ht
 e
xp
la
in
 th
e 
lo
w
er
 M
FI
 v
al
ue
s 
ag
ai
ns
t t
hi
s 
al
le
le
. 
Cynthia_Binnenwerk_V3.indd   92 9-8-2020   14:52:52
93
Towards HLA epitope matching in clinical transplantation
5
BCM Antigen 13 31 32 33 37 38
19022 DRB1*04:05 H F Y H Y V
18536 DRB1*04:04 H F Y H Y V
18293 DRB1*04:01 H F Y H Y V
18266 DRB1*04:02 H F Y H Y V
17788 DRB1*04:03 H F Y H Y V
8610 DRB1*13:03 S F Y N Y V
3547 DRB1*08:01 G F Y N Y V
3372 DRB1*08:02 G F Y N Y V
2351 DRB1*11:03 S F Y N Y V
1233 DRB1*11:04 S F Y N Y V
1006 DRB1*11:01 S F Y N Y V
834 DRB1*16:01 R F Y N S V
798 DRB1*16:02 R F Y N S V
467 DRB1*15:01 R F Y N S V
419 DRB1*15:02 R F Y N S V
195 DRB1*15:03 R F Y N S V
0 DRB1*01:01 F I Y N S V
0 DRB1*03:01 S F H N N V
0 DRB1*03:02 S F H N N V
0 DRB1*07:01 Y F Y N F V
0 DRB1*09:01 F I Y N N V
0 DRB1*10:01 F V H N Y A
0 DRB1*12:01 G F H N L L
0 DRB1*13:01 S F H N N V
0 DRB1*14:01 S F H N F V
0 DRB1*14:03 S F H N N V
0 DRB1*14:04 G F H N F V
0 DRB3*01:01 S F H N F L
0 DRB3*02:02 S F H N Y A
0 DRB4*01:01 C I Y N Y A
0 DRB5*01:01 Y I Y N D L
0 DRB5*02:02 Y I Y N N V
0 rest
31F
32Y
37Y
31F
32Y
37S
A
D
B
s
s
s
s
E F
13
C
31F
32Y
37Y
33H
33
3237
31
38
Figure 4: Reactivity analysis of LB_DR4_A monoclonal antibody. A) Comparison of the amino acid 
positions of interests of the reactive HLA-DR alleles of LB_DR4_A mAb and a selection of the non-reactive 
HLA-DR alleles. B) Locations of amino acid 31F (red), 32F (yellow), 33H (magenta), 37Y (orange), 38V (lilac) 
and C) 13H (green) are indicated on crystal structure of DRB1*04:01 (PDB: 4MD4). D) Schematic repre-
sentation of the footprint of LB_DR4_A mAb interacting with the functional epitope 31F 32Y 37Y (cyan) E) 
LB_DR4_A mAb weakly binds to HLA alleles containing 31F 32Y 37S. F) Schematic representation of the 
footprint of LB_DR4_A mAb interacting with the highly reactive HLA-DR4 alleles. In crystal structures the 
β chain is coloured dark blue, α chain light blue and peptide is grey. Purifi ed recombinant monoclonal 
antibody concentration tested was 62.5nM. BCM: background corrected mean fl uorescence intensity, 
negative values are presented as zero. s: self HLA alleles of antibody-producer.
The stronger interaction observed for the DR4 alleles suggests involvement of AAs solely 
present on DR4 alleles, which are 96Y, 180 leucine (L), and histidine (H) on position 13 and 33. 
The latter two AAs are within 15 Å radius of 32Y, but only 33 is exposed and is therefore most 
likely involved in the interaction with the antibody (Figure 4F). The functional epitope, 31F 
32Y 37Y, corresponds to eplet 31FYY and thereby this eplet can be considered as antibody-
verifi ed by LB_DR4_A.
Reactivity analysis of LB_DR7 mAbs
LB_DR7 mAbs were obtained from an individual of which the immunizing event was 
unknown. We analysed three LB_DR7 mAbs from which the variable domains were acquired 
by sequencing (Table 3), showing diff erent V(D)J usage, and unique VH and VL clonotypes. 
This indicates that memory B cells with BCRs recognizing diff erent AA confi gurations can be 
isolated with one tetramer specifi city.
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LB_DR7_A is only reactive with HLA-DRB1*07:01 (Figure 2C), strongly suggesting that this was 
the immunizing allele. Upon comparing the AA sequence of DRB1*07:01 with the non-reactive 
HLA-DR alleles present in SAB assay, glycine (G) on position 11, lysine (K) on position 14, Q 
on position 25, and L on position 30 were identified as unique AAs for DRB1*07:01 (Figure 
5A). Three of these AAs, are present within the eplet 25Q (25Q 30L 14K), which is also the 
eplet determined upon analysis with HLAMatchmaker v3.0. The four unique AA correspond 
to TerEp #160222,46 and have been previously described for mouse mAbs.47-50 Positions 11 
and are 30 located at the bottom of the peptide-binding groove (Figure 5B), while 14K and 
25Q are surface exposed and within 3.5 Å radius of each other (Figure 5C). Due to location of 
11G and 30L and as neither are within 3.5 Å radius of 14K and/or 25Q, it is unlikely that those 
form the functional epitope. Additionally, mutation assays with mouse mAbs showed that 
only mutation of 14K and 25Q affected binding.47-50 Altogether, we suggest that 14K and 25Q 
comprise the functional epitope without 30L being involved (Figure 5D).
LB_DR7_B and LB_DR7_D bind to DRB1*07:01 and DRB1*09:01 in both SAB assays (Figure 2C) 
and flow crossmatch, whereas HLA alleles with low reactivity to LB_DR7_D in SAB did not react 
with natively expressed alleles in flow (Supplementary Figure 1). DRB1*07:01 and DRB1*09:01 
share a valine (V) on position 78, which is absent on all non-reactive HLA alleles (Figure 5E) 
and located on top of the molecule (Figure 5F) and correspond to TerEp #1029. Concomitantly, 
eplets 77TV (77T 78V) and 98ES (98E 120S) were identified as unique for the reactive alleles. 
Analysis with HLAMatchmaker v2.0 suggested that 96H could potentially be involved, based 
on previously listed eplet 78V2, which was the predecessor of 77TV and 98ES. Interestingly, 
while the individual AAs 96H, 98E, and 120S are present on non-reactive HLA alleles, including 
self, the configuration of the three is only present on DRB1*07:01 and DRB1*09:01. Since this 
configuration is exposed but not within 15 Å radius of 78V (Figure 5G), either 78V (Figure 5H) 
or 96H 98E 120S (Figure 5I) act as contact site for the CDR-H3 of LB_DR7_B and/or LB_DR7_D. 
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5
BCM Antigen 11 14 25 30
19367 DRB1*07:01 G K Q L
0 DRB1*01:01 L E R C
0 DRB1*03:01 S E R Y
0 DRB1*04:01 V E R Y
0 DRB1*08:01 S E R Y
0 DRB1*09:01 D E R G
0 DRB1*10:01 V E R R
0 DRB1*11:01 S E R Y
0 DRB1*12:01 S E R H
0 DRB1*13:01 S E R Y
0 DRB1*14:01 S E R Y
0 DRB1*15:01 P E R Y
0 DRB1*16:01 P E R Y
0 DRB3*02:02 L E R H
0 DRB4*01:01 A E W Y
0 DRB5*01:01 D E R D
0 rest
B
11
30
25
14
D
F
78
78V
G
A
s
s
s
s
BCM Antigen 77 78 96 98 120
17813 DRB1*07:01 T V H E S
17651 DRB1*09:01 T V H E S
0 DRB1*01:01 T Y E K S
0 DRB1*03:01 N Y H K S
0 DRB1*04:01 T Y Y E N
0 DRB1*08:01 T Y H K S
0 DRB1*10:01 T Y Q K N
0 DRB1*11:01 T Y H K S
0 DRB1*12:01 T Y H K S
0 DRB1*13:01 T Y H K S
0 DRB1*14:01 T Y H K S
0 DRB1*15:01 T Y Q K S
0 DRB1*16:01 T Y Q K S
0 DRB3*02:02 N Y H Q S
0 DRB4*01:01 T Y Q K N
0 DRB5*01:01 T Y E K N
0 rest
E
s
s
s
s
96
98
120
IH
96H
98E
120S
C
14K 
25Q
Figure 5: Reactivity analyses of LB_DR7_A, and LB_DR7_B and LB_DR7_D monoclonal antibodies. A) 
Comparison of the amino acids of the reactive HLA-DR alleles of LB_DR7_A mAb with non-reactive HLA-DR 
alleles. B) Positions 30 (green), and 11 (magenta) and C) 25 (yellow), and 14 (orange) are indicated on the 
crystal structure of DRB1*01:01 (PDB: 3PDO). D) A schematic representation of the footprint of LB_DR7_A 
mAb with 14K 25Q as functional epitope (cyan). E) Comparison of the amino acids of the reactive HLA-DR 
alleles of LB_DR7_B and LB_DR7_D with the non-reactive HLA-DR alleles, of which only a selection is shown. 
Only BCM of LB_DR7_B are depicted. F) Location of position 78 (yellow) and G) of 96 (orange), 98 (magenta) 
and 120 (green) on the DRB1*01:01 crystal structure. H) A schematic representation of LB_DR7_B and 
LB_DR7_D footprint with 78V or I) with 96H 98E 120S as the functional epitope (cyan) of the mAb. In crystal 
structures the β chain is coloured dark blue, α chain light blue and peptide is grey. Purifi ed recombinant 
monoclonal antibody concentration tested was 62.5nM. BCM: background corrected mean fl uorescence 
intensity, negative values are presented as zero. s: self HLA-DR alleles of antibody-producer.
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DISCUSSION
Increasing numbers of HLA class II eplet mismatches are associated with the development 
of dnDSA,6-8 which led to the hypothesis that eplet mismatch loads can be used as predictor 
of DSA occurrence.9,10 However, eplets have been theoretically defined and for several eplets 
it remains to be established whether they are indeed reactive with antibodies, and thus 
clinically relevant. Therefore, eplets require experimental verification, either by human mAbs 
or absorption and elution studies,4,5,19-21 to establish if interaction with an antibody can occur. 
This is of importance for the implementation of eplet matching in allocation systems aiming at 
prevention of dnDSA development. By performing eplet matching solely on relevant functional 
eplets, patients will not be denied an organ offer based on irrelevant eplet disparities with 
the donor.
In this study, we isolated HLA-DR specific memory B cells from peripheral blood of immunised 
individuals using HLA-DR specific tetramers. While tetramers have been used to detect and 
isolate HLA class I-specific B cells,35,37,51 to our knowledge this study is the first to use tetramers 
for the isolation of HLA class II-specific memory B cells. Here, we describe generation of five 
HLA-DR mAbs with four different specificities: DR7, DR7/DR9, DR1/DR9/DR10/DR51 and DR4/
DR1303/DR8/DR11/DR15/DR16.
Overall, the specificity of the generated mAbs resembled the antibody repertoire observed in 
the serum. For LD_DR7_D additional reactive HLA alleles were observed, albeit with very low 
MFI. A possible explanation is that the memory B cell compartment may contain a broader 
repertoire than that of circulating antibodies.52-54 However, the additional reactive HLA alleles 
could not be confirmed with flow cytometric crossmatch assays using natively expressed HLA 
alleles (Supplementary Figure 1). Therefore, the additional reactivity for the mAbs appears to 
be due to non-specific binding in SAB assays or due to the mAb concentration used.
Based on both SAB and cellular data presented here, the eplets 70QA and 31FYY, corresponding 
to AA configurations 70Q 73A and 31F 32Y 37Y, have been antibody-verified by the human 
mAbs LB_DR1_B and LB_DR4_A, respectively, despite the limitation of missing HLA typing 
of the immuniser for LB_DR1_B. Eplet 31FFY was previously registered as antibody-verified 
based on reactivity analysis of mouse mAbs5,55 and pregnancy sera.25 Peculiarly, this eplet is no 
longer present on the HLA Epitope Registry as it was deemed redundant. The data presented 
here suggest that this eplet does actually exist and should be relisted on the Registry.
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For the narrow reactivity patterns of LB_DR7_A, LB_DR7_B and LB_DR7_D HLAMatchmaker 
defined eplets 25Q, and 77TV and 98ES, respectively, to be uniquely shared. For eplet 25Q the 
current description of the AAs involved exceeds the original definition of an eplet since the 
suggested residues are not located within 3.5 Å radius of each other. The same applies to eplet 
37YV, defined by HLAMatchmaker v3.0 for LB_DR4_A. Provided that eplet 25Q (25Q 14K 30L) 
is to be redefined as 14K and 25Q, mAb LB-DR7_A allows for antibody verification of this eplet.
Eplet 98ES is currently listed as antibody-verified based on pregnancy sera, but our reactivity 
analysis shows that either 78V or 96H 98E 120S can act as contact site for mAb reactive for 
HLA-DRB1*07:01 and HLA-DRB1*09:01. In contrast to HLAMatchmaker v2.0, the newly defined 
98ES no longer includes residue 96H in v3.0. Reactivity analysis of the HLA-DR mAbs showed 
that AAs on reactive HLA alleles not always correspond to pre-defined eplets identified by 
HLAMatchmaker. For some of these mAbs we were able to identify different eplets on basis 
of version 2.0 of HLAMatchmaker, indicating that the list of eplets in this program and on the 
HLA Epitope Registry is subject to change without broadly accepted and validated arguments 
showing the need to install an international nomenclature committee for the definition of 
antibody-verified eplets and/or epitopes. Overall, the data presented herein indicates that 
the current, widely used list of eplets contains inaccuracies. Furthermore, our results show 
that performing reactivity analysis of human HLA mAbs based on AA rather than on pre-
defined eplets may be more useful in defining the relevant AA configurations, and this will 
require several mAbs.18,56
Antibody reactivity analyses based solely on SAB assay can be complex and can benefit 
from additional functional assays to determine true reactivity. AA substitutions within the 
functional epitope which do not affect binding of mAbs to an HLA allele in SAB assay may 
affect the ability to induce complement-dependent cytotoxicity,17 as was the case for LB_
DR4_A. In addition, MFI values can reflect differential affinity of the mAbs for specific HLA 
alleles57 and AA substations within the structural epitope can lead to lower affinity, which can 
be reflected in the MFI values.58 Mutation studies have been informative on determining the 
involvement of single AAs in the interaction between the HLA molecule and antibody.48,49,59 
However, it is important to realise that AA substitutions can affect the tertiary structure and 
surface electrostatic potential of the HLA molecule.60,61
In the present study we obtained multiple B cell clones from one individual with subtle 
differences in specificity reflecting the polyclonal reactivity of serum. These observations 
substantiate the notion that antibody-verification of eplets should only be done by using 
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human mAbs or absorption and elution studies,22,62-64 and not based on sera of women after 
first or second pregnancy, as is currently done for various eplets.24-26 While in this proof of 
principle study, we present HLA-DR mAbs obtained from three subjects, the inventory of 
HLA-DR mAbs will expand soon, which will result in identification and antibody-verification 
of additional relevant AA configurations. In addition, we are developing methods to utilise 
HLA-DQ monomers33 to isolate HLA-DQ-specific memory B cells for the generation of 
recombinant HLA-DQ mAbs and subsequently reactivity analysis to verify HLA-DQ eplets, since 
HLA-DQ DSA are most prevalent after transplantation and associated with rejection.8,9,65-67
These human HLA class II mAbs can be used in functional studies to provide more insight 
in the respective roles of HLA-specific IgG antibodies in causing graft damage,68-72 with the 
possibility of all IgG subclasses to be generated.41 In addition, as shown for LB_DR7, distinct 
B cell clones with different levels of affinity maturation, as suggested by the different binding 
strengths and efficacy in cell lysis, can be obtained from a single individual. Thus, the method 
described herein can contribute to understanding the development of the HLA-specific 
memory B cell compartment73 besides their use in eplet verification.
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Supplementary Figure 1: Recombinant human HLA-DR mAbs bind only to reactive HLA expressed 
on cells. Flow cytometry crossmatches on EBV-LCL lines were performed with all fi ve DR mAbs to show 
that each mAb binds its respective natively expressed target HLA, as well as other reactive HLA, and does 
not bind to non-reactive HLA. Concentration mAbs used 62.5nM. HL A-typed DRB1*07:01, DQB1*02:01, 
DPB1*15:01 (A), DRB1*01:01, DQB1*05:01, DQA1*01:01, DPB1*04:01 (B) and DRB1*04:01, DRB4*01:03, 
DQB1*03:02, DQA1*03:01, DPB1*03:01, DPB1*04:01 (C), DRB1*09:01, DRB1*08:01, DRB4 (D), DRB1*15:01, 
DRB5*01:01, DQB1*06:02, DQA1*01:02, DPB1*02:01 (E) and DRB1*12:01, DRB3*02:02, DQB1*03:01 (F) 
EBV-LCL lines were used. 
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Supplementary Figure 2: Cytotoxicity reactivity of recombinant human HLA-DR mAbs. Complement 
dependent cell lysis was observed in a dose-dependent manner for LB_DR7 IgG1 mAbs (A), LB_DR1 IgG1 
mAb (B), and LB_DR4 IgG1 mAb (C). LB_DR4_A mAb only induced CDC reactivity for cells expressing 
HLA molecules DRB1*04:01 (C), DRB1*13:03 (D) and DRB1*08:01 (E) all having 31F 32Y 37Y, while similar 
background was observed for cells expressing DRB1*15:01 (F) and DRB1*16:01 (G) (31F 32Y 37S), and 
cells expressing non-reactive DRB1*01:01 (31I 32Y 37S) (H). CDC assays were performed with HLA-typed 
EBV-LCL lines and various concentrations of mAbs were added (1000, 500, 250, 125, 62.5, 31.25, and 15.62 
nM. Additional concentration 7.8nM was used for A-C. Data point with error bars represent the mean 
± standard deviation of triplicate wells. Lysis is relative to positive control (pan-HLA class II antibody).
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ABBREVIATIONS
Å: Angstrom
Amino acid: AA
APC: Allophycocyanin
BCM: Background corrected mean fluorescence intensity
BCR: B cell receptors
BSA: Bovine serum albumin
CDC: Complement-dependent cytotoxicity
cDNA: Complementary Deoxyribonucleic acid
CDR: Complementarity-determining region
DSA: Donor-specific antibodies
EBV-LCL: Epstein-Barr virus-transformed lymphoblastoid cell line 
EDTA: Ethylenediaminetetraacetic acid
ELISA: Enzyme-linked immunosorbent assay
FACS: Fluorescence-activated cell sorting
FITC: Fluorescein isothiocyanate
HLA: Human leukocyte antigen
IgG: Immunoglobulin G
IL: Interleukin
IMDM: Iscove’s modified Dullbecco’s medium
mAbs: Monoclonal antibodies
MFI: Mean fluorescence intensity
OD: Optical density
PBMC: Peripheral blood mononuclear cells
PBS: Phosphate-buffered saline
PCR: Polymerase chain reaction
PE: Phycoerythrin
RACE: Rapid amplification cDNA ends
RNA: Ribonucleic acid
SAB: Single antigen beads
TerEp: Teresaki epitope
VH: Heavy chain variable domain
VL: Light chain variable domain
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ABSTRACT
In renal transplantation, polymorphic amino acids on mismatched donor HLA molecules can 
lead to the induction of de novo donor-specific antibodies (DSA), which are associated with 
inferior graft survival. To ultimately prevent de novo DSA formation without unnecessarily 
precluding transplants it is essential to define which polymorphic amino acid mismatches 
can actually induce an antibody response. To facilitate this, we developed a user-friendly 
software program that establishes HLA class I and class II compatibility between donor and 
recipient on the amino acid level.
HLA epitope mismatch algorithm (HLA-EMMA) is a software program that compares 
simultaneously the HLA class I and class II amino acid sequences of the donor with the HLA 
amino acid sequences of the recipient and determines the polymorphic solvent accessible 
amino acid mismatches that are likely to be accessible to B cell receptors. Analysis can be 
performed for a large number of donor-recipient pairs at once.
As proof of principle, a previously described study cohort of 191 lymphocyte immunotherapy 
recipients was analysed with HLA-EMMA and showed a higher frequency of DSA formation 
with higher number of solvent accessible amino acids mismatches.
Overall, HLA-EMMA can be used to analyse compatibility on amino acid level between donor 
and recipient HLA class I and class II simultaneously for large cohorts to ultimately determine 
the most immunogenic amino acid mismatches.
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INTRODUCTION
In renal transplantation, human leukocyte antigen (HLA) antigen matching enhances long-term 
graft survival.1,2 Nonetheless, most recipients receive a graft with one or more HLA antigen 
mismatches due to high level of polymorphism of the HLA system and scarcity of donor 
organs. In addition, even grafts that are matched on the antigen level can be mismatched 
at the allelic level and can therefore induce an alloimmune response.3,4 The presence of 
mismatched HLA antigens on the donor graft can lead to the formation of de novo donor-
specific HLA antibodies (DSA), which are associated with graft loss.5,6 Moreover, sensitisation 
towards HLA significantly reduces the chance of receiving a repeat transplant.7
While current matching algorithms are mainly based on HLA-A, -B and -DR matching at 
the antigen level, one should realise that HLA antibodies are not specific for antigens, but 
recognise B cell epitopes present on HLA molecules.8 In addition, the immunogenicity of 
HLA mismatches has been shown to be dependent on configurations of polymorphic amino 
acids on antibody accessible positions, which have been theoretically defined and are 
called eplets.9,10 Indeed, several groups have shown that the chance of developing de novo 
DSA after transplantation increases with an increasing number of mismatched eplets.11-13 
However, not every eplet mismatch triggers an immune response, indicative of a difference 
in immunogenicity of individual eplet mismatches.14 The immunogenicity of a mismatched 
HLA allele is, amongst others, dependent on the HLA class II phenotype of the recipient as 
it determines if a specific eplet mismatch will lead to a full-blown antibody response. B cells 
require CD4+ T cell help to switch towards IgG antibody producing cells and this help depends 
on the recognition of T cell epitopes presented by the recipients HLA class II molecules on the 
B cells.15,16 Furthermore, the type of amino acid substitution (i.e. difference in size, charge) can 
play a role in immunogenicity as it can affect the structure and physicochemical properties of 
an HLA molecule.17 As eplets are theoretically defined, experimental verification is required to 
determine if an antibody can actually bind to an eplet, which has only been done for a limited 
number of eplets, mainly present on HLA class I.18-20
Other approaches based on amino acid mismatches and/or physicochemical scores have 
shown also to be useful to assess sensitisation risk of HLA allele mismatches on the population 
level.12,21-23 While eplets are predefined entities that are still subject to change,24 the amino 
acids that are the underlying basis of the eplets are fixed entities on HLA molecules. Therefore, 
we aim to define the immunogenicity of specific HLA mismatches based on polymorphic 
amino acids rather than eplets on HLA class I and class II molecules using large datasets of 
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donor and recipient pairs. Based on these mismatches and the information on de novo DSA 
formation, polymorphic amino acids crucial for the induction of an antibody response can 
be defined. For this purpose, we have developed a user-friendly software program, which 
analyses HLA class I and class II compatibility between donor and recipient on amino acid 
level focussing on the solvent accessible amino acid mismatches. For the analyses of large 
cohorts, a batch analysis option was incorporated into the software program.
METHODS
Development of HLA-EMMA
The HLA Epitope Mismatch Algorithm (HLA-EMMA) was developed in Microsoft Visual Studio 
and uses the .NET framework 4.6. It was written in VB.NET language. The software package 
is freely available for download (http://www.HLA-EMMA.com).
HLA amino acid sequences
All available HLA amino acid sequences were extracted from the IPD-IMGT/HLA database 
version 3.39 for HLA-A, -B, -C, -DRB1,3,4,5, -DQA1, -DQB1, -DPA1 and -DPB1 in January 2020,25 
and will be periodically updated in the software program. HLA alleles are included up to the 
second field typing resolution,26 since higher resolution typing does not affect the amino acid 
sequence of the protein. Null alleles, such as DRB4*01:03N, are recognised by the software 
program and will not be considered for analysis as these HLA alleles are not expressed on 
cells. HLA-EMMA contains the amino acid sequences for position 1 to 275 for HLA class I, and 
position 1 to 226 for HLA class II, the beginning of the mature proteins and regions that are of 
interest for antibody induction. For some HLA alleles, amino acid data at the beginning and/
or end of the sequence are lacking. These HLA alleles, often rare HLA alleles, are marked in 
the algorithm but not excluded from analysis.
Solvent accessible polymorphic positions
Solvent accessible polymorphic amino acid positions were determined using publicly available 
crystal structures and open source relative solvent accessibility prediction tools. HLA crystal 
structures were obtained from the Research Collaboratory for Structural Bioinformatics 
Protein Data Bank (PDB, https://www.rcsb.org/ accessed on February 4, 2019).27 More than 
690 PDB HLA structures were available, with the multiple structures of the same HLA allele. 
Therefore, the initial selection was based on previously described HLA structures used for 
modelling with accurate structural quality, based on parameters such as atomic resolution, R 
factor, total number of crystallographically resolved residues and stereochemical quality.17,28 
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Only HLA structures that are not in complex with a ligand and without any amino acid 
mutations were included. The list was extended with other, not yet included, HLA alleles of 
which structures are available with a correct amino acid sequence, not in complex with other 
ligands, and with finer atomic resolution (≤2.8Å). In case of multiple structures for a specific 
HLA allele the structure with highest atomic resolution was selected. This resulted in a total 
of 43 HLA class I crystal structures (Supplementary Table 1) and 20 HLA class II structures 
(Supplementary Table 2). Recently, an online database of HLA class I modelled structures of 
HLA molecules became available at https://www.phla3d.com.br/.29 Here, HLA class I tertiary 
structures were predicted by homology modelling using the amino acid sequences and 
homologous HLA class I structures, and then refined to improve the quality of the structures. 
From these HLA class I modelled structures only HLA alleles that were missing from the PDB 
list were selected (database accessed on April 11, 2019), resulting in 72 modelled structures 
(Supplementary Table 3).
Open source tools NetSurfP2.030 and Porter Pale4.031 were used to predict solvent inaccessible 
amino acid positions. First, for each HLA structure the relative solvent accessibility of each 
amino acid positions was predicted using both tools. Next, if both tools predicted a relative 
solvent accessibility of lower than 25% for a specific amino acid position on all HLA structures 
of an HLA locus than this position was defined as solvent inaccessible. All the remaining 
positions were defined as solvent accessible. Only positions that are polymorphic within a 
locus and, in addition, solvent accessible are considered for defining solvent accessible amino 
acid mismatches.
Due to limited availability of structures for HLA-DR, the polymorphic solvent accessible 
positions of HLA-DR loci were defined by all positions that are not predicted as solvent 
inaccessible for the available DRB1, DRB3, DRB4, and DRB5 structures and if a position is 
polymorphic for at least one of the DRB1, DRB3, DRB4 or DRB5 amino acid sequences. In 
addition, the amino acid sequences of the HLA class II structures are incomplete, and as a 
result solvent inaccessible prediction was lacking for the positions near the end of the amino 
acid sequences (HLA-DR positions 198-226, -DQB1 positions 198-226, -DQA1 position 199-226, 
-DPB1 positions 190-226 and -DPA1 positions 183-226). Those positions are currently defined 
as solvent accessible if polymorphic.
Input and output of HLA-EMMA
The donor and recipient HLA typing input of HLA-EMMA is preferentially second field HLA 
typing, since this resolution describes the specific HLA protein. In case an HLA allele is entered 
Cynthia_Binnenwerk_V3.indd   113 9-8-2020   14:52:55
114
that is not present in the IPD-IMGT/HLA database, HLA-EMMA will show a warning. However, 
incomplete HLA typing information can be entered, e.g. if DQA1 typing is missing, an output 
will still be generated. 
In case of serological typing or first field DNA typing HLA-EMMA will convert to the most 
likely second field typing, based on a panel of high-resolution typing results of a pre-defined 
population. Currently, conversion can be based on most common alleles of the population 
“the Netherlands, Leiden” (NL n=1305) (http://www.allelefrequencies.net), or most common 
HLA alleles of European Caucasians generated from the National Marrow Donor Program 
(EURCAU n=81106).32,33 If required, upon request the conversion option can be extended to 
other populations of which high resolution typing data is available and published.
Besides manual entry, a batch analysis option is included for which the input format is a 
Microsoft Excel file. For comparing donor and recipient HLA, a file containing the HLA typing 
of an individual is present on each row, and each column represents an allele (Supplementary 
Figure 1). The order of recipient and donor in file is irrelevant, provided that each recipient-
donor couple has a unique identification code, e.g. R1 and D1, for recipient and donor 
respectively.
Upon batch analysis, an export file .xml file is generated as an output file, which can be 
opened with Microsoft Excel (Supplementary Figure 2). While the output of the manual entry 
is generated and presented immediately, it can also be exported as .xml file for downstream 
application.
Study cohort for validation
To validate HLA-EMMA, we used a previously described lymphocyte immunotherapy study 
cohort (n=191).17 Briefly, this cohort consists of women that received their first lymphocyte 
immunotherapy from their male partner in 2009 and 2010. The HLA type of the women and 
their partner was determined by genotyping array (Illumina, San Diego, CA, USA) and HLA 
imputation. In addition, reverse PCR sequence-specific oligonucleotide was used to type 
HLA-A and HLA-B that were used as quality control. Antibodies against donor antigen were 
identified by testing sera, obtained 5 weeks (median 33 days, SD 4.5) following lymphocyte 
immunotherapy, with luminex single antigen bead (SAB) assays (One Lambda, Canoga Park, 
CA, USA) and DSA were defined as MFI of ≥2000. HLA mismatches of which HLA second field 
typing could not be determined, towards which DSA were present before treatment, or that 
were not present in luminex SAB assay were excluded from analysis.
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Figure 1: Polymorphic solvent accessible amino acid positions. For each locus the defined polymorphic 
solvent amino acid positions are indicated in grey for HLA class I (A) and HLA class II (B). C) The polymorphic 
solvent accessible positions defined by the HLA class I modelled structures.
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RESULTS
Polymorphic solvent accessible amino acid positions
The main goal of HLA-EMMA is to analyse HLA class I and class II compatibility on the amino 
acid level for a large number of donor-recipient pairs. The software program is based on the 
hypothesis that any polymorphic amino acid exposed on the surface of an HLA molecule can 
trigger an antibody response. To this aim, the polymorphic solvent accessible amino acid 
positions were defined per HLA locus using all known HLA alleles to determine polymorphic 
positions, and available HLA crystal structures to predict the solvent inaccessible positions, 
used for deduction of solvent accessible positions. Overall, this led to identification of 174 
polymorphic solvent accessible positions for HLA-A, 169 for HLA-B, 162 for HLA-C (Figure 
1A), 106 for HLA-DRB1/3/4/5, 149 for HLA-DQB1, 48 for HLA-DQA1, 86 for HLA-DPB1 and 
16 for HLA-DPA1 (Figure 1B). By analysing the HLA class I modelled structures, additional 
polymorphic solvent accessible positions were defined; 2 for HLA-A, 3 for HLA-B and 10 for 
HLA-C (Figure 1C).
HLA class I and class II solvent accessible amino acid mismatches between 
donor and recipient
HLA-EMMA compares the amino acid sequence of each donor HLA allele with the alleles from 
the same locus of the recipient, known as intralocus comparison, except for HLA-DRB1/3/4/5 
which is interlocus compared. For HLA class I, the default setting is intralocus comparison, 
but interlocus option can be selected when required. Amino acid mismatches are calculated 
for: 1) each donor HLA allele by total amino acid mismatches irrespective of location on the 
molecule, and 2) amino acid mismatches that are solvent accessible. In case of an incomplete 
HLA allele, indicated by *, only amino acid mismatches are calculated for the known amino 
acid sequence.
An example of manual entry for defining HLA solvent accessible amino acid mismatches 
between donor and recipient is shown in Figure 2A. After computation, a table containing the 
number of amino acid mismatches per donor HLA allele is generated (Figure 2B). In addition, 
HLA-EMMA provides detailed information on the position and the type of amino acid that are 
mismatched for both total amino acid sequence and solvent accessible positions (Figure 2C).
HLA-EMMA can be used to perform compatibility analysis for large numbers of donor-recipient 
pairs simultaneously in the form of a batch analysis. This requires uploading of an input file 
containing the HLA typing of the respective donor and recipient pairs (Supplementary Figure 
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1). HLA-EMMA generates an output file that consists of both the number of total and solvent 
accessible amino acid mismatches for each pair, as well as the position and the type of amino 
acid that are mismatched for each donor HLA allele (Supplementary Figure 2). In addition, the 
amino acids of the recipient’s HLA on the corresponding positions are provided in a separate 
column. This output can then be used for further analysis.
Another option available in HLA-EMMA is an amino acid sequence overview of all HLA alleles 
(Supplementary Figure 3). With this overview, multiple HLA alleles can be compared, and it 
can also be used to consult which HLA alleles share a specific amino acid.
A CB
Figure 2: HLA-EMMA manual entry with an example of a donor-recipient couple. A) Input field for 
HLA typing of donor and recipient. B) After selecting compute, the number of amino acid mismatches are 
generated for each donor HLA allele and shown in the result table. C) Details of a mismatched donor HLA 
allele shown after selecting the donor HLA allele in result table. Here, the mismatched amino acids and 
positions are shown. Residue properties are shown when selecting a specific amino acid.
Proof of principle
For validation of HLA-EMMA we used a previously described cohort of which the HLA-specific 
antibody response was defined for women that received lymphocyte immunotherapy from 
their male partner.17 Here, for each HLA-A, -B, -DRB1 and -DQ mismatch the number of solvent 
accessible amino acids was determined with HLA-EMMA using the default settings. For HLA-DQ 
the number of solvent accessible amino acids of DQA1 and DQB1 were combined (Figure 
3). We determined how often an HLA mismatch with specific solvent accessible amino acid 
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mismatches resulted in DSA formation and observed that the proportion of HLA mismatches 
that resulted in DSA formation increased with higher number of solvent accessible amino 
acids. For HLA-A, -B, and -DQ mismatches, the incidence of DSA was 80% in the group with 
the highest number of solvent accessible amino acid mismatches.
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Figure 3: Association between DSA formation and the number of solvent accessible amino acid 
mismatches. The number of solvent accessible amino acid mismatches were defined and DSA were 
determined per mismatched donor HLA allele. For HLA-A (A), HLA-B (B), HLA-DRB1 (C) and HLA-DQ (D) an 
increased proportion of HLA mismatches formed DSA with higher number of solvent accessible amino 
acid mismatches.
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DISCUSSION
Here, we present a software program HLA-EMMA that allows to determine the molecular HLA 
class I and class II compatibility between donor and recipient. Since amino acids are fixed 
entities on HLA molecules not dependent on assumptions or preconceptions, as well as the 
fact that single surface exposed amino acid mismatches can already be sufficient to induce 
an antibody response, HLA-EMMA was developed to analyse compatibility on the amino acid 
level. The software program focuses on solvent accessible amino acids mismatches, since B 
cell epitopes are known to consist of polymorphic amino acids that are surface exposed.34-36 
Data from recent studies showed no significant differences between eplet and amino acid 
mismatch scores for the prediction of DSA,12,21 indicating that both strategies are potentially 
useful. The benefit of HLA-EMMA is that large datasets of donor-recipient pairs from diverse 
populations can be analysed for both HLA class I and class II simultaneously. Since the position 
and type of amino acid mismatches are provided these can be used to identify relevant 
mismatches that are associated with development of de novo DSA.
Currently, HLAMatchmaker is the main tool used to determine HLA compatibility on structural 
level by analysing eplet mismatches. Eplets are defined as patches of polymorphic amino 
acids on surface exposed areas of the HLA molecules. The definition of surface exposure in 
HLAMatchmaker is based on the analysis of polymorphic positions on a select number of HLA 
crystal structures with Cn3D structure viewer.9,10 Surface exposure was labelled as prominent, 
readily visible or somewhat visible. In contrast, in HLA-EMMA, solvent accessible amino acid 
positions were defined per HLA locus and by excluding positions that were predicted by two 
validated tools to be solvent inaccessible for the available HLA structures per locus. These 
tools are neural network-based models trained to predict secondary structural features, such 
as relative solvent accessibility.30,31 The reason to define accessibility in this way and not by 
predicted solvent accessibility is the fact that not for every HLA allele a crystal structure is 
available, which may result in an amino acid position being incorrectly classified as solvent 
accessible for a specific HLA allele. When more HLA crystal structures or models become 
available, the solvent accessible amino acid position database in HLA-EMMA will be updated.
Besides solvent accessible amino acid mismatches, HLA-EMMA also calculates the total 
number of amino acid mismatches. This is useful in cases where no solvent accessible amino 
acid mismatches are defined for a donor HLA antigen mismatch that has resulted in DSA. 
Such antibody responses may be explained by non-exposed amino acid mismatches as they 
could have been induced by surface changes due to buried amino acid polymorphisms.28,37 
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A previously described tool, the Cambridge HLA immunogenicity algorithm developed by 
Kosmoliaptsis and colleagues, also determines the number of total amino acids mismatches 
as well as hydrophobicity and electrostatic mismatch scores.22,23
The default setting of HLA-EMMA is intralocus comparison for HLA class I. This is in contrast 
with HLAMatchmaker that performs interlocus comparison to determine the eplet mismatches 
for HLA class I.10,38 This difference in strategy is due to the fact that eplets are combinations 
of amino acids, while HLA-EMMA considers individual amino acids. A possible consequence 
of interlocus comparison on the individual amino acid level may be that polymorphic amino 
acids shared by HLA alleles are incorrectly classified as being compatible. With the interlocus 
comparison option for HLA class I the relevance of inter- versus intralocus comparison and 
antibody induction can be further investigated. In contrast, for HLA-DR the amino acid 
sequences are interlocus compared. This is due to the difference in expression of DRB3/4/5 
molecules of which an individual can have no more than two of the three possible alleles. 
Thus, if a donor carries one of the DRB3/4/5 loci that the recipient lacks, all amino acids on this 
allele would be mismatched by intralocus comparison. This will result in an overestimation of 
the number of mismatches without any indication of the relevant mismatches.
A previously described clinical cohort was used to validate HLA-EMMA as a tool to determine 
the immunogenicity of HLA mismatches on basis of a large data set. As expected, this cohort 
showed a higher frequency of DSA induction with a higher number of solvent accessible 
amino acid mismatches, indicating the validity of the software. Strikingly, for two HLA class I 
mismatches DSA were observed while there were no amino acid mismatches at the solvent 
accessible level nor at the total amino acid level, when analysed in the default intralocus 
manner. Interestingly, these cases were analysed with HLAMatchmaker, no eplet mismatches 
were observed (data not shown). It is important to note that the HLA typing of the individuals 
of this cohort was not all based on HLA sequencing but was largely done by a genotyping array 
and HLA imputation, which may have led to false classification of the second field HLA data, 
potentially resulting in zero amino acid mismatches, whilst DSA were formed.
By using HLA-EMMA we aim to establish the ability of specific amino acid mismatches to induce 
an antibody response by determining the incidence of de novo DSA in case of a mismatch of 
that specific amino acid. Immunogenicity depends on the HLA phenotype of the recipient 
but also of the donor, and HLA allele frequencies differ between populations and even within 
regions.39-41 This population difference is important to consider as amino acids that are highly 
immunogenic in one population, might be less immunogenic in another due to difference in 
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HLA allele distribution in the populations.42 Therefore, HLA-EMMA is one of the tools that will 
be used during the 18th International HLA and Immunogenetics Workshop (IHIWS) to identify 
immunogenic amino acid mismatches for a large group of donor-recipient pairs from diverse 
populations with information on de novo DSA development.
Ultimately, defining the immunogenic polymorphic amino acids is just the beginning. Based 
on this knowledge, we want to define specific polymorphic amino acid configurations similar 
as what has been done for the definition of the eplets. The immunogenic polymorphic amino 
acids will serve as a basis for the definition of the relevant amino acid configurations involved 
in antibody binding. While single amino acid can induce an antibody response, indicating 
immunogenicity, configurations of amino acids are involved in antibody-antigen interaction, 
which is antigenicity.43
Preventing the induction of de novo DSA formation after transplantation is essential for 
maximizing graft survival and the chance of potential repeat transplantation and therefore 
of utmost importance in paediatric setting where children will certainly need a repeat 
transplant. With HLA-EMMA, we developed a software program to perform HLA class I and 
class II compatibility analysis on amino acid level for recipient and donor couple individually 
and for large population studies that will contribute to the identification of these immunogenic 
polymorphic amino acid mismatches.
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DSA: Donor-specific antibodies
HLA: Human leukocyte antigen
HLA-EMMA: HLA epitope mismatch algorithm
IHIWS: International HLA and Immunogenetics Workshop
PDB: Protein Data Bank
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SUPPLEMENTAL MATERIAL
Supplementary Figure 1: An example of HLA typing input file for batch analysis with HLA-EMMA 
 
 
Supplementary Figure 2: An example of output file of batch analysis with HLA-EMMA 
 
Code A_1 A_2 B_1 B_2 C_1 C_2 DRB1_1 DRB1_2 DRB3/4/5_1 DRB3/4/5_2 DQB1_1 DQB1_2 DQA1_1 DQA1_2 DPB1_1 DPB1_2 DPA1_1 DPA1_2
R1 A*01:01 A*32:01 B*08:01 B*40:02 C*02:02 C*07:01 DRB1*11:01 DRB1*13:01 DRB3*02:01 DQB1*03:01 DQB1*06:03 DQA1*01:03 DQA1*05:05 DPB1*04:01 DPB1*105:01 DPA1*01:03
R303 A*01:01 A*02:01 B*07:02 B*37:01 C*06:02 C*07:02 DRB1*08:01 DRB1*15:01 DRB5*01:01 DQB1*04:02 DQB1*06:02 DQA1*01:02 DQA1*04:01 DPB1*02:01 DPB1*04:01 DPA1*01:03
D1 A*02:01 B*07:02 B*35:03 C*04:01 C*07:02 DRB1*04:01 DRB1*11:04 DRB4*01:03N DQB1*03:01 DQB1*03:02 DQA1*03:01 DQA1*05:05 DPB1*05:01 DPB1*05:01 DPA1*01:03
D303 A*01:01 A*68:01 B*40:02 B*51:01 C*02:02 DRB1*07:01 DRB1*13:01 DRB3*02:02 DRB4*01:03N DQB1*03:03 DQB1*06:03 DQA1*01:03 DQA1*02:01
R20Ser A1 A2 B7 B37 Cw6 Cw7 DR8 DR15 DR51 DQ4 DQ6
D20Ser A1 A68 B61 B51 Cw2 DR7 DR13 DR52 DR53 DQ9 DQ6
Code_recipient Locus_recipient HLA_allele_recipient Code_donor Locus_donor HLA_allele_donor Allele_Mismatches Total_AA_Mismatches Solvent_Accessibility Total_AA_Mismatches_Value Solvent_Accessibility_Value Profile_recipient Info
R1 A_1 A*01:01 D1 A_1 A*02:01 1 14 12 62G 66K 74H 76V 77D 95V 97R 105S 107W 114H 116Y 127K 142T 145H 62G 66K 76V 77D 97R 105S 107W 114H 116Y 127K 142T 145H 62Q 66N 74D 76A 77N 95I 97I 105P 107G 114R 116D 127N 142I 145R | 76E 77S 97M 114Q Version:  (1.00), Date:21-11-2019, Subtotals per locus:
R1 A_2 A*32:01 D1 A_2 Version:  (1.00), Date:21-11-2019, Subtotals per locus:
R1 D1 Subtotal HLA-A: 1 14 12 62G 66K 74H 76V 77D 95V 97R 105S 107W 114H 116Y 127K 142T 145H 62G 66K 76V 77D 97R 105S 107W 114H 116Y 127K 142T 145H Version:  (1.00), Date:21-11-2019, Subtotals per locus:
R1 B_1 B*08:01 D1 B_1 B*07:02 1 9 6 9Y 67Y 69A 70Q 71A 114D 152E 156R 178K 69A 70Q 71A 114D 152E 178K 9D 67F 69T 70N 71T 114N 152V 156D 178T | 9H 67S 156L Version:  (1.00), Date:21-11-2019, Subtotals per locus:
R1 B_2 B*40:02 D1 B_2 B*35:03 1 12 6 9Y 24A 45T 94I 95I 97R 103L 114D 116F 131S 163L 194V 45T 103L 114D 131S 163L 194V 9D 24S 45E 94T 95L 97S 103V 114N 116Y 131R 163T 194I | 9H 24T 45K 163E Version:  (1.00), Date:21-11-2019, Subtotals per locus:
R1 D1 Subtotal HLA-B: 2 19 11 9Y 24A 45T 67Y 69A 70Q 71A 94I 95I 97R 103L 114D 116F 131S 152E 156R 163L 178K 194V 45T 69A 70Q 71A 103L 114D 131S 152E 163L 178K 194V Version:  (1.00), Date:21-11-2019, Subtotals per locus:
R1 C_1 C*02:02 D1 C_1 C*04:01 1 11 5 1G 9S 11S 14W 49E 99F 114N 116F 156R 219W 275K 1G 14W 49E 219W 275K 1C 9Y 11A 14R 49A 99Y 114D 116S 156W 219R 275E | 9D 156L Version:  (1.00), Date:21-11-2019, Subtotals per locus:
R1 C_2 C*07:01 D1 C_2 C*07:02 1 1 0 99S 99Y | Version:  (1.00), Date:21-11-2019, Subtotals per locus:
R1 D1 Subtotal HLA-C: 2 12 5 1G 9S 11S 14W 49E 99F 99S 114N 116F 156R 219W 275K 1G 14W 49E 219W 275K Version:  (1.00), Date:21-11-2019, Subtotals per locus:
R1 DRB1_1 DRB1*11:01 D1 DRB1_2 DRB1*11:04 1 0 0 Version:  (1.00), Date:21-11-2019, Subtotals per locus:
R1 DRB1_2 DRB1*13:01 D1 DRB1_1 DRB1*04:01 1 8 7 10Q 11V 13H 33H 96Y 98E 120N 180L 10Q 11V 13H 33H 96Y 98E 120N 10Y 11S 13S 33N 96H 98K 120S 180V | 10L 11L 98Q Version:  (1.00), Date:21-11-2019, Subtotals per locus:
R1 DRB3/4/5_1 DRB3*02:01 D1 DRB3/4/5_1 DRB4*01:03N 1 0 0 Version:  (1.00), Date:21-11-2019, Subtotals per locus:
R1 DRB3/4/5_2 D1 DRB3/4/5_2 Version:  (1.00), Date:21-11-2019, Subtotals per locus:
R1 D1 Subtotal HLA-DR: 3 8 7 10Q 11V 13H 33H 96Y 98E 120N 180L 10Q 11V 13H 33H 96Y 98E 120N Version:  (1.00), Date:21-11-2019, Subtotals per locus:
R1 DQB1_1 DQB1*03:01 D1 DQB1_1 DQB1*03:01 0 0 0 Version:  (1.00), Date:21-11-2019, Subtotals per locus:
R1 DQB1_2 DQB1*06:03 D1 DQB1_2 DQB1*03:02 1 2 2 57A 185I 57A 185I 57D 185T | Version:  (1.00), Date:21-11-2019, Subtotals per locus:
R1 DQA1_1 DQA1*01:03 D1 DQA1_1 DQA1*03:01 1 10 8 26S 34E 47Q 50L 53R 56R 76V 175E 187T 215L 26S 47Q 50L 53R 56R 175E 187T 215L 26T 34Q 47R 50E 53K 56G 76M 175Q 187A 215F | 47C 50V 53Q 56F 76L 175K Version:  (1.00), Date:21-11-2019, Subtotals per locus:
R1 DQA1_2 DQA1*05:05 D1 DQA1_2 DQA1*05:05 0 0 0 Version:  (1.00), Date:21-11-2019, Subtotals per locus:
R1 D1 Subtotal HLA-DQ: 2 12 10 26S 34E 47Q 50L 53R 56R 57A 76V 175E 185I 187T 215L 26S 47Q 50L 53R 56R 57A 175E 185I 187T 215L Version:  (1.00), Date:21-11-2019, Subtotals per locus:
R1 DPB1_1 DPB1*04:01 D1 DPB1_1 DPB1*05:01 1 9 6 35L 55E 84D 85E 86A 87V 96K 170I 205M 84D 85E 86A 87V 96K 205M 35F 55A 84G 85G 86P 87M 96R 170T 205V | 55D Version:  (1.00), Date:21-11-2019, Subtotals per locus:
R1 DPB1_2 DPB1*105:01 D1 DPB1_2 Version:  (1.00), Date:21-11-2019, Subtotals per locus:
R1 DPA1_1 DPA1*01:03 D1 DPA1_1 DPA1*01:03 0 0 0 Version:  (1.00), Date:21-11-2019, Subtotals per locus:
R1 DPA1_2 D1 DPA1_2 Version:  (1.00), Date:21-11-2019, Subtotals per locus:
R1 D1 Subtotal HLA-DP: 1 9 6 35L 55E 84D 85E 86A 87V 96K 170I 205M 84D 85E 86A 87V 96K 205M Version:  (1.00), Date:21-11-2019, Subtotals per locus:
R303 A_1 A*01:01 D303 A_1 A*01:01 0 0 0 Version:  (1.00), Date:21-11-2019, Subtotals per locus:
R303 A_2 A*02:01 D303 A_2 A*68:01 1 7 3 9Y 62R 63N 70Q 97M 156W 245V 62R 70Q 97M 9F 62Q 63E 70H 97I 156R 245A | 62G 97R 156L Version:  (1.00), Date:21-11-2019, Subtotals per locus:
R303 D303 Subtotal HLA-A: 1 7 3 9Y 62R 63N 70Q 97M 156W 245V 62R 70Q 97M Version:  (1.00), Date:21-11-2019, Subtotals per locus:
R303 B_1 B*07:02 D303 B_1 B*40:02 1 5 3 24T 32L 41T 45K 156L 32L 41T 45K 24S 32Q 41A 45E 156R | 45T 156D Version:  (1.00), Date:21-11-2019, Subtotals per locus:
R303 B_2 B*37:01 D303 B_2 B*51:01 1 13 4 11A 12M 24A 67F 77N 80I 81A 95W 97T 156L 163L 171H 194V 77N 80I 163L 194V 11S 12V 24S 67Y 77S 80N 81L 95L 97S 156R 163E 171Y 194I | 67S 77D 80T 95I 97R 156D 163T Version:  (1.00), Date:21-11-2019, Subtotals per locus:
R303 D303 Subtotal HLA-B: 2 17 7 11A 12M 24A 24T 32L 41T 45K 67F 77N 80I 81A 95W 97T 156L 163L 171H 194V 32L 41T 45K 77N 80I 163L 194V Version:  (1.00), Date:21-11-2019, Subtotals per locus:
R303 C_1 C*06:02 D303 C_1 C*02:02 1 8 6 9Y 16S 21H 24A 73T 90A 163E 211T 16S 21H 73T 90A 163E 211T 9D 16G 21R 24S 73A 90D 163T 211A | Version:  (1.00), Date:21-11-2019, Subtotals per locus:
R303 C_2 C*07:02 D303 C_2 Version:  (1.00), Date:21-11-2019, Subtotals per locus:
R303 D303 Subtotal HLA-C: 1 8 6 9Y 16S 21H 24A 73T 90A 163E 211T 16S 21H 73T 90A 163E 211T Version:  (1.00), Date:21-11-2019, Subtotals per locus:
R303 DRB1_1 DRB1*08:01 D303 DRB1_1 DRB1*07:01 1 14 11 4Q 11G 14K 25Q 28E 30L 37F 57V 60S 73G 74Q 78V 98E 181M 4Q 11G 14K 25Q 57V 60S 73G 74Q 78V 98E 181M 4R 11S 14E 25R 28D 30Y 37Y 57S 60Y 73A 74L 78Y 98K 181T | 11D 28H 30D 37D 57D 74A Version:  (1.00), Date:21-11-2019, Subtotals per locus:
R303 DRB1_2 DRB1*15:01 D303 DRB1_2 DRB1*13:01 1 4 3 13S 32H 37N 71E 13S 32H 71E 13G 32Y 37Y 71R | 13Y 37D Version:  (1.00), Date:21-11-2019, Subtotals per locus:
R303 DRB3/4/5_1 D303 DRB3/4/5_2 DRB4*01:03N 1 0 0 Version:  (1.00), Date:21-11-2019, Subtotals per locus:
R303 DRB3/4/5_1 DRB5*01:01 D303 DRB3/4/5_1 DRB3*02:02 1 14 11 10L 11L 13S 28E 30H 32H 38A 51R 67L 71K 73G 74Q 77N 98Q 10L 11L 13S 32H 51R 67L 71K 73G 74Q 77N 98Q Version:  (1.00), Date:21-11-2019, Subtotals per locus:
R303 D303 Subtotal HLA-DR: 4 27 21
4Q 10L 11G 11L 13S 14K 25Q 28E 30H 30L 32H 37F 37N 38A 51R 57V 60S 67L 71E 71K 73G 74Q 
77N 78V 98E 98Q 181M 4Q 10L 11G 11L 13S 14K 25Q 32H 51R 57V 60S 67L 71E 71K 73G 74Q 77N 78V 98E 98Q 181M Version:  (1.00), Date:21-11-2019, Subtotals per locus:
R303 DQB1_1 DQB1*04:02 D303 DQB1_1 DQB1*03:03 1 3 3 9Y 55P 70R 9Y 55P 70R 9F 55R 70E | 70G Version:  (1.00), Date:21-11-2019, Subtotals per locus:
R303 DQB1_2 DQB1*06:02 D303 DQB1_2 DQB1*06:03 1 2 1 9Y 30H 9Y 9F 30Y | Version:  (1.00), Date:21-11-2019, Subtotals per locus:
R303 DQA1_1 DQA1*01:02 D303 DQA1_1 DQA1*01:03 1 3 3 25F 41K 130A 25F 41K 130A 25Y 41R 130S | Version:  (1.00), Date:21-11-2019, Subtotals per locus:
R303 DQA1_2 DQA1*04:01 D303 DQA1_2 DQA1*02:01 1 9 7 25F 34E 47K 50L 52H 53R 54L 69L 215L 25F 47K 50L 52H 53R 54L 215L 25Y 34Q 47R 50E 52S 53K 54F 69A 215F | 47C 50V 52R 53Q 69T Version:  (1.00), Date:21-11-2019, Subtotals per locus:
R303 D303 Subtotal HLA-DQ: 4 15 12 9Y 25F 30H 34E 41K 47K 50L 52H 53R 54L 55P 69L 70R 130A 215L 9Y 25F 41K 47K 50L 52H 53R 54L 55P 70R 130A 215L Version:  (1.00), Date:21-11-2019, Subtotals per locus:
R303 DPB1_1 DPB1*02:01 D303 DPB1_1 Version:  (1.00), Date:21-11-2019, Subtotals per locus:
R303 DPB1_2 DPB1*04:01 D303 DPB1_2 Version:  (1.00), Date:21-11-2019, Subtotals per locus:
R303 DPA1_1 DPA1*01:03 D303 DPA1_1 Version:  (1.00), Date:21-11-2019, Subtotals per locus:
R303 DPA1_2 D303 DPA1_2 Version:  (1.00), Date:21-11-2019, Subtotals per locus:
R303 D303 Subtotal HLA-DP: 0 0 0 Version:  (1.00), Date:21-11-2019, Subtotals per locus:
R20Ser A_1 A*01:01 D20Ser A_1 A*01:01 0 0 0 Version:  (1.00), Date:21-11-2019, Subtotals per locus:
R20Ser A_2 A*02:01 D20Ser A_2 A*68:01 1 7 3 9Y 62R 63N 70Q 97M 156W 245V 62R 70Q 97M 9F 62Q 63E 70H 97I 156R 245A | 62G 97R 156L Version:  (1.00), Date:21-11-2019, Subtotals per locus:
R20Ser D20Ser Subtotal HLA-A: 1 7 3 9Y 62R 63N 70Q 97M 156W 245V 62R 70Q 97M Version:  (1.00), Date:21-11-2019, Subtotals per locus:
R20Ser B_1 B*07:02 D20Ser B_1 B*40:02 1 5 3 24T 32L 41T 45K 156L 32L 41T 45K 24S 32Q 41A 45E 156R | 45T 156D Version:  (1.00), Date:21-11-2019, Subtotals per locus:
R20Ser B_2 B*37:01 D20Ser B_2 B*51:01 1 13 4 11A 12M 24A 67F 77N 80I 81A 95W 97T 156L 163L 171H 194V 77N 80I 163L 194V 11S 12V 24S 67Y 77S 80N 81L 95L 97S 156R 163E 171Y 194I | 67S 77D 80T 95I 97R 156D 163T Version:  (1.00), Date:21-11-2019, Subtotals per locus:
R20Ser D20Ser Subtotal HLA-B: 2 17 7 11A 12M 24A 24T 32L 41T 45K 67F 77N 80I 81A 95W 97T 156L 163L 171H 194V 32L 41T 45K 77N 80I 163L 194V Version:  (1.00), Date:21-11-2019, Subtotals per locus:
R20Ser C_1 C*06:02 D20Ser C_1 C*02:02 1 8 6 9Y 16S 21H 24A 73T 90A 163E 211T 16S 21H 73T 90A 163E 211T 9D 16G 21R 24S 73A 90D 163T 211A | Version:  (1.00), Date:21-11-2019, Subtotals per locus:
R20Ser C_2 C*07:02 D20Ser C_2 Version:  (1.00), Date:21-11-2019, Subtotals per locus:
R20Ser D20Ser Subtotal HLA-C: 1 8 6 9Y 16S 21H 24A 73T 90A 163E 211T 16S 21H 73T 90A 163E 211T Version:  (1.00), Date:21-11-2019, Subtotals per locus:
R20Ser DRB1_1 DRB1*08:01 D20Ser DRB1_1 DRB1*07:01 1 14 11 4Q 11G 14K 25Q 28E 30L 37F 57V 60S 73G 74Q 78V 98E 181M 4Q 11G 14K 25Q 57V 60S 73G 74Q 78V 98E 181M 4R 11S 14E 25R 28D 30Y 37Y 57S 60Y 73A 74L 78Y 98K 181T | 11D 28H 30D 37D 57D 74A Version:  (1.00), Date:21-11-2019, Subtotals per locus:
R20Ser DRB1_2 DRB1*15:01 D20Ser DRB1_2 DRB1*13:01 1 4 3 13S 32H 37N 71E 13S 32H 71E 13G 32Y 37Y 71R | 13Y 37D Version:  (1.00), Date:21-11-2019, Subtotals per locus:
R20Ser DRB3/4/5_1 D20Ser DRB3/4/5_2 DRB4*01:01 1 20 13 4Q 11A 13C 18L 25W 26N 28I 38A 40Y 41N 44L 48Q 67L 70R 74E 81Y 180M 181M 187Q 215T 4Q 11A 13C 18L 25W 41N 44L 48Q 67L 70R 74E 81Y 181M
4R 11S 13G 18F 25R 26F 28D 38V 40F 41D 44V 48R 67F 70D 74L 81H 180V 181T 187E 215A | 11D 
13Y 28H 38L 74A Version:  (1.00), Date:21-11-2019, Subtotals per locus:
R20Ser DRB3/4/5_1 DRB5*01:01 D20Ser DRB3/4/5_1 DRB3*02:02 1 14 11 10L 11L 13S 28E 30H 32H 38A 51R 67L 71K 73G 74Q 77N 98Q 10L 11L 13S 32H 51R 67L 71K 73G 74Q 77N 98Q Version:  (1.00), Date:21-11-2019, Subtotals per locus:
R20Ser D20Ser Subtotal HLA-DR: 4 43 31
4Q 10L 11A 11G 11L 13C 13S 14K 18L 25Q 25W 26N 28E 28I 30H 30L 32H 37F 37N 38A 40Y 41N 
44L 48Q 51R 57V 60S 67L 70R 71E 71K 73G 74E 74Q 77N 78V 81Y 98E 98Q 180M 181M 187Q 215T
4Q 10L 11A 11G 11L 13C 13S 14K 18L 25Q 25W 32H 41N 44L 48Q 51R 57V 60S 67L 70R 71E 71K 
73G 74E 74Q 77N 78V 81Y 98E 98Q 181M Version:  (1.00), Date:21-11-2019, Subtotals per locus:
R20Ser DQB1_1 DQB1*04:02 D20Ser DQB1_1 DQB1*03:03 1 3 3 9Y 55P 70R 9Y 55P 70R 9F 55R 70E | 70G Version:  (1.00), Date:21-11-2019, Subtotals per locus:
R20Ser DQB1_2 DQB1*06:02 D20Ser DQB1_2 DQB1*06:02 0 0 0 Version:  (1.00), Date:21-11-2019, Subtotals per locus:
R20Ser DQA1_1 D20Ser DQA1_1 Version:  (1.00), Date:21-11-2019, Subtotals per locus:
R20Ser DQA1_2 D20Ser DQA1_2 Version:  (1.00), Date:21-11-2019, Subtotals per locus:
R20Ser D20Ser Subtotal HLA-DQ: 1 3 3 9Y 55P 70R 9Y 55P 70R Version:  (1.00), Date:21-11-2019, Subtotals per locus:
R20Ser DPB1_1 D20Ser DPB1_1 Version:  (1.00), Date:21-11-2019, Subtotals per locus:
R20Ser DPB1_2 D20Ser DPB1_2 Version:  (1.00), Date:21-11-2019, Subtotals per locus:
R20Ser DPA1_1 D20Ser DPA1_1 Version:  (1.00), Date:21-11-2019, Subtotals per locus:
R20Ser DPA1_2 D20Ser DPA1_2 Version:  (1.00), Date:21-11-2019, Subtotals per locus:
R20Ser D20Ser Subtotal HLA-DP: 0 0 0 Version:  (1.00), Date:21-11-2019, Subtotals per locus:
Supplementary Figure 1: An example of an HLA typing input file for batch analysis with HLA-EMMA. 
For batch analysis the input format is a Microsoft Excel file according to the template as indic ted in the 
figure. Donor and recipient pairs are indicated by corresponding codes, here indicated by sam  n mber, 
thus compatibility analysis between D1 and R1 will be performed and same applies for D303 nd R303, 
and 20Ser and R20Ser. Both second field typing, and serological typing can be entered, as shown for 
D20Ser and R20ser.
Supplementary Figure 1: An example of HLA typing input file for batch analysis with HLA-EMMA 
 
 
Supplementary Figure 2: An example of output file of batch analysis with HLA-EMMA 
 
Code A_1 A_2 B_1 B_2 C_1 C_2 DRB1_1 DRB1_2 DRB3/4/5_1 DRB3/4/5_2 DQB1_1 DQB1_2 DQA1_1 DQA1_2 DPB1_1 DPB1_2 DPA1_1 DPA1_2
R1 A*01:01 A*32:01 B*08:01 B*40:02 C*02:02 C*07:01 DRB1*11:01 DRB1*13:01 DRB3*02:01 DQB1*03:01 DQB1*06:03 DQA1*01:03 DQA1*05:05 DPB1*04:01 DPB1*105:01 DPA1*01:03
R303 A*01:01 A*02:01 B*07:02 B*37:01 C*06:02 C*07:02 DRB1*08:01 DRB1*15:01 DRB5*01:01 DQB1*04:02 DQB1*06:02 DQA1*01:02 DQA1*04:01 DPB1*02:01 DPB1*04:01 DPA *01:03
D1 A*02:01 B*07:02 B*35:03 C*04:01 C*07:02 DRB1*04:01 DRB1*11:04 DRB4*01:03N DQB1*03:01 DQB1*03:02 DQA1*03:01 DQA1*05:05 DPB1*05:01 DPB1*05:01 DPA1*01:03
D303 A*01:01 A*68:01 B*40:02 B*51:01 C*02:02 DRB1*07:01 DRB1*13:01 DRB3*02:02 DRB4*01:03N DQB1*03:03 DQB1*06:03 DQA1*01:03 DQA1*02:01
R20Ser A1 A2 B7 B37 Cw6 Cw7 DR8 DR15 DR51 D 4 DQ6
D20Ser A1 A68 B61 B51 Cw2 DR7 DR13 DR52 DR53 DQ9 DQ6
Code_recipient Locus_recipient HLA_allele_recipient Code_donor Locus_donor HLA_allele_donor Allele_Mismatches Total_AA_Mismatches Solvent_Accessibility Total_AA_Mismatches_Value Solvent_Accessibility_Value Profile_recipient Info
R1 A_1 A*01:01 D1 A_1 A*02:01 1 14 12 62G 66K 74H 76V 77D 95V 97R 105S 107W 114H 116Y 127K 142T 145H 62G 66K 76V 77D 97R 105S 107W 114H 116Y 127K 142T 145H 62Q 66N 74D 76A 77N 95I 97I 105P 107G 114R 116D 127N 142I 145R | 76E 77S 97M 114Q Version:  (1.00), Date:21-11-2019, Subtotals per locus:
R1 A_2 A*32:01 D1 A_2 Version:  (1.00), Date:21-11-2019, Subtotals per locus:
R1 D1 Subtotal HLA-A: 1 14 12 62G 66K 74H 76V 77D 95V 97R 105S 107W 114H 116Y 127K 142T 145H 62G 66K 76V 77D 97R 105S 107W 114H 116Y 127K 142T 145H Version:  (1.00), Date:21-11-2019, Subtotals per locus:
R1 B_1 B*08:01 D1 B_1 B*07:02 1 9 6 9Y 67Y 69A 70Q 71A 114D 152E 156R 178K 69A 70Q 71A 114D 152E 178K 9D 67F 69T 70N 71T 114N 152V 156D 178T | 9H 67S 156L Version:  (1.00), Date:21-11-2019, Subtotals per locus:
R1 B_2 B*40:02 D1 B_2 B*35:03 1 12 6 9Y 24A 45T 94I 95I 97R 103L 114D 116F 131S 163L 194V 45T 103L 114D 131S 163L 194V 9D 24S 45E 94T 95L 97S 103V 114N 116Y 131R 163T 194I | 9H 24T 45K 163E Version:  (1.00), Date:21-11-2019, Subtotals per locus:
R1 D1 Subtotal HLA-B: 2 19 11 9Y 24A 45T 67Y 69A 70Q 71A 94I 95I 97R 103L 114D 116F 131S 152E 156R 163L 178K 194V 45T 69A 70Q 71A 103L 114D 131S 152E 163L 178K 194V Version:  (1.00), Date:21-11-2019, Subtotals per locus:
R1 C_1 C*02:02 D1 C_1 C*04:01 1 11 5 1G 9S 11S 14W 49E 99F 114N 116F 156R 219W 275K 1G 14W 49E 219W 275K 1C 9Y 11A 14R 49A 99Y 114D 116S 156W 219R 275E | 9D 156L Version:  (1.00), Date:21-11-2019, Subtotals per locus:
R1 C_2 C*07:01 D1 C_2 C*07:02 1 1 0 99S 99Y | Version:  (1.00), Date:21-11-2019, Subtotals per locus:
R1 D1 Subtotal HLA-C: 2 12 5 1G 9S 11S 14W 49E 99F 99S 114N 116F 156R 219W 275K 1G 14W 49E 219W 275K Version:  (1.00), Date:21-11-2019, Subtotals per locus:
R1 DRB1_1 DRB1*11:01 D1 DRB1_2 DRB1*11:04 1 0 0 Version:  (1.00), Date:21-11-2019, Subtotals per locus:
R1 DRB1_2 DRB1*13:01 D1 DRB1_1 DRB1*04:01 1 8 7 10Q 11V 13H 33H 96Y 98E 120N 180L 10Q 11V 13H 33H 96Y 98E 120N 10Y 11S 13S 33N 96H 98K 120S 180V | 10L 11L 98Q Version:  (1.00), Date:21-11-2019, Subtotals per locus:
R1 DRB3/4/5_1 DRB3*02:01 D1 DRB3/4/5_1 DRB4*01:03N 1 0 0 Version:  (1.00), Date:21-11-2019, Subtotals per locus:
R1 DRB3/4/5_2 D1 DRB3/4/5_2 Version:  (1.00), Date:21-11-2019, Subtotals per locus:
R1 D1 Subtotal HLA-DR: 3 8 7 10Q 11V 13H 33H 96Y 98E 120N 180L 10Q 11V 13H 33H 96Y 98E 120N Version:  (1.00), Date:21-11-2019, Subtotals per locus:
R1 DQB1_1 DQB1*03:01 D1 DQB1_1 DQB1*03:01 0 0 0 Version:  (1.00), Date:21-11-2019, Subtotals per locus:
R1 DQB1_2 DQB1*06:03 D1 DQB1_2 DQB1*03:02 1 2 2 57A 185I 57A 185I 57D 185T | Version:  (1.00), Date:21-11-2019, Subtotals per locus:
R1 DQA1_1 DQA1*01:03 D1 DQA1_1 DQA1*03:01 1 10 8 26S 34E 47Q 50L 53R 56R 76V 175E 187T 215L 26S 47Q 50L 53R 56R 175E 187T 215L 26T 34Q 47R 50E 53K 56G 76M 175Q 187A 215F | 47C 50V 53Q 56F 76L 175K Version:  (1.00), Date:21-11-2019, Subtotals per locus:
R1 DQA1_2 DQA1*05:05 D1 DQA1_2 DQA1*05:05 0 0 0 Version:  (1.00), Date:21-11-2019, Subtotals per locus:
R1 D1 Subtotal HLA-DQ: 2 12 10 26S 34E 47Q 50L 53R 56R 57A 76V 175E 185I 187T 215L 26S 47Q 50L 53R 56R 57A 175E 185I 187T 215L Version:  (1.00), Date:21-11-2019, Subtotals per locus:
R1 DPB1_1 DPB1*04:01 D1 DPB1_1 DPB1*05:01 1 9 6 35L 55E 84D 85E 86A 87V 96K 170I 205M 84D 85E 86A 87V 96K 205M 35F 55A 84G 85G 86P 87M 96R 170T 205V | 55D Version:  (1.00), Date:21-11-2019, Subtotals per locus:
R1 DPB1_2 DPB1*105:01 D1 DPB1_2 Version:  (1.00), Date:21-11-2019, Subtotals per locus:
R1 DPA1_1 DPA1*01:03 D1 DPA1_1 DPA1*01:03 0 0 0 Version:  (1.00), Date:21-11-2019, Subtotals per locus:
R1 DPA1_2 D1 DPA1_2 Version:  (1.00), Date:21-11-2019, Subtotals per locus:
R1 D1 Subtotal HLA-DP: 1 9 6 35L 55E 84D 85E 86A 87V 96K 170I 205M 84D 85E 86A 87V 96K 205M Version:  (1.00), Date:21-11-2019, Subtotals per locus:
R303 A_1 A*01:01 D303 A_1 A*01:01 0 0 0 Version:  (1.00), Date:21-11-2019, Subtotals per locus:
R303 A_2 A*02:01 D303 A_2 A*68:01 1 7 3 9Y 62R 63N 70Q 97M 156W 2 5V 62R 70Q 97M 9F 62Q 63E 70H 97I 156R 245A | 62G 97R 156L Version:  (1.00), Date:21-1 -2019, Subtotals per locus:
R303 D303 Subtotal HLA-A: 1 7 3 9Y 62R 63N 7 Q 97M 156W 245V 62R 70Q 97M Version:  (1.00), Date:21-1 -2019, Subtotals per locus:
R303 B_1 B*07:02 D303 B_1 B*40:02 1 5 3 24T 32L 41T 45K 156L 32L 41T 45K 24S 32Q 41A 45E 156R | 45T 156D Version:  (1.00), Date:21-11-2019, Subtotals per locus:
R303 B_2 B*37:01 D303 B_2 B*51:01 1 13 4 11A 12M 24A 67F 7N 80I 81A 95W 97T 156L 163L 1 1H 194V 7N 80I 163L 194V 11S 12V 24S 67Y 77S 80N 81L 95L 97S 156R 163E 171Y 194I | 67S 77D 80T 95I 97R 156D 163T Version:  (1.00), Date:21-1 -2019, Subtotals per locus:
R303 D303 Subtotal HLA-B: 2 17 7 11A 12M 24A 24T 32L 41T 45K 67F 77N 80I 81A 95W 97T 156L 163L 171H 194V 32L 41T 45K 77N 80I 163L 194V Version:  (1.00), Date:21-1 -2019, Subtotals per locus:
R303 C 1 C D303 C 1 C 2 1 8 6 9Y 16S 21H 24A 73T 90A 163E 211T 16S 21H 73T 90A 163E 211T 9D 16G 21R 24S 73A 90D 163T 211A | Version:  (1.00), Date:21-1 -2019, Subtotals per locus:
R303 C 2 C*07:02 D303 C 2 Version:  (1.00), Date:21-1 -2019, Subtotals per locus:
R303 D303 Subtotal HLA-C: 1 8 6 9Y 16S 21H 24A 73T 90A 163E 211T 16S 21H 73T 90A 163E 211T Version:  (1.00), Date:21-1 -2019, Subtotals per locus:
R303 DRB1_1 DRB1*08:01 D303 DRB1_1 DRB1*07:01 1 14 11 4Q 11G 14K 25Q 28E 30L 37F 57V 60S 73G 74Q 78V 98E 181M 4Q 11G 14K 25Q 57V 60S 73G 74Q 78V 98E 181M 4R 11S 14E 25R 28D 30Y 37Y 57S 60Y 73A 74L 78Y 98K 181T | 11D 28H 30D 37D 57D 74A Version:  (1.00), Date:21-1 -2019, Subtotals per locus:
R303 DRB1_2 DRB1*15:01 D303 DRB1_2 DRB1*13:01 1 4 3 13S 32H 37N 71E 13S 32H 71E 13G 32Y 37Y 71R | 13Y 37D Version:  (1.00), Date:21-1 -2019, Subtotals per locus:
R303 DRB3/4/5_1 D303 DRB3/4/5_2 DRB4*01:03N 1 0 0 Version:  (1.00), Date:21-1 -2019, Subtotals per locus:
R303 DRB3/4/5_1 DRB5*01:01 D303 DRB3/4/5_1 DRB3*02:02 1 14 11 10L 11L 13S 28E 30H 32H 38A 51R 67L 71K 73G 74Q 77N 98Q 10L 11L 13S 32H 51R 67L 71K 73G 74Q 77N 98Q Version:  (1.00), Date:21-1 -2019, Subtotals per locus:
R303 D303 Subtotal HLA-DR: 4 27 21
4Q 10L 11G 11L 13S 14K 25Q 28E 30H 30L 32H 37F 37N 38A 51R 57V 60S 67L 71E 71K 73G 74Q 
77N 78V 98E 98Q 181M 4Q 10L 11G 11L 13S 14K 25Q 32H 51R 57V 60S 67L 71E 71K 73G 74Q 77N 78V 98E 98Q 181M Version:  (1.00), Date:21-1 -2019, Subtotals per locus:
R303 DQB1_1 DQB1*04:02 D303 DQB1_1 DQB1*03:03 1 3 3 9Y 55P 70R 9Y 55P 70R 9F 55R 70E | 70G Version:  (1.00), Date:21-11-2019, Subtotals per locus:
R303 DQB1_2 DQB1*06:02 D303 DQB1_2 DQB1*06:03 1 2 1 9Y 30H 9Y 9F 30Y | Version:  (1.00), Date:21-11-2019, Subtotals per locus:
R303 DQA1_1 DQA1*01:02 D303 DQA1_1 DQA1*01:03 1 3 3 25F 41K 130A 25F 41K 130A 25Y 41R 130S | Version:  (1.00), Date:21-11-2019, Subtotals per locus:
R303 DQA1_2 DQA1*04:01 D303 DQA1_2 DQA1*02:01 1 9 7 25F 34E 47K 50L 52H 53R 54L 69L 215L 25F 47K 50L 52H 53R 54L 215L 25Y 34Q 47R 50E 52S 53K 54F 69A 215F | 47C 50V 52R 53Q 69T Version:  (1.00), Date:21-11-2019, Subtotals per locus:
R303 D303 Subtotal HLA-DQ: 4 15 12 9Y 25F 30H 34E 41K 47K 50L 52H 53R 54L 55P 69L 70R 130A 215L 9Y 25F 41K 47K 50L 52H 53R 54L 55P 70R 130A 215L Version:  (1.00), Date:21-11-2019, Subtotals per locus:
R303 DPB1_1 DPB1*02:01 D303 DPB1_1 Version:  (1.00), Date:21-11-2019, Subtotals per locus:
R303 DPB1_2 DPB1*04:01 D303 DPB1_2 Version:  (1.00), Date:21-11-2019, Subtotals per locus:
R303 DPA1_1 DPA1*01:03 D303 DPA1_1 Version:  (1.00), Date:21-11-2019, Subtotals per locus:
R303 DPA1_2 D303 DPA1_2 Version:  (1.00), Date:21-11-2019, Subtotals per locus:
R303 D303 Subtotal HLA-DP: 0 0 0 Version:  (1.00), Date:21-11-2019, Subtotals per locus:
R20Ser A_1 A*01:01 D20Ser A_1 A*01:01 0 0 0 Version:  (1.00), Date:21-11-2019, Subtotals per locus:
R20Ser A_2 A*02:01 D20Ser A_2 A*68:01 1 7 3 9Y 62R 63N 70Q 97M 156W 245V 62R 70Q 97M 9F 62Q 63E 70H 97I 156R 245A | 62G 97R 156L Version:  (1.00), Date:21-11-2019, Subtotals per locus:
R20Ser D20Ser Subtotal HLA-A: 1 7 3 9Y 62R 63N 70Q 97M 156W 245V 62R 70Q 97M Version:  (1.00), Date:21-11-2019, Subtotals per locus:
R20Ser B_1 B*07:02 D20Ser B_1 B*40:02 1 5 3 24T 32L 41T 45K 156L 32L 41T 45K 24S 32Q 41A 45E 156R | 45T 156D Version:  (1.00), Date:21-11-2019, Subtotals per locus:
R20Ser B_2 B*37:01 D20Ser B_2 B*51:01 1 13 4 11A 12M 24A 67F 77N 80I 81A 95W 97T 156L 163L 171H 194V 77N 80I 163L 194V 11S 12V 24S 67Y 77S 80N 81L 95L 97S 156R 163E 171Y 194I | 67S 77D 80T 95I 97R 156D 163T Version:  (1.00), Date:21-11-2019, Subtotals per locus:
R20Ser D20Ser Subtotal HLA-B: 2 17 7 11A 12M 24A 24T 32L 41T 45K 67F 77N 80I 81A 95W 97T 156L 163L 171H 194V 32L 41T 45K 77N 80I 163L 194V Version:  (1.00), Date:21-11-2019, Subtotals per locus:
R20Ser C_1 C*06:02 D20Ser C_1 C*02:02 1 8 6 9Y 16S 21H 24A 73T 90A 163E 211T 16S 21H 73T 90A 163E 211T 9D 16G 21R 24S 73A 90D 163T 211A | Version:  (1.00), Date:21-11-2019, Subtotals per locus:
R20Ser C_2 C*07:02 D20Ser C_2 Version:  (1.00), Date:21-11-2019, Subtotals per locus:
R20Ser D20Ser Subtotal HLA-C: 1 8 6 9Y 16S 21H 24A 73T 90A 163E 211T 16S 21H 73T 90A 163E 211T Version:  (1.00), Date:21-11-2019, Subtotals per locus:
R20Ser DRB1_1 DRB1*08:01 D20Ser DRB1_1 DRB1*07:01 1 14 11 4Q 11G 14K 25Q 28E 30L 37F 57V 60S 73G 74Q 78V 98E 181M 4Q 11G 14K 25Q 57V 60S 73G 74Q 78V 98E 181M 4R 11S 14E 25R 28D 30Y 37Y 57S 60Y 73A 74L 78Y 98K 181T | 11D 28H 30D 37D 57D 74A Version:  (1.00), Date:21-11-2019, Subtotals per locus:
R20Ser DRB1_2 DRB1*15:01 D20Ser DRB1_2 DRB1*13:01 1 4 3 13S 32H 37N 71E 13S 32H 71E 13G 32Y 37Y 71R | 13Y 37D Version:  (1.00), Date:21-11-2019, Subtotals per locus:
R20Ser DRB3/4/5_1 D20Ser DRB3/4/5_2 DRB4*01:01 1 20 13 4Q 11A 13C 18L 25W 26N 28I 38A 40Y 41N 44L 48Q 67L 70R 74E 81Y 180M 181M 187Q 215T 4Q 11A 13C 18L 25W 41N 44L 48Q 67L 70R 74E 81Y 181M
4R 11S 13G 18F 25R 26F 28D 38V 40F 41D 44V 48R 67F 70D 74L 81H 180V 181T 187E 215A | 11D 
13Y 28H 38L 74A Version:  (1.00), Date:21-11-2019, Subtotals per locus:
R20Ser DRB3/4/5_1 DRB5*01:01 D20Ser DRB3/4/5_1 DRB3*02:02 1 14 11 10L 11L 13S 28E 30H 32H 38A 51R 67L 71K 73G 74Q 77N 98Q 10L 11L 13S 32H 51R 67L 71K 73G 74Q 77N 98Q Version:  (1.00), Date:21-11-2019, Subtotals per locus:
R20Ser D20Ser Subtotal HLA-DR: 4 43 31
4Q 10L 11A 11G 11L 13C 13S 14K 18L 25Q 25W 26N 28E 28I 30H 30L 32H 37F 37N 38A 40Y 41N 
44L 48Q 51R 57V 60S 67L 70R 71E 71K 73G 74E 74Q 77N 78V 81Y 98E 98Q 180M 181M 187Q 215T
4Q 10L 11A 11G 11L 13C 13S 14K 18L 25Q 25W 32H 41N 44L 48Q 51R 57V 60S 67L 70R 71E 71K 
73G 74E 74Q 77N 78V 81Y 98E 98Q 181M Version:  (1.00), Date:21-11-2019, Subtotals per locus:
R20Ser DQB1_1 DQB1*04:02 D20Ser DQB1_1 DQB1*03:03 1 3 3 9Y 55P 70R 9Y 55P 70R 9F 55R 70E | 70G Version:  (1.00), Date:21-11-2019, Subtotals per locus:
R20Ser DQB1_2 DQB1*06:02 D20Ser DQB1_2 DQB1*06:02 0 0 0 Version:  (1.00), Date:21-11-2019, Subtotals per locus:
R20Ser DQA1_1 D20Ser DQA1_1 Version:  (1.00), Date:21-11-2019, Subtotals per locus:
R20Ser DQA1_2 D20Ser DQA1_2 Version:  (1.00), Date:21-11-2019, Subtotals per locus:
R20Ser D20Ser Subtotal HLA-DQ: 1 3 3 9Y 55P 70R 9Y 55P 70R Version:  (1.00), Date:21-11-2019, Subtotals per locus:
R20Ser DPB1_1 D20Ser DPB1_1 Version:  (1.00), Date:21-11-2019, Subtotals per locus:
R20Ser DPB1_2 D20Ser DPB1_2 Version:  (1.00), Date:21-11-2019, Subtotals per locus:
R20Ser DPA1_1 D20Ser DPA1_1 Version:  (1.00), Date:21-11-2019, Subtotals per locus:
R20Ser DPA1_2 D20Ser DPA1_2 Version:  (1.00), Date:21-11-2019, Subtotals per locus:
R20Ser D20Ser Subtotal HLA-DP: 0 0 0 Version:  (1.00), Date:21-11-2019, Subtotals per locus:
Supplementary Figure 2: An example of output file of batch analysis with HLA-EMMA. The output file 
of HLA-EMMA batch analysis is a Microsoft Excel file. Here the output file of input file from supplementary 
figure 1 is shown. In the output file the HLA alleles of donor and recipient are presented. The first six col-
umns show the information of the input file, thus code_recipient, Locus_recipient, HLA_allele_recipient, 
code_donor, Locus_donor, and HLA_allele_donor. Then each column provides information of the analysis. 
Allele_Mismatches column indicates if the donor allele of that specific row is mismatched with recipient 
by the number 1 and if the donor allele is matched than a 0 is given. Next, in Total_AA_mismatches the 
number of total amino acid mismatches is provided for the donor allele, and the number of solvent ac-
cessible amino acid mismatches can be found in Solvent_Accessibility column. The Total_AA_Mismatch-
es_Value and Solvent_Accessibility_Value columns list the positions and the type of amino acid that are 
mismatched. Next column, Profile_Recipients, shows the amino acids of the recipient’s HLA allele on the 
mismatched positions, divided by | to separate each HLA allele within the locus. The HLA-EMMA version, 
run date, and other additional information can be found in the last column.
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Supplementary Figure 3: Amino acid sequence overview. HLA-EMMA also provides all the amino acid 
sequences in an overview. This can be used to compare different alleles on full amino acid sequence 
(A) or compact and therefore only showing the positions that are different (B). In addition, filter option 
is present to filter on HLA alleles or on a specific amino acids (C) to view only the HLA alleles with that 
specific amino acid.
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Supplementary Table 1: HLA class I crystal structures used to predict solvent accessibility
PDB Resolution Antigen
3BO8 1.8Å A*01:01
1I4F 1.4Å A*02:01
3OX8 2.16Å A*02:03
3OXR 1.7Å A*02:06
3OXS 1.75Å A*02:07
3RL1 2Å A*03:01
1X7Q 1.45Å A*11:01
3WL9 1.66Å A*24:02
4HWZ 2.397Å A*68:01
4HX1 1.802Å A*68:02
4U1H 1.59Å B*07:02
3SPV 1.3Å B*08:01
3BXN 1.864Å B*14:02
1XR9 1.788Å B*15:01
4XXC 1.426Å B*18:01
5DEF 1.6Å B*27:04
2A83 1.4Å B*27:05
5DEG 1.83Å B*27:06
1K5N 1.09Å B*27:09
2CIK 1.75Å B*35:01
3BWA 1.3Å B*35:08
6MT6 1.31Å B*37:01
4O2C 1.802Å B*39:01
5IEK 1.8Å B*40:02
3LN4 1.296Å B*41:03
3LN5 1.9Å B*41:04
4U1N 1.77Å B*42:02
1M6O 1.6Å B*44:02
1N2R 1.7Å B*44:03
1SYV 1.7Å B*44:05
4LCY 1.6Å B*46:01
1E27 2.2Å B*51:01
3W39 3.1Å B*52:01
1A1O 2.3Å B*53:01
3VRI 1.6Å B*57:01
2BVP 1.35Å B*57:03
5VWH 1.648Å B*58:01
5IND 2.132Å B*58:11
4U1S 1.76Å B*81:01
1QQD 2.7Å C*04:01
5VGD 2.4Å C*05:01
5W6A 1.74Å C*06:02
4NT6 1.84Å C*08:01
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Supplementary Table 2: HLA class II structures used to predict solvent accessibility
PDB Resolution Antigen
3PDO 1.95Å DRB1*01:01
1A6A 2.75Å DRB1*03:01
4MD4 1.95Å DRB1*04:01
4MD5 1.65Å DRB1*04:04
4MDJ 1.7Å DRB1*04:02
6BIR 2.3Å DRB1*04:05
6CPN 2Å DRB1*11:01
6ATF 1.9Å DRB1*14:02
5V4M 2.1Å DRB1*15:01
6CPO 2.4Å DRB1*15:02
2Q6W 2.25Å DRB3*01:01
3C5J 1.8Å DRB3*03:01
1FV1 1.9Å DRB5*01:01
1S9V 2.22Å DQB1*02:01 / DQA1*05:01
1JK8 2.4Å DQB1*03:02 / DQA1*03:02
2NNA 2.1Å DQB1*03:02 / DQA1*03:01
1UVQ 1.8Å DQB1*06:02 / DQA1*01:02
3WEX 2.4Å DPB1*05:01 / DPA1*02:02
4P5M 1.7Å DPB1*02:01 / DPA1*01:03
4P57 2.6Å DPB1*105:01 / DPA1*01:03
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Supplementary Table 3: HLA class I modelled structures
PDB used for modelling Resolution Antigen
3BH9 1.7Å A*02:02
3HH9 1.7Å A*02:05
2HN7 1.6Å A*11:02
4F7T 1.7Å A*23:01
4F7T 1.7Å A*24:03
1X7Q 1.5Å A*25:01
2HN7 1.6Å A*26:01
3LR1 2.0Å A*29:01
3LR1 2.0Å A*29:02
2HN7 1.6Å A*30:01
1X7Q 1.5Å A*30:02
3LR1 2.0Å A*31:01
5E00 1.7Å A*32:01
4HWZ 2.4Å A*33:01
4HWZ 2.4Å A*33:03
4HX1 1.8Å A*34:01
1X7Q 1.5Å A*34:02
3BO8 1.8Å A*36:01
1X7Q 1.5Å A*43:01
1X7Q 1.5Å A*66:01
4HWZ 2.4Å A*66:02
4WJ5 1.6Å A*69:01
3LR1 2.0Å A*74:01
1X7Q 1.5Å A*80:01
4U1H 1.59Å B*07:03
4JQX 1.9Å B*13:01
1M6O 1.6Å B*13:02
3BXN 1.9Å B*14:01
1XR9 1.8Å B*15:02
1XR9 1.8Å B*15:03
3C9N 1.9Å B*15:10
3C9N 1.9Å B*15:11
1XR9 1.8Å B*15:12
1XR9 1.8Å B*15:13
3VRI 1.6Å B*15:16
3C9N 1.87Å B*15:18
5IB2 1.44Å B*27:03
1UXS 1.5Å B*27:08
4O2C 1.8Å B*38:01
3LN4 1.3Å B*40:01
5IEK 1.8Å B*40:06
3LN4 1.3Å B*41:01
4U1J 1.4Å B*42:01
3LN4 1.3Å B*45:01
4JQX 1.9Å B*47:01
4UIS 1.8Å B*48:01
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Supplementary Table 3:  (Continued)
PDB used for modelling Resolution Antigen
3L3I 1.7Å B*49:01
5IEH 1.5Å B*50:01
1E27 2.2Å B*51:02
4U1N 1.8Å B*54:01
4U1J 1.4Å B*55:01
4U1J 1.4Å B*56:01
1E27 2.2Å B*59:01
4O2C 1.8Å B*67:01
1OGT 1.5Å B*73:01
1E27 2.2Å B*78:01
4U1J 1.4Å B*82:01
4NT6 1.8Å C*01:02
4NT6 1.8Å C*02:02
4NT6 1.8Å C*03:02
4NT6 1.8Å C*03:03
4NT6 1.8Å C*03:04
4NT6 1.8Å C*04:03
4NT6 1.8Å C*07:02
4NT6 1.8Å C*08:02
4NT6 1.8Å C*12:02
4NT6 1.8Å C*12:03
4NT6 1.8Å C*14:02
4NT6 1.8Å C*15:02
4NT6 1.8Å C*16:01
4NT6 1.8Å C*17:01
4NT6 1.8Å C*18:02
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ABSTRACT
In kidney transplantation, polymorphic amino acid configurations on mismatched donor HLA 
molecules can lead to the development of de novo donor-specific antibodies (dnDSA). These 
dnDSA are mainly directed against HLA class II, and especially HLA-DQ, and are associated with 
graft loss. Defining which polymorphic residues are able to induce an antibody response and 
which not, is pivotal for the development of strategies to prevent dnDSA formation. Therefore, 
the aim of this study was to define the most immunogenic HLA-DQ polymorphic amino acid 
mismatches in a cohort of kidney transplant recipients.
From multiple Dutch transplant centres we selected non-immunised male recipients that 
received their first kidney transplant with at least one HLA class II antigen mismatch and 
subsequently lost their graft due to immunological failure (n=79). Donor and recipient HLA 
typing was performed at high resolution using next generation sequencing (NGS) and the 
number of solvent accessible amino acid mismatches was established with HLA-EMMA. 
Formation of dnDSA was determined by screening recipients’ sera collected upon graft failure 
with Luminex single antigen bead assays.
HLA-DQ-specific dnDSA were most prevalent, occurring in 35% of the 79 recipients. Increasing 
numbers of solvent accessible amino acid mismatches resulted in a higher frequency of HLA-
DQB1 or HLA-DQA1 dnDSA. However, we also observed that a single solvent accessible amino 
acid mismatch on HLA-DQB1 or HLA-DQA1 was sufficient for the induction of dnDSA. In this 
pilot study with a limited number of cases, it was not yet possible to identify specific amino 
acid positions or types, which were significantly more immunogenic than others.
Overall, we showed that within this cohort the chance of HLA-DQ-specific dnDSA increased 
with more solvent accessible amino acid mismatches, although on individual level a single 
amino acid mismatch can be sufficient to trigger an antibody response. This latter observation 
supports the importance to define the most immunogenic residues, which requires a much 
larger and diverse cohort.
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INTRODUCTION
Human leukocyte antigen (HLA) matching can prevent the occurrence of an alloimmune 
response. However, most grafts are transplanted with one or more HLA antigen mismatches, 
which can result in immunisation of the recipient as reflected by the formation of donor 
specific HLA antibodies. These de novo donor-specific antibodies (dnDSA) are strongly 
associated with graft loss,1-3 and reduce the chance of repeat transplantation.4 Therefore, it 
is of utmost importance to prevent the development of dnDSA after transplantation.
Induction of dnDSA can be triggered by polymorphic amino acid configurations on mismatched 
HLA antigens and are mainly directed against HLA class II, and more specifically HLA-DQ.1,2,5 
There are several ways of defining and analysing these polymorphic residues. One of these is 
used by the HLAMatchmaker algorithm, which defines patches of (dis)continuous polymorphic 
amino acids, called eplets, that theoretically can induce an antibody response.6,7 Indeed the 
number of eplet mismatches between donor and recipient have been associated with dnDSA 
formation 8-11 as well as transplant glomerulopathy.12 In addition, the immunogenicity of HLA 
mismatches on the population level have also been assessed based on amino acid mismatches 
and/or physiochemical disparity scores.13,14 While these approaches provide mismatch scores 
that are good predictors of sensitisation risk on population level, it remains to be determined 
which mismatched amino acids triggered the formation of dnDSA in an individual patient.
It has been shown that not every eplet mismatch is equally immunogenic15 and dnDSA are 
observed even when only a low number of triplet, predecessor of eplet, mismatches are 
present on the mismatched donor HLA.16 In addition, as mentioned, eplets are theoretically 
defined and require experimental verification to determine if an antibody can actually bind 
to these polymorphic residues.17,18 While data of a recent study showed that both HLA class I 
and class II antibody-verified eplets were good indicators for risk of graft loss for individual 
patients, especially for HLA class II additional verification of eplets is required to further 
improve this risk stratification.11 Thus, the current list of potential immunogenic polymorphic 
amino acid configurations is still incomplete.
Recently, we developed a software program, HLA-EMMA, to analyse the compatibility between 
donor and recipient HLA class I and class II molecules on the amino acid level.19 The benefits 
of HLA-EMMA are that large cohorts of donor-recipient pairs from diverse populations can 
be analysed for HLA class I and class II simultaneously and, in addition, it provides the type 
and position of the amino acid mismatches. Using this software program, we aim to define 
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the most immunogenic polymorphic amino acids that ultimately form the basis of specific 
polymorphic amino acid configurations involved in antibody binding.
As mentioned, the most frequently observed dnDSA after transplantation are directed against 
mismatched HLA-DQ. To prevent HLA-DQ-specific dnDSA formation it is essential to determine 
the immunogenic polymorphic amino acids on the HLA-DQB1 and HLA-DQA1 molecules. To 
this aim, we performed a pilot study using a kidney transplant cohort study of non-immunised 
male transplant recipients with at least one HLA class II antigen mismatch, who lost their graft 
due to immunological failure.
MATERIALS AND METHODS
Study population
From multiple Dutch transplant centres, we selected non-immunised male recipients that 
received their first renal transplant with at least one HLA class II antigen mismatch, and 
who subsequently lost their graft due to immunological failure. From Leiden and Rotterdam 
transplant centre we selected recipients that underwent their first kidney transplantation 
between 1992 and 2015 (n=40) (Figure 1). Subsequently, the cohort was extended with patients 
from the PROCARE consortium (PROfiling Consortium on Antibody Repertoire and Effector 
functions) database with recipients that received their first kidney transplantation between 
1995 and 2005 (n=129).
HLA typing
DNA samples were collected from recipients and donors for HLA typing by next-generation 
sequencing (NGS) of HLA-A, -B, -C, -DRB1, -DRB3/4/5, -DQB1, -DQA1, -DPB1, and -DPA1 loci. 
NGSgo-AmpX kit (GenDx, Utrecht, the Netherlands) was used for the amplification of HLA 
genes. Next, library and sequence preparation were performed with NGSgo-LibrX/IndX kit 
(GenDX) and subsequently sequencing was carried on Illumina MiSeq or MiniSeq (Illumina, 
San Diego, CA, USA). NGS data was analysed with NGSengine software (GenDx).
Ambiguities at the second field level were still observed for several HLA alleles (n=6 DRB1, n=3 
DQB1, n=17 DPB1) after NGS typing. Therefore, we selected the first allele of the ambiguity 
group.
Definition of donor-specific antibodies
Recipients’ sera before transplantation and after graft failure were collected for screening 
for the presence of HLA antibodies with Lifecodes Lifescreen Deluxe screening kit (LMX, 
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Immucor Transplant Diagnostics, Stamford, CT, USA). Subsequently, positive serum samples 
were treated with ethylenediaminetetraacetic acid (6% EDTA) and tested with Lifecodes HLA 
class I and class II single antigen beads (SAB) (Immucor Transplant Diagnostics). Data was 
analysed with Match It! Antibody software version 1.3.0 (Immucor Transplant Diagnostics). 
The screening data were analysed using raw mean fluorescence intensity (MFI) and for the 
SAB data background corrected MFI (BCM) as provided by software were used. For defining 
DSA from the SAB data of each individual both the software positive assignments and the 
BCM of recipient’ alleles were considered. For HLA-DRB1, HLA-DRB3, HLA-DRB4, and HLA-
DRB5 donor alleles with BCM > 1000 were defined as DSA. For HLA-DQB1 and HLA-DQA1 DSA 
was assigned if the actual mismatched HLA-DQB or HLA-DQA donor allele present on a bead 
in combination with respectively the self HLA-DQA or HLA-DQB allele of the recipient was 
positive, BCM > 1000. If the mismatched allele was not present on a bead in combination with 
a recipient allele, then DSA was assigned if all beads with mismatched allele were positive 
and the reactivity was not caused by the other allele on the bead. In case donor HLA allele 
was not present in SAB assay, no dnDSA could be defined (n=3 DRB1, n=1 DRB4, n=1 DQB1, 
n=1 DQA1) and these cases were excluded from analysis.
Solvent accessible amino acid mismatches
HLA-EMMA software program version 1.0 was used to define the solvent accessible amino 
acid mismatches between donor and recipient.19 With this software program the amino acid 
sequences of the donor HLA alleles are compared with the recipient’ sequences, interlocus 
for HLA-DRB1, HLA-DRB3, HLA-DRB4, and HLA-DRB5, and intralocus for HLA-DQB1 and HLA-
DQA1. HLA-EMMA identified and quantified the position and type of solvent accessible amino 
acid mismatches of each donor allele.
Visualising solvent accessible amino acid positions
HLA-DQB1*03:02-DQA1*03:02 crystal structure PDB 1JK8 (downloaded from https://www.
rcsb.org/ on January 16, 2020) was used to visualise solvent accessible amino acid positions 
with Swissviewer.20
Statistical analysis
SPSS statistics version 25 (IBM, Armonk, NY, USA) was used to perform statistical analysis. 
Binary logistic regression was used to assess the significance of antigen, allele, or solvent 
accessible amino acid mismatches as predictors of dnDSA formation. P values of <0.05 were 
considered statistically significant.
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Table 1: dnDSA formation in study cohort
dnDSA N (missing*) % of 79
HLA class I 13 (2) 16.5
HLA-DRB1 10 (4) 12.7
HLA-DRB3/4/5 8 (8) 10.1
HLA-DQB1 26 (1) 32.9
HLA-DQA1 22 (1) 27.8
*HLA alleles that are not present in single antigen bead assay
RESULTS
Study cohort
The selection criteria of the study cohort were non-immunised first kidney transplant 
male recipients with at least one HLA class II antigen mismatch with graft failure due to 
immunological failure. This resulted in a study cohort consisting of 79 donor-recipient couples 
for analysis (Figure 1).
Overall within this cohort, 39% of recipients developed HLA class II dnDSA (n=31) of which 
45% recipients (n=14) also had HLA class I dnDSA (Table 1). HLA-DQB1 and/or HLA-DQA1-
specific dnDSA were most prevalent in the recipients (35% n=28) and 11 of those recipients 
also developed HLA-DRB1/3/4/5 specific dnDSA, while HLA-DRB1/3/4/5 dnDSA were only 
observed in 3 recipients.
Leiden/Ro�erdam Kidney transplana�on
between 1992 - 2015
(n=40)
PROCARE Kidney transplana�on
between 1995 - 2005
(n=129)
Excluded
No sample (n=55)
Failed typing due to poor quality DNA (n=17)
Excluded
DSA pre-transplanta�on (n=3)
No sample (n=3)
Failed typing due to poor quality DNA (n=6)
Recipient - Donor couples study cohort
(n=85)
Recipient - Donor couples 
included in analysis
(n=79)
Excluded
Unexplainable High MFI against self HLA (n=6)
Figure 1: Flow chart of inclusions and exclusions for the study cohort.
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Solvent accessible amino acid mismatches are associated with dnDSA for-
mation
Per individual we determined if a HLA-DQB1 and/or HLA-DQA1 dnDSA was formed and 
observed that for HLA-DQB1 the chance of antibody response was higher for two HLA-DQB1 
antigen mismatches, based on serological split typing, compared to one antigen mismatch 
although this was not significant (Table 2). Interestingly, the chance of dnDSA formation was 
lower for 2 HLA-DQB1 or HLA-DQA1 allele mismatches compared to 1 allele mismatch (Tables 
2 and 3), although this was only significant for HLA-DQB1. However, when defining the sum 
solvent accessible amino acid mismatches for HLA-DQB1 and HLA-DQA1 per individual we 
found that the chance of dnDSA formation was higher for solvent accessible amino acid 
mismatches above the mean, 12 for HLA-DQB1 and 10 for HLA-DQA1. This was further 
supported when comparing the number of HLA-DQB1 and HLA-DQA1 solvent accessible 
amino acid mismatches of one allele mismatch with two allele mismatches (Figure 2). For 
many double allele mismatches the sum of solvent accessible amino acid mismatches was 
very low and often lower than the number of solvent accessible amino acid mismatches of 
several single allele mismatches.
Table 2: HLA-DQB1 mismatches predicting dnDSA using logistic regression analysis
OR (95% C.I.) p value No DSA DSA
DQB1 antigen 1 mm (ref) 33 23
DQB1 antigen 2 mm 2.323 (0.575-9.381) 0.237 10 3
DQB1 allele 1 mm (ref) 30 22
DQB1 allele 2 mm 0.260 (0.078-0.865) 0.028 21 4
DQB1 SA AA mm <=12 (ref) 35 11
DQB1 SA AA mm >12* 2.983 (1.123-7.927) 0.028 16 15
OR = Odds Ratio, C.I. = Confidence Interval
* grouped based on mean
Table 3: HLA-DQA1 mismatches predicting dnDSA using logistic regression analysis
OR (95% C.I.) p value No DSA DSA
DQA1 allele 1 mm (ref) 37 18
DQA1 allele 2 mm 0.514 (0.150-1.762) 0.290 16 4
DQA1 SA AA mm <=10 (ref) 39 8
DQA1 SA AA mm >10* 4.875 (1.686-14.097) 0.003 14 14
 OR = Odds Ratio, C.I. = Confidence Interval
* grouped based on mean
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Figure 2: HLA-DQB1 and HLA-DQA1 solvent accessible amino acid mismatches and association with 
dnDSA formation. The number of solvent accessible amino acid mismatches were defined and dnDSA per 
mismatched donor allele for HLA-DQB1 (A) and HLA-DQA1 (B). A higher frequency of dnDSA formation 
is observed with increased number of solvent accessible amino acid mismatches. Groups were equally 
divided in tertiles and zero amino acid mismatches was set as separate group.
Next, we defined the number of solvent accessible amino acid mismatches for each 
mismatched donor allele, and we analysed whether an antibody response was formed against 
that donor allele. Mismatched donor HLA alleles that were not present in SAB assay were 
not included in the analysis. For HLA-DRB1/3/4/5, HLA-DQB1 and HLA-DQA1 we determined 
whether a correlation between the number of solvent accessible amino acid mismatches 
and dnDSA existed. For HLA-DR, no association was observed between dnDSA formed and 
number of solvent accessible amino acid mismatches due to low number of pairs (data not 
shown). For both HLA-DQB1 and HLA-DQA1 a higher frequency of dnDSA formation was 
observed with increasing number solvent accessible amino acid mismatches (Figure 3). The 
HLA-DQB1 and HLA-DQA1 solvent accessible amino acid mismatched were grouped based on 
tertiles, and this resulted in odds ratio (OR) 3.788 (1.1912 – 7.504) and OR 3.677 (1.908 – 7.086), 
respectively. The risk of dnDSA formation was also associated with an increased number of 
solvent accessible amino acid mismatches with OR 1.121 (1.049 – 1.198) for HLA-DQB1 and OR 
1.138 (1.064 – 1.217) for HLA-DQA1 if no groups were defined on basis of tertiles.
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Figure 3: HLA-DQB1 and HLA-DQA1 allele mismatch was associated with a wide range of solvent 
accessible amino acid mismatches. Each data point represents the sum of solvent accessible amino 
acid mismatches for HLA-DQB1 (A) or HLA-DQA1 (B). The boxplot indicates the median with minimum 
and maximum values.
A single HLA-DQB1 or HLA-DQA solvent accessible amino acid mismatch can 
already be sufficient to induce dnDSA
In many publications a specific cut-off of epitopes or eplets is used to stratify patients into low 
or high risk to develop dnDSA. Also in our analysis above, we could identify a cut-off for HLA-
DQB1 and HLA-DQA1 that correlated with a high risk of dnDSA development. However, low 
numbers of solvent accessible amino acid mismatches can already result in dnDSA formation. 
Upon in-depth analysis, we found that for one mismatched donor HLA-DQB1 allele and for 
one mismatched donor HLA-DQA1 allele there was only a single solvent accessible amino acid 
mismatch leading to dnDSA formation. For the HLA-DQB1 allele, DQB1*03:02, the mismatch 
was alanine on position 57 (Figure 4A), which is located on the top of HLA-DQ molecule (Figure 
4B). In contrast, the amino acid aspartic acid on position 160 located near the bottom of the 
HLA-DQ molecule was the only mismatched amino acid of HLA-DQA1*03:03 but is nonetheless 
still regarded as solvent accessible (Figure 4C and D).
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57
160
Amino acid on 
position 160
Highest BCM in SAB
Recipient DQA1*03:01 Alanine 273
DQA1*05:05 Alanine 44
Donor DQA1*03:03 Aspartic acid 1426 (in combination with self DQB1)
Amino acid on 
position 57
Highest BCM in SAB
Recipient DQB1*03:19 Aspartic acid n.d.
DQB1*05:01 Valine 0
Donor DQB1*03:02 Alanine 6894 (in combination with donor DQA1)
Figure 4: A single solvent accessible amino acid mismatch is sufficient to induce dnDSA formation. 
The amino acid alanine on position 57 was the only mismatch between donor HLA-DQB1*03:02 and recip-
ient’s HLA-DQB1 alleles (A), but still resulted in dnDSA formation. Position 57 is located on the top of the 
molecule (B). Aspartic acid on position 160 was the only mismatch between donor HLA-DQA1*03:03 and 
recipient HLA-DQA1 alleles (C), but position 160 is located near the bottom of the molecule (D).
No specific amino acid position is preferentially associated with dnDSA 
formation
Next, we determined whether in this pilot study it was already possible to define specific 
amino acid positions or type preferentially resulting in dnDSA formation. To this aim, we 
calculated how often specific position or type occurred as mismatches and how often that 
specific position or type was mismatched on a mismatched donor HLA-DQ allele that resulted 
in dnDSA formation. So far, no specific amino acid position could be identified for HLA-DQB1 
(Figure 5A), nor for HLA-DQA1 (Figure 5B), as the average frequency of dnDSA of positions is 
39% (range 15-53%) and 40% (range 0-57%), respectively. Interestingly, in the current cohort no 
mismatches were observed for 116 solvent accessible amino acid positions of HLA-DQB1 and 
for 17 positions of HLA-DQA1. In addition, when further looking into the type of mismatched 
amino acids, no specific solvent accessible amino acid type resulting more frequently in dnDSA 
formation could be identified (data not shown).
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Figure 5: Overview of all mismatched solvent accessible amino acid positions. All solvent accessible 
amino acid positions of HLA-DQB1 and HLA-DQA1 are depicted in the columns, and each row is a mis-
matched donor allele. Yellow indicates the positions that were mismatched between donor and recipient 
and blue are the matched positions. DnDSA was observed against the donor HLA alleles above the line 
and no dnDSA was observed for mismatched donor alleles below the line.
DISCUSSION
The development of dnDSA after transplantation is associated with inferior graft survival 
and reduces the chance of repeat transplantation. Interestingly, since the introduction of 
the sensitive Luminex SAB assays it is appreciated that dnDSA are often directed against 
HLA-DQ.1-5 In the current study, we showed that the formation of HLA-DQB1 and HLA-DQA1-
specific dnDSA is associated with the number of solvent accessible amino acid mismatches on 
mismatched HLA-DQ antigens. These findings are in accordance with previous studies based 
on eplet, amino acid, or physiochemical properties mismatches.8,9,14,21 However, in the present 
study no association was observed between the number of HLA-DR solvent accessible amino 
acid mismatches and dnDSA formation, which is probably due to exclusion of large number 
of donor-recipient pairs (n=30) as the mismatched HLA alleles were not present in SAB assay 
used in this study resulting in low number of pairs and subsequently allele mismatches for 
analysis.
In addition, dnDSA formation, albeit at lower frequency, was observed for low number, or 
even a single, solvent accessible amino acid mismatches on both HLA-DQB1 allele or HLA-
DQA1 alleles, similar as recently observed for HLA-DQ molecule mismatches.22 One should 
take this into consideration, both in donor selection and risk estimation, and not only trust 
on the definition of eplet loads that have been proposed as good indicators for sensitisation 
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risk9,21,23 and have already been applied in kidney allocation to paediatric patients.24 These 
data support the notion that with an increasing number of amino acid differences, the chance 
that an immunogenic disparity is present increases, but that in individual cases, a single amino 
acid can already be immunogenic.25
On the other hand, not every mismatched donor HLA allele with a high number of solvent 
accessible amino acid mismatches resulted in dnDSA formation, as in this group the 
dnDSA frequency was 48% and 52%, for HLA-DQB1 and HLA-DQA1 respectively. The data 
suggest that for some allele mismatches the amino acids mismatches that are present are 
of low immunogenicity.26 The HLA phenotype of the recipient itself plays a major role in 
immunogenicity. So is class switching to IgG antibody producing cells dependent on the T 
cell epitopes presented by the recipients’ HLA class II molecules of the B cell.27,28 However, in 
current study, we could not find an association between the recipients’ HLA-DR phenotype 
and dnDSA HLA-DQ-specific formation could be defined (data not shown), also likely due to 
limited sample size. Besides T cell dependency for IgG antibody formation, also the type of 
amino acid substitution plays a role in immunogenicity, because if the size and charge are 
like those of the recipients than the HLA molecules structure and physiochemical properties 
can be similar.29
Defining either an immunogenic amino acid position or type of the HLA-DQB1 and HLA-DQA1 
alleles was not reached. This is probably due to the relatively low number of donor-recipient 
pairs. While the cohort consist of high number of HLA-DQB1 and HLA-DQA1 allele mismatches 
and HLA-DQ-specific dnDSA formation, the strict selection rules and the requirement of 
presence of DNA samples for NGS-based HLA typing resulted in a low number of donor-
recipient couples. In addition, the numbers for analysis were even more reduced as not all HLA 
alleles obtained with NGS typing were present in SAB assay used in this study and therefore 
were excluded from analysis.
Nonetheless, high resolution typing is essential as it provides optimal accuracy in compatibility 
analysis on the amino acid level, and while for certain populations translation from low 
resolution to high resolution typing is possible,30 for individuals with rare alleles this does 
not apply. High resolution HLA typing was also pivotal for assigning dnDSA towards HLA-DQ. 
In this study, we analysed HLA-DQB1 and HLA-DQA1 separately, and while indeed antibodies 
can be clearly specific for one chain, it is also possible that an antibody is specifically directed 
against the whole HLA-DQ molecule.31,32 This is further complicated by the fact that certain 
HLA-DQB1 and HLA-DQA1 alleles can not only occur in cis form but also as trans-encoded 
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heterodimers,33 and dnDSA against trans-encoded heterodimers have been observed.34 Thus, 
further studies are required to fully understand what the HLA-DQ antibodies recognise.
To facilitate the analysis of HLA-DQ immunogenicity, it has been proposed that a cohort 
consisting of patients that have been transplanted with two HLA-DQ mismatches an developing 
dnDSA to only one of the mismatches can be useful, as well as recipients homozygous at the 
HLA-DQ locus.22 This will be one of the components of the 18th International Immunogenetics 
and Histocompatibility Workshop (IHIWS) (https://www.ihiw18.org/). Our study indicates 
the need to perform larger and more diverse studies, such as the ones proposed in the 
IHIWS, to identify the most immunogenic HLA-DQ amino acid mismatches. In the current, 
relative small cohort, we observed that for the HLA-DQB1 locus most of polymorphic solvent 
accessible amino acid positions were never mismatched, because HLA-EMMA software 
includes the polymorphic positions for all HLA alleles in IMGT database, even rare alleles. 
The reason why these positions were never mismatched in the current study may be due to 
their monomorphic character in our study population, which does not exclude that these 
positions may be relevant in other study populations with other ethnicities.
Eventually, identification of the immunogenic polymorphic amino acids should lead to defining 
the relevant amino acid configurations to which an antibody can actual bind, similar as has 
been done for eplets. These configurations can then be used as parameters for allocation to 
prevent dnDSA formation after transplantation. In addition, amino acid configurations can 
be used for highly sensitised patients to define acceptable and unacceptable HLA alleles.26,35
In summary, in this pilot study we showed that even though the chance of HLA-DQ-specific 
dnDSA is higher with more solvent accessible amino acid mismatches, on individual level a 
single amino acid mismatch can already be sufficient to trigger an antibody response. Thus, to 
prevent dnDSA formation the most immunogenic residues must be avoided during allocation 
rather than the HLA alleles with high number of polymorphic amino acid mismatches with 
relative low immunogenicity. To accomplish this, it is pivotal to define the most immunogenic 
residues, especially for HLA-DQ, in larger and more diverse cohorts. 
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Since the beginning of solid organ transplantation HLA matching has been shown 
to be beneficial for graft survival,1 which is still the case even in the modern era of 
immunosuppressive drugs. However, due to high polymorphism of the HLA system and 
scarcity of organs, most recipients receive a (partially) HLA mismatched graft. The allogeneic 
HLA molecules of the donor can be recognised as foreign by the immune system of the 
recipient, which may result in the development of antibodies directed against donor HLA, 
known as donor-specific antibodies (DSA). These de novo DSA can develop early or late after 
transplantation,2,3 and the presence of these antibodies often leads to graft injury and 
eventually rejection.4 In addition, the presence of DSA severely impacts the chance of finding a 
suitable donor for repeat transplantation.5 This is also the case for patients on the transplant 
waiting list that developed HLA antibodies upon pregnancy or blood transfusion.
Towards definition of immunogenic amino acid configurations (epitopes)
Interestingly, not every HLA antigen mismatch leads to a humoral alloimmune response. 
As reviewed in Chapter 2 and Chapter 3, while each HLA antigen consists of unique set of 
epitopes, or configurations of polymorphic amino acids, epitopes can be shared by several 
HLA antigens. Therefore, the number of foreign antibody epitopes present on mismatched 
donor HLA antigen varies and depends on the HLA phenotype of the recipient. In addition, the 
type and physicochemical properties of the amino acid substitution, as well as the presence 
of accompanying T helper cell epitopes contribute to the immunogenicity of a mismatched 
antibody epitope. These aspects have been implemented in several algorithms aiming at the 
prediction of the immunogenicity of a mismatched HLA antigen, such as eplets,6,7 amino acid 
mismatches, electrostatic mismatch scores,8,9 and Predicted Indirectly ReCognizable HLA 
Epitopes presented by recipient HLA class II (PIRCHE-II).10,11 Indeed, mismatch scores based 
on these approaches have shown to predict the chance of de novo DSA formation on the 
population level, while none of these algorithms is superior over the others.12,13 However, we 
argue that on the level of the individual patient it is not a numbers game, as a single amino 
acid or configuration present on a mismatched HLA allele can already be sufficient to induce 
an antibody response. This was observed previously for HLA class I configuration (triplet) 
mismatches,14 and confirmed in our cohort study on amino acid mismatches for HLA class 
II (Chapter 7).
Therefore, as highlighted in Chapter 2 and Chapter 3, it is essential to define immunogenic 
configurations of amino acids (Figure 1), eplets, or single amino acids so that these can be 
avoided during donor selection in order to prevent de novo DSA formation. With HLA-EMMA 
software, we developed a tool that enables analyses on amino acid compatibility between 
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donor and recipient (Chapter 6). This tool can perform analyses for large number of donor-
recipient pairs at once due to batch option, and for HLA class I and HLA class II simultaneously, 
which is either very laborious or impossible with the other available algorithms. Additionally, 
HLA-EMMA considers all available HLA alleles from the IMGT, so there are no restrictions 
in analysing donor-recipient pairs with rare HLA alleles. Therefore, HLA-EMMA is a very 
useful and user-friendly tool, which can be used in cohort studies to define the relevant/
immunogenic amino acids and positions. This software was further validated in a cohort study 
of non-immunised male recipients of a first renal allograft (Chapter 7).
While the aim of defining the most immunogenic HLA class II amino acids and/or positions 
was not accomplished in this cohort study due to small numbers, we did observe that a 
high number of amino acid mismatches is not always a guarantee for the induction of an 
antibody response. The latter suggests that not all mismatches are immunogenic, as previous 
mentioned (Chapter 2 and Chapter 3), but also that not all defined polymorphic solvent 
accessible positions included in HLA-EMMA are equally important for the induction of an 
antibody response. Narrowing down the solvent accessible positions to only those that 
are proven to be able to induce an antibody response can be achieved by using human 
HLA-specific monoclonal antibodies (mAbs), as reactivity analysis of these mAbs allows 
for identification of amino acids and/or positions that are involved in antibody binding 
(Chapter 5), and thus amino acid and/or positions that can be immunogenic. Including only 
confirmed immunogenic or relevant polymorphic amino acid and/or positions will improve 
the prevention of DSA formation without unnecessarily preventing allocation based on non-
immunogenic epitope mismatches.15 Additionally, amino acids or amino acid configurations 
associated with de novo DSA formation identified in clinical cohort studies can be verified by 
human HLA mAbs, using methods described in Chapter 5.
Upon transplantation antibodies directed against HLA class II and more specifically against 
HLA-DQ are most prominent. Therefore, understanding of the immunogenicity of especially 
HLA-DQ is of great interest. One of the features of HLA-DQ is that both the alpha and beta 
chain are polymorphic. Therefore we analysed the HLA-DQ chains separately with respect to 
their ability to induce an antibody response (Chapter 7), in contrast to previous studies that 
consider the whole HLA-DQ molecule.16-19 Of course, once an antibody is formed the whole 
HLA molecule should be considered as the antibody-footprint could cover both alpha and beta 
chain of the HLA-DQ molecule. However, we observed that a single amino acid mismatch on 
either the alpha or beta chain was sufficient to induce an antibody response that was clearly 
directed against that specific chain. In addition, we often detected an antibody response in 
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case only the HLA-DQB1 or HLA-DQA1 allele was mismatched. Important to note that this 
analysis was performed on first transplant recipients that did not have any detectable HLA 
antibodies prior to transplantation by sensitive single antigen bead assays. This indicates that 
for predicting immunogenicity not the whole HLA-DQ molecule should be considered, because 
then recipients can be incorrectly classified as being at low risk for allloimmunisation.17,19
One could argue that our tools are of no additive value, as on the group level eplets have 
shown to be good predictors of sensitization,18,20-22 graft damage,23 and subsequently 
rejection.24,25 This has resulted in the introduction of cut-offs of numbers of eplets to identify 
alloimmunisation risk,17,18,26,27 which has even been applied in allocation strategy for paediatric 
patients.28 However, as discussed in Chapter 2 and Chapter 3 eplets are theoretically defined 
and not every eplet mismatch is immunogenic.29 Furthermore, eplets require experimental 
verification to establish if an antibody indeed can bind to the eplet. Both absorption and 
elution studies30,31 as well as human mAbs32,33 have been shown to be very useful for 
antibody-verification of eplets.34,35 However, we emphasised that there is a need for HLA 
class II eplet verification, and as shown in Chapter 5 the newly generated human HLA-DR 
mAbs contribute to antibody-verification of eplets. More importantly, our antibody reactivity 
analysis also highlighted that the current list of eplets on HLA Epitope Registry contains 
inaccuracies and is subject to change without valid reasoning and validation. In addition, when 
defining polymorphic solvent accessible positions to incorporate in HLA-EMMA (Chapter 6) 
we observed discrepancies between our definition of surface exposed positions and those 
considered for defining eplets,6,7,36 This clearly indicates there is a need for standardisation for 
defining antibody-verified eplets. Both HLA-EMMA and human HLA mAbs will contribute to 
define the immunogenic polymorphic amino acids and subsequently immunogenic or relevant 
amino acids configurations in a more standardised and validated manner.
Our cohort study already highlighted that for defining immunogenic polymorphic amino 
acids a large number of donor-recipient pairs of diverse population is required (Chapter 7). 
The latter is essential, as currently the proposed cut-offs are based on Caucasian population 
studies, but just like HLA allele frequency the frequency of the most immunogenic epitope 
can differ between populations (Chapter 3). One of such studies will be the upcoming 
International Immunogenetics and Histocompatibility Workshop, in which not only HLA-
EMMA but all factors that regulate antibody induction will be included, such as T cell epitopes 
(PIRCHE-II) and physicochemical properties (EMS-3D), for a comprehensive analysis.
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VH3
VH1
VH2
VL2
VL1
VL3
An�genicity
An�body-footprint on HLA molecule involves 
addi�onal configura�ons required for binding
VH3
Immunogenicity
Amino acid configura�on 
induces an an�body response
Figure 1: Immunogenicity and antigenicity. An immunogenic amino acid confi guration (epitope) on 
mismatched donor HLA induces alloantibody response and determines the specifi city of antibody as it 
interacts with CDR-H3 of the antibody. However, the antibody-footprint on HLA molecules involves addi-
tional confi gurations required for binding, which is the antigenicity of HLA antibody.
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Antigenicity of formed HLA antibodies
Besides immunogenicity, definition of relevant amino acid configurations is also essential for 
understanding the antigenicity of HLA antibodies (Figure 1), which is imperative for sensitised 
patients to determine acceptable and unacceptable HLA antigen mismatches to predict a 
negative crossmatch (Chapter 2). HLAMatchmaker was developed to identify uniquely shared 
eplets by reactive HLA antigens in single antigen bead assay and used for reactivity analysis 
of mAbs32,33 and sera37-40 for antibody-verification of eplets. In recent years, eplets have been 
incorporated in analysis software of both single antigen bead assay used by HLA laboratories, 
and also a software tool to perform epitope analysis and virtual crossmatching based on 
eplets was developed.41 However, as depicted in Chapter 2, reactivity of HLA antibodies is 
determined by crucial amino acid configurations in addition to the eplet or functional epitope. 
While some antibody reactivity patterns can indeed be explained by a single eplets/amino 
acid configuration, which is the functional epitope as it determines the specificity of antibody, 
this is not always the case as shown for both human HLA class I (Chapter 3) and HLA class II 
(Chapter 5) mAbs. In addition, not every reactive HLA antigen detected with single antigen 
bead assay is relevant, as mAbs can bind to HLA expressed on beads, but not to natively HLA 
expressed on cells (Chapter 5). Many HLA laboratories assign every HLA allele with a mean 
fluorescence intensity (MFI) value in single antigen bead assay as unacceptable, but our data 
shows that not every reactive HLA allele is relevant.
In addition, polyclonal serum consists of multiple antibodies, including HLA antibodies 
recognising different epitopes on same HLA antigen. This is nicely illustrated by our findings 
on mAbs directed against different epitopes on same HLA antigen that were generated from 
single memory B cell clones isolated from one individual with one tetramer specificity. The 
different memory B cell clones obtained showed different V(D)J usage indicating that the 
clonotypes are unique and not caused by somatic hypermutation (Chapter 5). Functional 
assays with cell expressing the target HLA showed differences in binding strength and 
differential efficiency in complement mediated cell lysis of the generated mAbs and therefore 
we surmised that the antibodies had different affinity for target HLA. Overall, this indicates 
that the abovementioned methods to interpret single antigen bead assay data of neat serum 
based on shared eplets is not so straightforward, as multiple factors such as immunising 
event, both immunogenic/functional epitopes and additional crucial configurations, and 
dilutions42 should be taken into account to determine the true and relevant HLA alleles.
MFI values are often interpreted as being indicative of the relative concentration of HLA 
antibodies. However, the different level of reactivity of HLA antigens observed for mAbs 
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could also reflect the affinity the mAbs for specific HLA alleles (Chapter 5). It has been 
shown that the affinity for immunising antigen is often higher than for other antigens,43 
which might be due to the presence of the optimal set of crucial amino acid configurations. 
Additionally, amino acid substitution within the structural epitope can affect the affinity as 
well,44 on the other hand if amino acid substitution does not affect surface area structure 
due to similar electrostatic potential, hydrophobicity or size than binding ability most likely 
remains the same.45,46 Defining the affinity of HLA antibodies for various reactive HLA alleles 
will both elucidate on the interaction between antigen and antibody and the corresponding 
crucial additional contact sites and thus the antibody reactivity patterns observed in single 
antigen bead assays. Additionally, it will contribute in the understanding of the differential 
pathogenicity of HLA antibodies. This is essential because while de novo DSA are associated 
with graft rejection, not every recipient with detectable de novo DSA has clinical signs of 
rejection.3,47 In addition, antibody-mediated rejection is mainly associated with complement 
activation,48-50 but also complement independent graft injury has been observed.51-54 Human 
HLA class I mAbs have shown to be useful for methodological studies of HLA antibodies 
to establish the clinical effect of IgG isotype and epitopes recognised.51,52,55-57 However, 
as mentioned HLA class II antibodies are the dominant type of antibody to develop upon 
transplantation and recent studies demonstrated that non-human pan-HLA class II antibodies 
can induce endothelial cell damage independent of complement system.53,54,58 The newly 
generated human HLA class II mAbs can be used to more specifically study the effect of HLA 
class II antibodies on graft injury, especially the effect of mixture of antibodies recognising 
different epitopes on same HLA antigen. Additionally, the role of different IgG subclasses can 
be studied as this method allows for the generation of mAbs of all four IgG subclasses, fully 
human glycosylated, recognising the same epitope with identical binding affinity (Chapter 4).
Besides these methodological studies, crystal structures of antigen-antibody complex are 
pivotal for studying both the pathogenicity of HLA antibodies as well as defining antigenicity of 
HLA antibodies. These structures will provide insight on how paratope of the antibody exactly 
binds to the epitope on the HLA antigen and so which amino acid configurations interact with 
the different complementary-determining regions of the antibody.55 This will be especially 
of interest for HLA-DQ antibodies and how they bind to HLA-DQ molecule. Currently, we are 
working on isolating HLA-DQ-specific memory B cells similar as described in Chapter 5 but 
using a sorting strategy with HLA-DQ monomers instead.59 Preliminary data implies that 
specificities of memory B cell clones are often directed to one chain, which supports our 
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HLA-DQ dnDSA findings in clinical cohort study (Chapter 7), but we suspect to isolate B cell 
clones that produce antibodies direct against both chains as well.
Clinical application
Once immunogenic epitopes are defined these can be avoided during allocation of kidneys 
to prevent the formation of de novo DSA after transplantation (Chapter 2 and Chapter 
3). By basing allocation only on truly immunogenic epitopes, patients will not be denied 
an organ based on non-immunogenic polymorphisms. Besides allocation, immunogenic 
epitope mismatch scores can also be used for personalised medicine as these may serve as 
a biomarker for alloimmunisation risk.17,19 For individuals at low risk the immunosuppressive 
drugs can potentially be lowered, which will diminish the risk of side effects.60 Personalised 
medicine based on immunogenic epitope mismatch scores will not only apply to kidney 
transplantation, but also to liver,61,62 lung,63 and heart transplant.64-66 While allocation based 
on avoiding the most immunogenic epitopes may not always be feasible for these organs 
due to the necessity of short cold ischemia times and the lower number of available donor 
organs, immunogenic epitope mismatch scores may be used as indicator of the risk for 
alloimmunisation and therefore as a parameter upon which treatment can be adjusted.
As discussed, the presence of HLA antibodies complicates repeat transplantation, especially 
for highly sensitised patients. The Eurotransplant Acceptable Mismatch program has shown 
to be successful in determining acceptable mismatches to which the patient did not form 
antibodies, and which are used for selection of compatible donors.67,68 Highly sensitised 
patients transplanted through this program had a superior graft survival compared to 
patients transplanted based on merely avoiding unacceptable mismatches.69,70 In this 
program epitope analysis to define acceptable/unacceptable mismatches has already been 
incorporated, but will benefit from an inventory of well-defined immunogenic HLA class I and 
HLA class II epitopes. However, while it is important to note that for defining acceptable and 
unacceptable HLA mismatches understanding the exact antibody-antigen interaction and the 
crucial configurations involved are essential, this is extremely complex and requires additional 
research. Eventually, this knowledge can be used to define acceptable and unacceptable 
epitopes to be used for virtual crossmatching, as described in Chapter 2. Importantly, this 
approach allows for defining acceptability of HLA alleles not present in single antigen bead 
assays. Currently, we are working on implementing defining acceptable and unacceptable 
HLA mismatches in HLA-EMMA.
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While HLA epitope matching is becoming a hot topic in the transplant community and clinicians 
are eager to start epitope matching, more research is required to introduce HLA epitope 
matching properly. This thesis forms the basis for these additional studies to be performed.
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Het immuunsysteem
Het immuunsysteem beschermt de mens tegen schadelijke ziekteverwekkers (pathogenen) 
en daarvoor is het van belang dat het onderscheid kan maken tussen lichaamseigen en 
lichaamsvreemde antigenen. Het verdedigingssysteem doet dit in eerste instantie door middel 
van de aspecifiek aangeboren immuniteit die effectief en snel het pathogeen vernietigt. Het 
adaptieve (verworven) immuunsysteem is specifieker maar ook langzamer en bestaat uit 
antistoffen geproduceerd door B-cellen, de humorale immuunreactie, en T-cellen die zorgen 
voor een cellulair immuunreactie. De receptoren op zowel B-cellen als T-cellen moeten eerst 
een specifiek antigeen herkennen voordat de cellen differentiëren in zowel effector cellen 
die het pathogeen vernietigen als in langlevende geheugen cellen die een snelle en effectieve 
reactie kunnen veroorzaken bij nieuwe blootstelling aan hetzelfde antigeen.
HLA systeem
De humane leukocyten antigenen (HLA) spelen een belangrijke rol in het immuunsysteem. 
Het HLA-systeem bestaat uit HLA klasse I moleculen, HLA-A, -B en -C, en HLA klasse II 
moleculen, HLA-DR, -DQ, en -DP. HLA klasse I moleculen komen voor op alle cellen behalve 
rode bloedcellen en presenteren peptiden afkomstig van lichaamsvreemde eiwitten in de cel 
aan cytotoxische T-cellen (CD8+) die vervolgens die cel doodt. HLA klasse II moleculen komen 
vooral tot expressie op antigeen presenterende cellen (APC) en geactiveerde endotheel cellen. 
Deze cellen nemen eiwitten op uit de omgeving en de HLA klasse II moleculen en presenteren 
die als peptiden aan T-helper-cellen (CD4+) die vervolgens andere cellen activeren, zoals 
B-cellen om antistoffen uit te scheiden. Verschillende HLA moleculen presenteren andere 
peptiden. Er zijn inmiddels heel veel HLA moleculen geïdentificeerd terwijl bij elk individu 
verschillende, erfelijk bepaald, HLA moleculen op de cellen aanwezig zijn. Deze extreme 
polymorfisme van HLA zorgt ervoor dat er altijd een individu is dat een peptide van een 
bepaalde pathogeen kan presenteren waardoor de menselijke populatie altijd beschermd is 
tegen nieuwe of gemuteerde pathogenen.
Allo-immuun reactie in transplantatie
Waar het HLA polymorfisme voordelig is voor bescherming tegen pathogenen, is het 
ongunstig voor (orgaan) transplantaties. Al in de jaren 60 bleek dat HLA matchen cruciaal 
was voor niertransplantatie omdat donor nieren met dezelfde HLA als ontvanger een betere 
overlevingskans hadden. HLA moleculen van de donor kunnen namelijk worden herkend 
als lichaamsvreemd door het immuunsysteem van de ontvanger. Zo kunnen T-cellen van de 
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ontvanger zowel de intacte HLA moleculen op donor APC herkennen, directe herkenning, 
als peptiden afkomstig van een donor HLA molecuul gepresenteerd in HLA moleculen 
van ontvanger, indirecte herkenning. Beide reacties induceren immuunreacties die leiden 
tot acute en chronisch afstotingen. Transplantatie patiënten moeten levenslang afweer 
onderdrukkende medicijnen nemen en de meerderheid daarvan is dan ook gericht op het 
onderdrukken van T-cel activatie.
Maar ook de B-cel receptoren op de B-cellen van de ontvanger kunnen de intacte HLA 
moleculen van de donor herkennen als lichaamsvreemd. Vervolgens gaan de B-cellen HLA-
specifieke IgG antistoffen produceren waarbij ze geholpen worden door T-helper-cellen, die 
peptiden herkennen die afkomstig zijn van het donor HLA molecuul gepresenteerd door HLA 
klasse II moleculen op de B-cellen van de ontvanger.
Antistoffen specifiek gericht tegen donor HLA gevormd na transplantatie worden donor-
specifieke antistoffen (DSA) genoemd. De aanwezigheid van deze DSA is geassocieerd 
met een verhoogde kans op afstoting van de getransplanteerde nier. Daarnaast zorgen 
deze DSA ervoor dat het moeilijker is om een geschikte donor te vinden voor een nieuwe 
transplantatie, omdat de HLA antigenen waartegen de al voor transplantatie antistoffen 
aanwezig zijn, worden beschouwd als onacceptabel. Dit is nodig om te voorkomen dat een 
nier na transplantatie meteen wordt afgestoten omdat er antistoffen aanwezig zijn die de 
donor HLA op het orgaan kunnen herkennen. Deze ongewenste DSA kunnen ook worden 
gevormd na een zwangerschap of bloedtransfusie. Een bijkomend probleem is dat DSA niet 
alleen specifiek zijn voor het gemismatchte donor HLA, maar ook kunnen kruisreageren met 
andere HLA moleculen, die een beetje lijken op het donor HLA.
Dit proefschrift
Ondanks de verbeterde chirurgische technieken en de betere immunosuppressiva is HLA 
matchen nog steeds essentieel voor niertransplantatie. Maar door de hoge mate van HLA 
polymorfisme en schaarste van organen is de kans op het vinden van een HLA identieke 
(gematchte) donor klein. Nu blijkt dat niet elke HLA antigeen verschil (mismatch) een humorale 
allo-immuunreactie induceert. Ontwikkeling van nieuwe technieken, waarbij de genen die de 
erfelijke informatie bevatten voor de HLA moleculen in detail worden geanalyseerd, hebben 
geleid tot een betere kennis over de HLA moleculen. Het is inmiddels duidelijk dat elk HLA 
molecuul bestaat uit een unieke set van polymorfe aminozuur configuraties, vaak aangeduid 
als epitopen, maar dat individuele epitopen gedeeld kunnen worden door verschillende HLA 
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moleculen. Recente studies hebben aangetoond dat het aantal epitoop verschillen tussen 
donor en ontvanger geassocieerd is met vorming van DSA na transplantatie.
Daarom is het interessant om nieren te alloceren op basis van epitoop matchen in plaats 
van HLA antigeen matchen om DSA vorming na transplantatie te voorkomen. Hiervoor is het 
van belang om in kaart te brengen welke epitopen een antistofreactie kunnen veroorzaken. 
Het blijkt dat een configuratie van een paar aminozuren, ook wel functioneel epitoop 
genoemd, op het HLA molecuul verantwoordelijk is voor de inductie van antistoffen en ook 
de specificiteit van het antistof zal bepalen. He vermogen om een antistof reactie op te wekken 
wordt immunogeniciteit genoemd. Voor de binding van antistof aan antigeen zijn meerdere 
aminozuur configuraties betrokken en die bepalen de affiniteit en sterkte van binding. Dit 
laatste wordt aangeduid als de antigeniciteit van een HLA molecuul. Het complete gebied van 
antigeen waaraan antistof bindt wordt ook wel B-cel epitoop of structureel epitoop genoemd.
In hoofdstukken 2 en 3 beschrijven wij verschillende benaderingen die zijn geïntroduceerd 
om de immunogeniciteit van HLA moleculen te voorspellen en daarmee ook de kans op DSA 
vorming. Daarnaast beargumenteren wij dat DSA vorming niet enkel afhankelijk is van het 
aantal gemismatchte epitopen, maar dat de immunogeniciteit van individuele epitopen wellicht 
nog meer bepalend is (hoofdstuk 3). Het verschil tussen immunogeniciteit en antigeniciteit 
wordt ook uitgelegd (hoofdstuk 2). Dit is belangrijk omdat DSA vorming voorkomen kan 
worden door immunogene aminozuur configuraties, of epitopen, te vermijden tijdens allocatie 
van organen. Als DSA al gevormd zijn, zoals bij hoog geïmmuniseerde patiënten, is het van 
belang om de antigeniciteit in kaart te brengen teneinde de onacceptabele en acceptabele 
configuraties, of epitopen, te bepalen en op basis daarvan geschikte donoren te vinden.
De meeste bestudeerde benadering om de kans op immunisatie te bepalen is op basis 
van gemismatchte eplets. Eplets zijn theoretisch gedefinieerde configuraties van aan de 
oppervlakte van het HLA molecuul gelegen polymorfe aminozuren. Van veel van deze eplets 
moet nog worden vastgesteld of een antistof er inderdaad aan kan binden. Dit kan worden 
gedaan met behulp van humane monoklonale HLA antistoffen (mAbs). Dit is zeer succesvol 
gebleken voor de HLA klasse I moleculen maar deze zijn nauwelijks aanwezig voor het in 
kaart brengen van de relevante polymorfisme op HLA klasse II moleculen. Daarom hebben 
we een techniek opgezet om HLA klasse II mAbs genereren om zo eplets te verifiëren waaraan 
een antistof kan binden. In hoofdstuk 4 gebruiken wij bestaande B-cel hybridoma’s om 
een methode te verifiëren voor het genereren van recombinant humaan HLA mAbs van 
alle vier de IgG subklassen. Vervolgens hebben wij deze methode gebruikt in hoofdstuk 
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5 om recombinant humaan HLA-DR-specifieke mAbs te genereren uit geheugen (memory) 
B-cellen die door middel van HLA-DR tetrameren waren geïsoleerd uit perifeer bloed van 
zwangerschap geïmmuniseerde individuen. Reactiviteit analyse van deze mAbs hebben 
geresulteerd in de identificatie van uniek gedeelde aminozuur of aminozuur configuraties 
op de reactieve HLA allelen. Sommige van de geïdentificeerde configuraties kwamen overeen 
met bestaande eplets en daarmee bevestigden wij dat een antistof kan binden aan deze 
eplets. Andere geïdentificeerde configuraties toonden aan dat andere eplets niet helemaal 
juist waren gedefinieerd.
Een andere manier om de relevante epitopen te definiëren is door de immunogene polymorfe 
aminozuren te identificeren. In hoofdstuk 6 beschrijven wij de ontwikkeling van een 
gebruiksvriendelijke software HLA-EMMA dat aminozuur sequenties van gemismatchte donor 
HLA allelen vergelijkt met de aminozuur sequenties van dezelfde locus van de ontvanger. HLA-
EMMA bepaalt de aminozuur verschillen van zowel de hele sequentie als enkel die posities 
die gedefinieerd zijn als toegankelijk voor antistof. Naast de verschillen geeft HLA-EMMA ook 
de soort en positie van de gemismatchte aminozuren.
Aangezien DSA specifiek voor HLA klasse II voornamelijk worden gevormd na transplantatie, 
wilden wij de meest immunogene HLA klasse II aminozuren identificeren. Hiervoor analyseerde 
wij in hoofdstuk 7 niet-geïmmuniseerde mannen die voor het eerst een niertransplantatie 
hadden ondergaan met minimaal één HLA antigeen mismatch maar die uiteindelijk hun 
transplantaat verloren als gevolg van immunologisch falen. Met HLA-EMMA bepaalde wij 
de “solvent accessible” aminozuur verschillen voor HLA-DR en HLA-DQ allelen mismatches. 
In deze kleine studie zagen wij al voor het aantal gemismatchte HLA-DQ aminozuren een 
associatie met nieuwgevormde DSA. In tegenstelling tot andere studies, analyseerden wij de 
HLA-DQ ketens (alfa en bèta keten) afzonderlijk met betrekking tot hun vermogen om een 
antistofreactie te induceren en toonde aan dat één aminozuur mismatch op de alfa of op de 
bèta keten al voldoende kan zijn om een antistofreactie te veroorzaken.
Dit bevestigde onze hypothese dat niet alleen het aantal epitoop mismatches maar ook de 
immunogeniciteit van de individuele epitopen bijdraagt aan de inductie van HLA antistoffen.
HLA-EMMA en de door ons ontwikkelde humane HLA mAbs zullen beiden bijdragen aan 
de identificatie van immunogene en daarmee de relevante epitopen die de basis moeten 
vormen van toekomstige strategieën gebaseerd op epitoop matchen om zo DSA vorming 
te voorkomen en om niet onnodig een orgaan af te wijzen op basis van niet-immunogenen 
epitopen. Aanvullende studies met de recombinant humaan HLA klasse II mAbs zullen zeker 
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ook meer inzicht geven in de interactie tussen antistof en HLA antigeen. Daarnaast kunnen 
methodologische studies worden uitgevoerd met de recombinant humaan HLA mAbs vooral 
omdat we alle vier de IgG subklassen kunnen genereren en dit zal bijdragen aan het begrijpen 
van de differentiële pathogeniteit van HLA antistoffen die gevormd worden na transplantatie.
In conclusie, dit proefschrift vormt een goede basis voor aanvullende studies die nodig zijn 
om HLA epitoop matchen te introduceren in de praktijk.
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